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RESUMO 
A etiologia da hipertensão essencial é multifactorial e não está completamente 
esclarecida; no entanto, aparentemente, a persistência de uma actividade simpática 
elevada é um dos principais contributos para o aparecimento, desenvolvimento e 
manutenção da hipertensão arterial essencial (HTA) de origem neurogénica. 
De facto, a partir de dados, obtidos por aplicação de técnicas de microneurografia e 
de spillover de noradrenalina a modelos animais de hipertensão e a doentes hipertensos, 
observa-se que a influência simpática sobre o sistema cardiovascular está muitas vezes 
aumentada quando a pressão arterial está persistentemente elevada.  
No entanto, os mecanismos precisos responsáveis pela activação simpática na 
hipertensão essencial ainda precisam ser esclarecidos, uma vez que estes são complexos 
e multifactoriais. Podem, no entanto, ser discutidas várias possibilidades, algumas delas 
destacando o papel de substâncias libertadas para a circulação e outras dando ênfase aos 
mecanismos com origem no sistema nervoso central. 
Factores humorais como adipocitocinas, concentração de O2 e de CO2 no sangue, factores 
endoteliais e aldosterona também têm sido implicados na simpatoexcitação mas o mais 
estudado deles é a angiotensina II, devido à sua posição na cascata de acontecimentos 
pela qual o rim regula a pressão sanguínea. 
Assim, uma das hipóteses é que a activação do sistema nervoso simpático depende da 
concentração circulante de angiotensina II uma vez que a angiotensina exerce efeitos 
excitatórios centrais, facilita a libertação de noradrenalina e amplifica a resposta 
adrenorreceptora a estímulos não apenas nos indivíduos com elevados níveis de renina e 
angiotensina, mas, também, em indivíduos com baixos níveis de renina.   
Outra possibilidade é o facto da hiperactividade simpática ser devida à resistência à 
insulina, uma vez que é frequente a presença simultânea de hipertensão com 
hiperinsulinémia que se sabe aumentar o tráfego simpático e a libertação de 
noradrenalina. No entanto, o recíproco também é verdadeiro, pelo que será difícil 
determinar se é a simpatoexcitação que precede a resistência à insulina ou o contrário.  
xxvi 
Uma terceira possibilidade poderá ser o facto de a activação simpática estar relacionada 
com disfunção baroreflexa, uma vez que a hipertensão arterial se caracteriza por um  
resetting da modulação baroreflexa da pressão arterial e do tráfego simpático no sentido 
de valores tensionais elevados, um mecanismo que funciona mais para manter do que 
para reduzir o aumento da pressão arterial uma vez que, aparentemente, também a 
acção de outros arcos reflexos cardiovasculares que interferem no fluxo simpático para os 
vasos, na libertação de renina e de noradrenalina estão inibidos. 
Uma quarta possibilidade deve-se à manutenção de um fluxo simpático aumentado, de 
origem central, que poderá estar relacionado com excessivo controlo subcortical 
decorrente do stress ambiental persistente. 
A presente tese baseia-se no facto de que o aumento da actividade simpática pode 
resultar de uma actividade inapropriada mais elevada do tónus simpático em centros 
cerebrais. Dois deles são particularmente importantes na regulação cardiovascular na 
hipertensão: a face rostroventrolateral do bulbo (FRVLB) e o núcleo paraventricular do 
hipotálamo (PVN).  
A primeira é o maior grupo de neurónios do tronco cerebral com actividade tónica 
espontânea que controlam a actividade do sistema nervoso simpático. Através de 
projecções directas para a medula espinhal, os neurónios da FRVLB exercem um efeito 
estimulatório tónico contínuo para os neurónios motores pré-ganglionares da medula 
espinhal que regulam directamente a actividade do sistema nervoso simpático (SNS). Na 
hipertensão neurogénica, os neurónios da FRVLB exibem uma frequência de disparo 
anormalmente aumentada, o que leva ao aumento da actividade do SNS, que promove a 
vasoconstrição e o aumento da pressão arterial. A FRVLB também desempenha um papel 
fundamental na modulação do baroreflexo em condições fisiológicas e patológicas. Além 
disso, a actividade neuronal da FRVLB é extrinsecamente controlada por outras áreas 
cardiovasculares no sistema nervoso central, uma das quais é o PVN. O PVN surge como 
um dos principais reguladores deste output para o sistema nervoso autónomo e 
endócrino. 
O PVN apresenta projecções recíprocas para a FRVLB e projecções directas para o núcleo 
intermediolateral simpático da medula espinhal, daí que a estimulação dos neurónios do 
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PVN aumenta a actividade da FRVLB e a pressão arterial. Muitos neurónios do PVN que se 
projectam para a FRVLB também exibem uma autorritmicidade intrínseca, e a frequência 
de disparo destes neurónios está intimamente relacionada com a frequência de descarga 
simpática. 
As extensas projecções do PVN a regiões centrais (FRVLB, área postrema, NTS e núcleo 
intermediolateral da medula espinhal) indicam que o PVN desempenha um papel 
importante na modulação da actividade da FRVLB e do fluxo simpático. O PVN recebe 
informação de várias regiões do sistema nervoso central, incluindo aqueles associados 
com o controlo osmótico, apetite, metabolismo energético e stress, bem como de outras 
áreas que exercem efeitos sobre a pressão arterial. Assim, é evidente que o papel do PVN 
é integrar a informação a partir de diversas origens e modificar a actividade da FRVLB de 
acordo com a informação recebida. 
Igualmente, foi demonstrado que a lesão electrolítica do PVN em ratos espontâneamente 
hipertensos (SHR) induz uma redução aguda da actividade simpática, juntamente com 
uma diminuição da pressão arterial. Outros estudos de fase aguda, realizados sob 
anestesia geral, mostraram que injecções de muscimol no PVN diminuem a pressão 
arterial e a actividade nervosa simpática renal, tanto em SHR como em ratos Wistar, 
indicando que esta área é tonicamente activa no controlo da pressão arterial e da 
actividade simpática periférica tanto na hipertensão como na normotensão. Além disso, a 
relação entre os neurónios do PVN e da FRVLB para o controlo simpático sugere que a 
descarga espontânea pode ser modificada por alterações na frequência intrínseca de 
despolarização ou através de modificações do balanço de excitação e inibição de 
informação nervosa aferente. 
Assim, com o presente trabalho pretendeu-se modular a actividade simpática em áreas 
centrais - PVN e FRVLB - e estabelecer o papel desta modulação no tônus simpático, 
pressão arterial, reflexos cardiovasculares e nas alterações de sinalização nos órgãos alvo-
hipertensivos.  
Para isso, provocou-se a diminuição crónica da excitabilidade celular nestas duas áreas 
centrais num modelo animal de hipertensão através da sobre-expressão de canais de 
potássio induzida por um lentivírus monitorizando-se os valores tensionais, o output 
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autonómico, as funções baro e quimiorreceptora e a sinalização molecular nos órgãos-
alvo da hipertensão. Como área controlo utilizou-se a área pressora bulbo-cervical (APBC) 
localizada na região ventrolateral da junção bulbo-cervical e cujos neurónios projectam 
para os neurónios simpáticos pré-ganglionares. Esta área que tem pouca acção sobre o 
sistema cardiovascular e que não tem qualquer transmissão neuronal para a FRVLB ou 
para regiões suprabulbares foi  recentemente descrita como uma área simpatoexcitatória 
com grande interferência na função respiratória. 
Os resultados mostram que a sobre-expressão crónica de canais de potássio no PVN e na 
FRVLB em ratos SHR conscientes causou uma diminuição acentuada e sustentada da 
pressão arterial e do output simpático avaliado indirectamente pela diminuição da 
potência da banda das baixas frequências (LF) de pressão arterial sistólica (PAS). No PVN, 
em particular, observou-se uma remodelação reversa das funções baro e 
quimiorreceptora que se aproximaram da função fisiológica normal. Curiosamente, não 
se observaram modificações nestas funções com a intervenção na FRVLB, onde estes 
reflexos integram primariamente.  
Ocorreram igualmente alterações de sinalização nos órgãos-alvo da hipertensão, coração, 
rim e vasos. De facto, a manipulação central que promoveu a diminuição dos valores de 
pressão arterial e da actividade simpática, também, afectou a expressão génica nos 
órgãos-alvo, principalmente através do aumento da expressão dos genes 
angiotensinogénio e receptores da angiotensina II tipo 2 (AT-2) no rim e da diminuição de 
expressão de receptores da angiotensina II tipo 1 (AT-1) no coração.  
Estes resultados destacam o PVN e a FRVLB como locais importantes para o controlo da 
pressão arterial na hipertensão neurogénica, e espera-se que ao identificar a sua função 
específica nesta patologia elas se possam constituir alvos realistas para intervenções 
terapêuticas mais dirigidas na hipertensão. 
Em conclusão, o presente estudo mostra que a intervenção na excitabilidade neuronal de 
áreas centrais simpatoexcitatórias através da manipulação genética da expressão de 
canais de potássio é capaz de alterar a pressão arterial periférica a longo prazo. Isto 
ocorre pela remodelação do fluxo simpático e por alterações de sinalização que 
ocorreram nos órgãos-alvo para manter a homeostase cardiovascular. Os nossos dados, 
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obtidos a partir de um modelo animal, dão perspectivas sobre os mecanismos 
fisiopatológicos envolvidos na etiologia da hipertensão arterial neurogénica e poderão 
proporcionar novas intervenções terapêuticas a nível central do sistema nervoso 
autónomo para controlo da simpato-excitação e dos danos funcionais nos orgãos 
periféricos.  
 
 
Palavras-chave: Hipertensão Arterial, Sistema Nervoso Simpático, órgãos-alvo, núcleo 
paraventricular do hipotálamo (PVN), face rostroventrolateral do bulbo (FRVLB), 
Lentivirus (LVV), barorreflexo e quimioreflexo. 
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ABSTRACT 
 
The aetiology of essential hypertension is multi-factorial and not completely understood. 
Apparently, the persistence of elevated sympathetic activity is one of the major 
contributors to the onset, development and maintenance of neurogenic arterial 
hypertension (AHT). 
From experimental models of hypertension and hypertensive patients data using 
microneurography and norepinephrine spillover techniques, there is evidence that the 
sympathetic influence upon the cardiovascular system is often increased when blood 
pressure is chronically elevated. 
The mechanisms responsible for the sympathetic activation in essential hypertension are 
complex and multifactorial and remained to be completely elucidated. However, several 
working hypothesis can be discussed, some of them stressing the role of humoral 
substances and others concentrated on brain mechanisms.  
Humoral factors like adipokines, O2 and CO2 blood concentration, endothelial factors and 
aldosterone have also been implicated in sympathoexcitation but the most studied of 
them is angiotensin II due to its position on the cascade of events by which the kidney 
regulates blood pressure.  
Thus, one hypothesis is that the sympathetic nervous system activation depends on the 
circulating angiotensin II concentration, since it exerts central sympathoexcitatory effects, 
promotes the release of norepinephrine and amplifies the adrenoreceptor response to 
stimuli not only in subjects with elevated levels of renin and angiotensin, but also in 
subjects with low levels of renin.  
Other hypothesis is that the sympathetic hyperactivity may be due to insulin resistance, 
since the presence of hypertension is often associated with hyperinsulinemia and is 
known that insulin resistance/hyperinsulinemia increases the sympathetic traffic and the 
release of norepinephrine. However, the reciprocal is also true, so it is difficult to 
determine, in this case, whether it is the sympathoexcitation that precedes insulin 
resistance or otherwise.  
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A third assumption links sympathetic activation with baroreceptor reflex function. In fact, 
sympathetic activation is associated with baroreflex impairment, since hypertension is 
characterized by baroreflex remodeling and sympathetic nerves traffic resetting towards 
high blood pressure values. The major objective of this physiological adaptation is not to 
reduce the increased blood pressure values but to maintain a new steady-state of high 
values since, apparently, also the action of cardiac reflex arcs that may affect the 
sympathetic outflow to the vessels, the release of norepinephrine and renin is inhibited.  
A fourth theory deals with the maintenance of an increased central sympathetic outflow 
due to excessive subcortical control caused by persistent excessive environmental stress.  
This thesis is based on the possibility that increased sympathetic activity observed in 
hypertension may also result from an inappropriately elevated sympathetic drive from 
brain centres. Two of them are particularly important to cardiovascular regulation in 
hypertension: the rostroventrolateral medulla (RVLM) and the paraventricular nucleus of 
the hypothalamus (PVN).  
The first is the major brainstem cluster of neurons with spontaneous tonic activity that 
controls peripheral sympathetic activity. Through direct projections to the spinal cord, 
RVLM neurons provide tonic drive to the spinal cord preganglionic motor neurons that 
directly regulate SNS activity.  
In hypertensive conditions, RVLM neurons display abnormally increased discharge 
frequency, leading to increased sympathetic activity and vasoconstriction, thus elevating 
blood pressure values. RVLM also plays a key role in mediating baroreflex modulation in 
physiological and pathological conditions. Moreover, RVLM neuronal activity is 
extrinsically controlled by other cardiovascular regions in the CNS, one of which is the 
PVN.  
The PVN has emerged as one of the major regulators of the coordinated autonomic and 
endocrine output. PVN projects to both RVLM and the spinal sympathetic 
intermediolateral nucleus, and PVN neurons stimulation increases RVLM activity and 
arterial blood pressure. Several PVN neurons that project to RVLM also display an intrinsic 
auto-rhythmicity, and the discharge frequency correlates closely with sympathetic 
discharge rate.  
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The extensive projections of the PVN to central regions (RVLM, area postrema, NTS and 
intermediolateral nucleus of the spinal cord) indicate that PVN plays a significant role in 
modulating RVLM activity and sympathetic outflow. The PVN receives input from a large 
number of regions in the brain, including those associated with osmotic control, appetite, 
energy metabolism, stress, emotions and other areas that exert effects on BP. Thus, it is 
clear that the role of the PVN is to integrate inputs from a variety of sources and modify 
RVLM activity according.  
It was also showed that electrolytic lesions of the PVN in SHR elicited an acute reduction 
of sympathetic activity together with a decrease of blood pressure. Other acute animal 
studies, performed under general anaesthesia, showed that PVN muscimol injections 
lowered BP and renal sympathetic nerve activity both in SHR and WKY rats, indicating that 
this region was tonically active in both animal strains to control BP and peripheral 
sympathetic activity.  
Moreover, the relation of PVN and RVLM neurons to sympathetic control suggests that 
the spontaneous discharge can be modified through either changes to the intrinsic rate of 
depolarization or alterations in the balance of excitatory and inhibitory afferent input. 
Thus, the present work intended to modulate sympathetic activity in these two central 
sympathoexcitatory areas – PVN and RVLM - and establish the role of this modulation on 
sympathetic tone, blood pressure, cardiovascular reflexes function and signalling changes 
in hypertensive target organs.  
For that, a decrease in cellular excitability in PVN and RVLM was promoted in a chronic 
and conscious animal model of hypertension by the overexpression of a potassium 
channel induced by a lentivirus. Blood pressure values, autonomic output, the baro- and 
chemoreceptor function and the molecular signalling in hypertensive target organ were 
monitored. As a control area was used the medullo-cervical pressor area (MCPA) located 
in the ventrolateral region of the medullo-cervical junction, which neurons project to the 
preganglionic sympathetic neurons. It was recently described as an area with high 
sympathoexcitatory interference in respiratory function, but little action on the 
cardiovascular system and it doesn’t have any neuronal relay to RVLM or suprabulbar 
regions. 
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Results show that chronic overexpression of potassium channels in the PVN and RVLM of 
conscious unrestrained SHR caused a marked and sustained decrease in blood pressure 
and sympathetic output as revealed indirectly by a decrease in the power density of the 
Low frequency (LF) band of systolic blood pressure (SBP). In the PVN, in particular, there is 
a reversal remodelling of the baro- and chemoreceptor function that approached the 
normal physiological function. Interestingly, no changes in the baro- and chemoreceptor 
function were observed with intervention in RVLM, where the sympathetic efferent 
response is primarily generated. Signalling changes also occurred in hypertensive target 
organs, heart, kidney and vessels. In fact, the central manipulation that promoted a 
decrease in blood pressure and sympathetic activity also affected gene expression in 
target organs, mainly through the up-regulation of angiotensinogen and AT-2 genes in the 
kidney and down-regulation of AT-1 receptors in the heart.  
These results give support to PVN and RVLM role as powerful sites to control BP in 
neurogenic hypertension and we expect, by identifying the role of these central areas, to 
provide realistic targets for therapeutic interventions in hypertension. 
In conclusion, the present work shows that the intervention on central 
sympathoexcitatory neurons excitability through the genetic manipulation of K+ channels 
expression is able to long term alter peripheral blood pressure. This occurs by 
sympathetic outflow remodelling and by signalling changes that occurred in hypertensive 
target organs that maintain cardiovascular homeostasis. Our data, from an animal model, 
give insights into the pathophysiological mechanisms involved in the aetiology of essential 
hypertension of neurogenic origin and provide novel hypothetical therapeutic 
interventions at central level of the autonomic nervous system to control 
sympathoexcitation and functional damage on peripheral organs. 
 
Keywords: Arterial Hypertension, Sympathetic Nervous System, Target Organs, 
Paraventricular Nucleus of the Hypothalamus (PVN), Rostroventrolateral Medulla (RVLM), 
Lentiviral Vector (LVV), Baroreflex and Chemoreflex.  
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CHAPTER 1.  
ARTERIAL HYPERTENSION  
 
 
1.1. INTRODUCTION  
I. Defining arterial hypertension 
Hypertension is a sustained elevation of systemic arterial pressure that may be evoked by 
cardiac output increases, however sustained hypertension is due to an increase of total 
peripheral resistance. Hypertension is a very common abnormality in human subjects and 
can be produced by a serious of disorders. When, for a long period, an increase in 
afterload is observed, hypertrophy of the cardiac muscle cells develops. The primary 
response is the activation of immediate-early genes followed by the activation of a series 
of fetal genes involved in growing during the fetal period (Opie, 1998; Katz, 2001). In 
these conditions, O2 consumption increases not only due to the rise in cardiac work but 
also due to the further increase of cardiac muscle mass. Therefore, in these patients, any 
decrease of coronary blood flow has serious consequences and, if the ability of the heart 
to compensate for the high peripheral resistance is exceeded, the heart can fail (Opie, 
1998; Katz, 2001). Hypertensive patients have a higher risk of thrombosis and cerebral 
hemorrhage and renal failure. 
Quantitatively, hypertension is defined by values of systolic blood pressure (SBP) >140 
mmHg and/or of diastolic blood pressure (DBP) > 90 mmHg. These values were based on 
the evidence, from randomized controlled trials, that treatment-induced BP reductions 
are beneﬁcial for patients (Mancia et al., 2013; James et al., 2014).  
According to the 2013 ESH/ESC Guidelines and to the latest report of the Joint National 
Committee USA (JNC8), a classification of BP values has been made in accordance with 
the magnitude of the blood pressure (BP) values (see table 1.1). Individuals with values 
between 130-139 (systolic BP) and 85-89 (diastolic BP) are called pre-hypertensive and 
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already considered at risk for developing hypertension (Mancia et al., 2013; James et al., 
2014). This last category of a pre-hypertension category was created by the JNC7 report 
based on evidences taken from the Framingham study (Vasan et al., 2002; Chobanian et 
al., 2003). In such long term and particular study, was shown that, in such individuals, the 
chance of developing hypertension is higher than in those individuals with BP values 
<120/80 mmHg, termed normal blood pressure values (Chobanian et al., 2003). However 
this terminology was not adopted by the ESH/ESC (Mancia et al., 2013). 
 
Table 1.1. Definitions and classification of blood pressure (BP) levels (mmHg). The BP category is deﬁned 
by the highest level of BP, whether systolic or diastolic. Isolated systolic hypertension should be graded 1, 2, 
or 3 according to systolic and diastolic BP values in the ranges indicated. Adapted from ESH/ESC guidelines 
2013. 
Category of BP values Systolic BP 
(mmHg)  
Diastolic BP 
(mmHg) 
Optimal <120 and <80 
Normal 120–129 and/or 80–84 
High normal 130–139 and/or 85–89 
Grade 1 hypertension 140–159 and/or 90–99 
Grade 2 hypertension 160–179 and/or 100–109 
Grade 3 hypertension ≥180 and/or ≥110 
Isolated systolic hypertension ≥140 and <90 
 
The 2013 ESH/ESC Guidelines, in common with other guidelines, recommended two 
distinct BP targets, namely, 140/90 mmHg in low moderate risk hypertensive patients and 
130/80 mmHg to high-risk hypertensive subjects which are patients with co-morbidities 
like  diabetes, cerebrovascular, cardiovascular or renal disease. More recently, the 
European Guidelines on Cardiovascular Disease Prevention recommended a target of 
140/80 mmHg for diabetic patients (Perk et al., 2012). In 2013, the European Society of 
Cardiology Guidelines included a re-evaluation of the target BP upon therapeutics. The 
recommendation is to target a systolic BP <140 mmHg for most hypertensive patients but 
for those, aged > 80 years, with systolic BP >160 mmHg was recommends a reduction to 
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140-150 mmHg, with adjustments according to tolerability in the fragile elderly. A 
diastolic BP <90 mmHg was recommended for all hypertensive patients, except for 
diabetic patients, where the 85 mmHg is the target value (Mancia et al., 2013).  
Since this hypertension is a progressive cardiovascular syndrome arising from complex 
and interrelated etiologies it can be classified as essential or secondary arterial 
hypertension. 
 
I a. Essential hypertension 
The primary, essential or idiopathic hypertension can be defined as a rise in blood 
pressure with no identifiable cause. Is the most common form of arterial hypertension 
(AHT) affecting about 90 to 95% of patients (Carretero & Oparil, 2000; Bolívar, 2013). It is 
an heterogeneous disease in which different patients have different causative factors that 
lead to increased blood pressure values (see II) (Carretero & Oparil, 2000). 
The pathophysiology of essential hypertension is an area of research, and until now 
remains not well understood. It is known that BP regulation is a complex interaction of 
different cardiac, vascular, renal, neurologic, hormonal, humoral and metabolic 
mechanisms (Goldberger, 1958; Chopra et al., 2011; Bucher et al., 2013). Therefore, 
several different pathways may be simultaneously implicated in the development of 
essential hypertension, such as genetic predisposition, obesity, insulin resistance, excess 
dietary salt intake, sympathetic over-activation and alterations in sodium homeostasis, 
renin-angiotensin system, vascular function and inflammation (Lifton et al., 2001; 
Strazzullo et al., 2003; Geller, 2004; Sowers, 2004; Karppanen & Mervaala, 2006; Savoia & 
Schiffrin, 2006; Manrique et al., 2009; Savoia et al., 2011; Bucher et al., 2013). 
Among the various theories put forward to explain the pathophysiology of essential 
hypertension, one is the high blood pressure of neurogenic nature (Kuchel & Genest, 
1977). This hypothesis suggests that a dysfunction in the sympathetic modulation of 
cardiovascular function is responsible for the hypertensive state, which actively 
participates in the development and progression of this disease. Other theories refer to 
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the inability of kidneys to excrete sodium leading to salt and water retention, increased 
plasma volume, and cardiac output. The overactivity of the renin-angiotensin-aldosterone 
system has also been referred to increase the secretion of renin that elicits an increase in 
plasmatic angiotensin II leading to generalized vasoconstriction or to a renal salt and 
water retention (Cain & Khalil, 2002; Manrique et al., 2009; Santos et al., 2012). Changes 
in resistance arteries morphological and physical properties together with modifications 
of endothelial function leads to a decreased vascular relaxation and excessive 
vasoconstriction promoting significant increases in the peripheral vascular resistance and 
arterial pressure over time, particularly in aging (Intengan & Schiffrin, 2000; Oparil et al., 
2003; Lee & Oh, 2010). The mosaic theory suggests that after a single factor acts as a 
trigger to raise BP then multiple factors will sustain the increased BP values (Strazzullo et 
al., 2003). 
 
I b. Secondary hypertension 
The secondary hypertension is defined as elevated blood pressure due to an established, 
identifiable and potentially treatable cause (Mancia et al., 2013). The incidence of 
secondary AHT is estimated between 5–10% of the overall hypertensive population and is 
linked to diseases that can affect the kidney, heart, endocrine system, vascular system, 
lungs and central nervous system (Kaplan, 2005; Chiong et al., 2008). Also, the 
administration of certain drugs (hormonal contraceptives, antidepressants, 
corticosteroids), the ingestion of toxic agents (lead, mercury) and due to pregnancy 
(Nadar & Lip, 2009) can lead to AHT. 
Secondary AHT can be identified by symptoms (e.g., flushing and sweating suggestive of 
pheochromocytoma), examination findings (e.g., a renal bruit suggestive of renal artery 
stenosis), or laboratory abnormalities (e.g., hypokalemia suggestive of aldosteronism) 
(Viera & Neutze, 2010).  
Renovascular hypertension, the hypertension caused by renal artery stenosis, has two 
main etiologies - atherosclerosis and fibromuscular dysplasia- the first one with an higher 
incidence (80-90% of the overall patients) mainly in patients with >65 years (Zeina et al., 
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2007; Chrysant & Chrysant, 2014). Among all patients with AHT, renal artery stenosis is 
observed in only 1% to 6% (Simon et al., 1972; Vokonas et al., 1988; Ram, 1997), while 
the incidence of renal artery stenosis is more than 50% in elderly patients with known 
atherosclerotic disease (Swartbol et al., 1994; Miralles et al., 1998). However, in young 
adults (19-39 years), renal artery stenosis is one of the most common secondary 
etiologies (Elliott, 2008; Viera & Neutze, 2010). The progressive, occlusive process 
typically narrows the ostium and proximal third of the main renal artery, as well as the 
nearby aorta. As with all other atherosclerotic vascular diseases, it is found with 
increasing frequency with advancing age and has the usual associated risk factors 
(diabetes, dyslipidemia, tobacco use, and history of cardiovascular events) (Elliott WJ, 
2008). Fibromuscular dysplasia is a vascular disorder of unknown etiology that has a 
predilection for the renal arteries in women <40 years causing their narrowing and 
leading to a decreased renal perfusion (Elliott, 2008; Viera & Neutze, 2010). 
In middle-aged adults (40 to 64 years of age), aldosteronism is the most common 
endocrine cause of secondary AHT (Young, 2007; Viera & Neutze, 2010). Primary 
hyperaldosteronism is characterized by an overproduction of aldosterone that causes 
AHT, damage to the cardiovascular system, suppression of plasma renin, sodium 
retention, and potassium excretion, which leads to hypokalemia (Nyirenda & Padfield, 
2007). Aldosterone is also involved in collagen synthesis, producing vascular remodeling 
and myocardial fibrosis in a process that is independent of its effect on arterial blood 
pressure (Bunda et al., 2007; Abad-Cardiel et al., 2013). Thus, it is important to identify 
patients with primary hyperaldosteronism, since an increase in plasma aldosterone is 
associated with negative cardiac and vascular effects and a greater risk of suffering a 
cardiovascular event (Milliez et al., 2005; Abad-Cardiel et al., 2013).  
Other causes of secondary AHT in middle-aged adults are: obstructive sleep apnea, 
pheochromocytoma and the Cushing syndrome (Viera & Neutze, 2010). Thyroid 
dysfunction is also a cause of secondary AHT, mainly in young adults. Thyroid hormones 
affect cardiac output and systemic vascular resistance impacting blood pressure values. 
Hypothyroidism can cause an elevation in diastolic blood pressure, whereas 
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hyperthyroidism can cause an isolated elevation of systolic blood pressure, leading to a 
widened pulse pressure (Klein & Danzi, 2007).  
In children (0 to 18 years of age) with AHT, up to 85% have an identifiable cause, most 
often renal parenchymal disease (Roccella EJ et al., 2004; Viera & Neutze, 2010). In this 
age group, such renal pathology includes glomerulonephritis, congenital abnormalities, 
and reflux nephropathy. Coarctation of the aorta is the second most common cause of 
hypertension in children, and is two to five times more common in boys than in girls 
(Brickner et al., 2000). Rarely, mild cases of coarctation have occurred in adults (Viera & 
Neutze, 2010).  
In the coming years, some forms of secondary hypertension tend to come more 
prevalent. Renovascular disease due to atherosclerosis is an example, since it is 
associated with greater longevity and with aging population. Likewise, primary 
aldosteronism by changes in screening paradigms and obstructive sleep apnea syndrome, 
due to the rise in obesity (Thomopoulos et al., 2011; Abad-Cardiel et al., 2013; Fleg et al., 
2013) are increasing their prevalence among hypertensive patients. 
 
II. Epidemiology of arterial hypertension  
Arterial Hypertension (AHT) is considered one of the major risk factors for cardiovascular 
and cerebrovascular diseases. Affects approximately one billion people worldwide and is 
estimated that could kill nine million people each year (World Health Organization, 2013).  
A study from Kearney et al., showed that 26,4% of the adult population in 2000 had AHT 
(26,6% of men and 26,1% of women), and 29,2% were projected to have this condition by 
2025 (29,0% of men and 29,5% of women). The estimated total number of adults with 
AHT in 2000 was 972 million; 333 million in economically developed countries and 639 
million in economically developing countries. The number of adults with hypertension in 
2025 was predicted to increase to 1,56 billion (Kearney et al., 2005). 
The ESH/ESC 2013 Guidelines for the management of arterial hypertension recognize that 
the prevalence of hypertension is underestimated, but appears to be about 30–45% of 
the general population, with a steep increase with ageing (Mancia et al., 2013) . 
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In Portugal, AHT is highly prevalent, since it is estimated that 42.1% of the Portuguese 
adult population, aged 18 to 90 years, have hypertension. In a study that included a total 
of 5023 adults, the age-specific prevalence of AHT in the three age-groups studied - under 
35 years, 35-64 years, and over 64 years - was 26.2%, 54.7% and 79% in men and 12.4%, 
41.1% and 78.7% in women respectively (De Macedo et al., 2007) (Fig. 1-1). 
 
 
Figure 1-1. Prevalence of AHT in Portugal by sex and age group (<35, 35-64, and >64 years). Extracted from 
De Macedo et al., 2007. 
 
Analysis by region revealed that the North region had the lowest prevalence of 
hypertension (33.4%) and the Alentejo had the highest (49.5%) (Fig.1-2).  
 
 
Figure 1-2. Prevalence of AHT in Continental Portugal by region. The country was divided into 5 regions. 
Black indicates an higher prevalence and white a lower prevalence. Extracted from De Macedo et al., 2007. 
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In this study, was also found that hypertension was sub-diagnosed as among hypertensive 
subjects, only 46.1% were aware of their high blood pressure. Thirty-nine percent of the 
individuals included in the study were taking antihypertensive medication and 11.2% had 
their blood pressure controlled (De Macedo et al., 2007). From this study, it is evident 
that AHT is an important public health challenge in Portugal as well as worldwide because 
its complications, including cardiovascular, cerebrovascular, and renal diseases, are the 
major causes of morbidity and mortality. Therefore, prevention, detection, treatment, 
and control of this condition should receive high priority (Kearney et al., 2005; Messerli et 
al., 2007).  
 
III. Risk factors for essential hypertension  
There are several risk factors that may contribute to the development of the essential 
hypertension including genetic predisposition, environmental factors and lifestyle. 
Results from family studies suggest an hereditary predisposition to the development of 
essential hypertension, with the heritability estimated to vary between 35% and 50% in 
the majority of studies. Two Genome-Wide Association Studies (GWAS) have shown 13 
loci associated with BP/AHT, and an extensive meta-analysis of GWAS data, with a total 
sample size of nearly 200 000 people of European descent, have identified 16 novel loci 
associated with systolic BP and diastolic BP (Levy et al., 2009; Newton-Cheh et al., 2009; 
Ehret et al., 2011). Indeed, a total of 29 single nucleotide polymorphisms associated with 
systolic and/or diastolic BP (Mancia et al., 2013). It also been showed that these 
polymorphisms are associated with the incidence of coronary events and stroke (Ehret et 
al., 2011). Identifying genes associated with high blood pressure advances our 
understanding of blood pressure regulation and highlights the potential drug targets for 
the prevention or treatment of hypertension (Levy et al., 2009). However, the genetic 
heterogeneity, the imprecision in measuring specific phenotypes and the variability of the 
sampling methods contribute to weaknesses and inconsistencies between reported 
studies (Williams et al., 1994).  
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Environmental causes of hypertension include poor diet (especially those that include 
large quantities of salt), smoking, heavy and regular use of alcohol and lack of physical 
activity (Chobanian et al., 2003; Ong et al., 2008). In fact, the development of AHT 
appears to be more common in heavy salt consumers. However, on a similar dietary salt 
ingestion, some individuals develop hypertension while others do not with the probability 
to develop hypertension dependent on the individual weight of the hypertension 
adjunctive factors (Juan J. Bolívar, 2013). Hence, in general terms, a controlled diet can 
significantly reduce blood pressure (Appel et al., 1997). Other factors that lead to 
increased BP are insulin resistance, low potassium intake and low calcium intake 
(Carretero & Oparil, 2000).  
It is well established that the incidence of AHT is higher among smokers, alcoholics and 
people with a stressful life (Arkwright et al., 1982; Lee et al., 2001), which is a reason why 
AHT predominates in industrialized societies and it is included in the so-called diseases of 
civilization. The coincidence of two or more risk factors - overweight, high salt intake, 
smoking, alcohol and stress - significantly increases the possibility of developing arterial 
hypertension (Appel et al., 2003; Dickinson et al., 2006; The Trials of Hypertension 
Prevention Collaborative Research Group, 1997). 
Several reports published controversial results about the association of physical activity 
with risk of hypertension. In fact, a meta-analysis of prospective cohort studies was 
performed to investigate the effect of physical activity on hypertension risk and the 
results suggested that there was an inverse dose–response association between levels of 
recreational physical activity and risk of hypertension, whereas there was no significant 
association between occupational physical activity and hypertension (Huai et al., 2013). 
Individuals with a sedentary lifestyle have 30% greater risk of developing hypertension 
compared with active individuals (Paffenbarger et al., 1991). 
It was found that the AHT is more common among obese people, settling up a direct link 
between the significant excess weight and the disease. Sedentary lifestyles, changes in 
dietary habits, among others, contribute to the development of obesity, and this 
consequently leads to the onset of the disease (De Macedo et al., 2007). In addition, in 
patients with hypertension associated with obesity, there is an increase in renal 
CHAPTER 1 – ARTERIAL HYPERTENSION 
12 
sympathetic outflow when compared to obese people with normal BP. It is, therefore, 
considered that the obesity-related hypertension has an important neurogenic 
component (Tuck, 1992). 
Blood pressure values have a physiological linear increase with age. With an increasingly 
aging population, age is becoming the major risk factor for arterial hypertension (Wolf-
Maier et al., 2003). About 60% of the elderly population in the world, aged > 60 years has 
hypertension (Bobrie & Potter, 2002). In older people, the AHT appears mainly as a result 
of an increase in SBP, being named isolated systolic hypertension, whereas in young 
subjects, the onset of AHT is mainly due to the raise in DBP (Sobotka et al., 2011). The 
change in blood pressure with age is manly associated with increased arterial stiffness, 
which results in a progressive replacement of elastin by collagen in the walls of large 
arteries also referred to as arteriosclerosis. This process leads to dilation and stretching of 
the aorta and its branches through fibrosis and hypertrophy of arterial muscle (Izzo et al., 
2000).  
Even so, these risk factors cannot be considered in isolation. Thus, an effective strategy 
for the treatment of hypertension should involve either pharmacological therapeutics or 
therapeutics of other natures complemented with lifestyle changes. 
 
IV. Target organs damage 
The target organs damage due to chronic arterial hypertension is a major cause of 
cardiovascular morbidity and mortality. The classic manifestations of hypertensive end 
organ damage include vascular and hemorrhagic stroke, retinopathy, coronary heart 
disease/myocardial infarction and heart failure, proteinuria and renal failure and in the 
vasculature, atherosclerotic change including the development of stenosis and aneurysms 
(Schmieder, 2010; Table. 1.2). 
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Table 1.2. End organ damage in arterial hypertension. Adapted from Schmieder, 2010. 
End organ damage in arterial hypertension 
Vasculopathy 
 Endothelial dysfunction 
 Remodelling 
 Generalized atherosclerosis 
 Arteriosclerotic stenosis 
 Aortic aneurysm 
Cerebrovascular damage 
 Acute hypertensive encephalopathy 
 Stroke 
 Intracerebral haemorrhage 
 Lacunar infarction 
 Vascular dementia 
 Retinopathy 
Heart disease 
 Left ventricular hypertrophy 
 Atrial fibrillation 
 Coronary microangiopathy 
 CHD, myocardial infarction 
 Heart failure 
Nephropathy 
 Albuminuria 
 Proteinuria 
 Chronic renal insufficiency 
 Renal failure 
 
The sympathetic nervous system (SNS) overactivity in essential AHT is not only important 
for the initiation and maintenance of elevated blood pressure (BP) values, but also for the 
progression of organ damage in both humans and animal models (Mancia et al., 1999; 
Rahn et al., 1999; Morise et al., 2000; Kasparov & Teschemacher, 2008; Fisher & Fadel, 
2010; Tan et al., 2010). Progression of the disease is strongly associated with functional 
and structural abnormalities that damage the heart, kidneys, brain, vasculature and other 
organs and the manifestations due to chronic elevation of BP are a direct consequence of 
changes in these organs (Giles & Sander, 2005). Hence, the reduction of BP when there is 
target organ damage or if the functional precursor of the target organ damage is present 
and still reversible, generally reduces the risk for cardiovascular events. 
 
IV a. Effect in the heart 
Hypertensive heart disease has been defined as the response of the heart to the afterload 
imposed to the left ventricle by the progressive increasing of BP and total peripheral 
resistance by the hypertensive vascular disease (Rafique, 1993).  In particular, 
hypertensive heart disease is characterized by altered coronary hemodynamics and 
reserve, cardiac dysrhythmias, left ventricular hypertrophy and enlargement, ventricular 
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fibrosis, systolic/diastolic dysfunction and cardiac failure. There are many factors that 
contribute jointly to develop the disease. These are genetic determinants, environmental 
risk factors and hemodynamic and non-hemodynamic mechanisms (Crawford et al., 2004) 
(Fig. 1-3). 
 
Figure 1-3. Determinants of hypertensive heart disease. Adapted from Crawford et al., 2004. 
 
However, the hemodynamic factors do not act isolated but in conjunction with non-
hemodynamic factors - age, race, obesity, salt intake, insulin resistance together with 
neuroendocrine (angiotensin II, aldosterone, endothelin) and hemorrheologic factors 
(blood viscosity and plasma volume) (Crawford et al., 2004). All of them undergo a 
complex and interrelated degenerative/adaptive process in order to answer to the 
persistent increase of blood pressure (see table 1-3 for details). 
The hemodynamic load, either by an increase in peripheral resistance or in cardiac 
output, is the basic initial stimulus to begin the sequence of events that lead to heart 
disease in hypertension. Early hemodynamic changes in hypertension often include 
increased or inappropriately high resting cardiac output, especially in obese patients, 
whereas vascular resistance tends to be normal or inappropriately high in proportion to 
the chronic level of blood pressure (FREIS, 1960; Messerli, 1982; Izzo et al., 2008). In non-
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obese subjects with established essential hypertension the hemodynamic pattern seen at 
rest, most often, is normal blood flow with elevated vascular resistance (Messerli et al., 
1983; Izzo et al., 2008) along with increased arterial stiffness (Mitchell, 2004).  
Table 1-3. Pathogenetic processes underlying cardiac damage in hypertension. Extracted from Crawford et 
al., 2004. 
Pathogenetic processes underlying cardiac damage from hypertension 
Neurohormonal 
Activation of the rennin-angiotensin-aldosterone system 
Enhanced adrenergic activity 
Increased production or reduced degradation of biomolecules 
(eg angiotensin, cytokines) 
Hemodynamic 
Increased peripheral resistance 
Increased wall stress 
Decreased coronary reserve 
Vascular 
Endothelial dysfunction 
Vascular remodelling 
Decreased vascular compliance 
Exaggerated vascular reactivity 
Coronary and peripheral vascular atherosclerosis 
Myocardial 
Left ventricular remodelling 
Foetal gene expression 
Myocite hypertrophy 
Alterations in extracellular matrix 
 
The variation in performance between a normal and an hypertrophied heart may be quite 
marked. For example, Beznak found an initial drop in cardiac output and cardiac reserve 
following acute experimental coarctation of the aorta in the rat (Beznak, 1958). However, 
in animals with chronic coarctation and the resulting myocardial hypertrophy, the cardiac 
output was normal. It appears, therefore, that there are at least three possible 
mechanisms by which the left ventricle might adjust to an elevated peripheral resistance: 
I) an increase in residual volume, and, hence, diastolic fiber length; II) augmentation of 
intrinsic contractility of the myocardial fibres independent of fibre length, and III) 
hypertrophy (Freis, 1960).  
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IV b. Effect in the vascular system  
The increase in pulse pressure in the presence of a normal cardiac output indicates loss of 
large artery distensibility (Freis, 1960; Mitchell et al., 2008). This appears to be brought 
about in chronic hypertension by passive distension, accelerated atherosclerosis and, 
occasionally, by degenerative changes in elastic tissue. As a result of these changes 
pulsatile pressures are transmitted further than normally into the peripheral circulation.  
Abnormalities of the small vessels have been described in hypertensive patients. In the 
conjunctivae, these abnormalities include diminished number of visible capillaries (189), 
abnormally thin and tortuous capillaries (Lack & Adolph, 1949; Lee & Holze, 1951; Landau 
& Davis, 1957; Freis, 1960), constricted terminal arterioles and metarterioles which 
exhibit increased reactivity to topical epinephrine (Lee & Holze, 1951; Jackson, 1958), and 
increased intermittency of capillaries (Jackson, 1958). Any one of these changes is seen 
occasionally in normal individuals, but the presence of all features is characteristic of 
hypertension (Lee & Holze, 1951), and they were seen with much greater frequency in 
hypertensive patients (Landau & Davis, 1957). 
One of the most serious complications of arterial hypertension is at the level of the 
arteries. The persistent elevation of blood pressure tends to cause lesions in the walls of 
arteries, leading to the hardness of blood vessels (arteriosclerosis) and promoting fat 
deposits in the vessels which leads to the formation of atherosclerotic plaques 
(atherosclerosis) (Susic, 1997). This promotes a decrease in blood flow as well as an 
increased risk of bleeding.  
Regional blood flows are generally not impaired in hypertension although blood flow 
reserve may be reduced in circumstances requiring increased blood flow (e.g. exercise). 
Oxygen consumption is also normal (Izzo et al., 2008). Therefore, in chronic human AHT, 
with the exception of the kidney, where flow usually is slightly to moderately reduced, 
cerebral, coronary and hepatic blood flows are all within the normal range (Freis, 1960).  
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IV c. Effect upon renal function 
Scientific data demonstrated that systemic hypertension has a major role in the 
progressive loss of renal function (Ruilope, 2008) as hypertension is frequently associated 
with fibrinoid deposition in the renal glomeruli and proteinuria (Cohuet & Struijker-
Boudier, 2006). Renal injury occurs when the preglomerular autoregulatory mechanism is 
insufficient to maintain flow and pressure in the kidney (Griffin et al., 2003). Loss of renal 
autoregulation with glomerular hypertrophy, hyperfiltration and focal segmental 
glomerulosclerosis is now recognized to contribute significantly to nephrosclerosis which 
functional and morphological abnormalities are intimately linked to the overactivation of 
renin-angiotensin system (Volpe et al., 2002). Uncontrolled AHT is a risk factor for 
developing chronic kidney disease and is associated with a more rapid progression of the 
disease. Progressive renal disease can exacerbate uncontrolled AHT due to volume 
expansion and increased systemic vascular resistance. Therefore, several guidelines 
discussed the importance of lowering blood pressure to slow the progression of renal 
disease and reduce cardiovascular morbidity and mortality (Mancia et al., 2013; James et 
al., 2014). It is also known that chronic kidney disease is a risk factor for cardiovascular 
disease, and that a reduced glomerular filtration rate (GFR) and albuminuria are 
associated with an increase in cardiovascular and all-cause mortality (Rashidi et al., 2008; 
Matsushita et al., 2010).  
 
IV d. Effect in the brain  
AHT causes changes in cerebral circulation leading to four major cerebrovascular illnesses 
such as ischemic stroke, lacunar infarction, hypertensive encephalopathy, and 
hypertensive brain haemorrhage are associated with AHT (Lee, 1989).  In fact, the 
cerebral circulation is susceptible to damage by sudden increases in arterial pressure. 
During episodes of acute, severe hypertension, cerebral vessels dilate passively and there 
is a "break- through" of autoregulation (Baumbach & Heistad, 1988). An hypertensive 
crisis may cause ischemic stroke, due to a thromboembolic event or a hemorrhagic stroke 
(Johansson, 1999). The majority of diagnosed stroke cases (80%) are due to ischemia and 
infarction secondary to occlusive disease of the small and medium size cerebral arteries 
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(Lewington et al., 2002). Regarding in particular the cerebral circulation, it has been 
suggested that there are at least two distinct pathological processes that play a role in 
AHT-induced cerebrovascular damage, separated on the basis of vessel size and type 
(Doyle, 1983). The evidence supporting this hypothesis is histological, since in the larger 
intracranial and extracranial arteries of hypertensive patients, complex atherosclerotic 
lesions are the main finding. In smaller vessels, hyaline necrosis, the formation of 
microaneurysms, and lipid degeneration of the arterial wall are more commonly observed 
(Dinsdale, 1978; Conomy, 1980). AHT can induce rupture of diseased large and small 
arteries, possibly as a result of localized cellular degeneration within the arterial wall 
(Takebayashi & Kaneko, 1983).  
Hypertension may also cause damage in specific regions of the brain (Conomy, 1980; 
Dinsdale, 1983). As an example, hypertensive haemorrhage occurs predominantly in the 
cerebral hemispheres, whereas the arterial lesions in hypertensive encephalopathy occur 
predominantly in the brain stem and basal ganglia and to a lesser extent, in the cerebral 
hemispheres (Conomy, 1980). Damages in cerebral vasculature may be also associated 
with at least one form of dementia, defined as an irreversible and usually progressive loss 
of cognitive and intellectual functions (Lee, 1989). A significant impairment of attention 
span and vigilance was reported in untreated hypertensive patients compared with the 
normotensive patients (Boller et al., 1977). Therefore, high blood pressure is indirectly an 
important risk factor for cognitive decline later in life. 
As mentioned above, autoregulatory mechanisms are altered in chronic hypertension. 
Some of these changes are compensatory and beneficial, since the normotensive patients 
are more susceptible to hypertensive encephalopathy from sudden pressure rise than 
hypertensive patients (Lee, 1989). Others changes are not beneficial and predispose the 
individual to ischemia and stroke. Blockade of angiotensin II formation or bradykinin 
degradation, with ACE inhibitors, prevents and reverses these alterations, improves 
tolerance to hypotension (Torup et al., 1993) and protects against focal cerebral ischemia 
in spontaneously hypertensive rats (SHR) (Hajdu et al., 1991; Fujii et al., 1992). In a similar 
way, acute administration of candersartan - a potent AT1 receptor antagonist - in SHR 
shifts their cerebrovascular autoregulatory response, in the direction of lower BP 
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(Vraamark et al., 1995). In summary, chronic hypertension is clearly damaging the 
cerebral vasculature and has been termed the “preeminent precursor of stroke”(Lee, 
1989). 
 
V. Signalling in hypertension 
Evidence from clinical and basic research has demonstrated that the functional changes 
evoked by a primary increase of sympathetic activity and blood pressure elicit signalling 
changes which are intimately implicated in the regulation of adaptive events in 
hypertension including those related to peripheral artery resistance, vasodilation, 
contraction and vascular tone. There is an extensive bibliography on this subject but only 
those directly related to the core of the present work will be mentioned. These include 
natriuretic peptides, angiotensin II and other elements of the renin angiotensin 
aldosterone system (RAAS), endothelin-1, redox and mitochondrial factors, all of them 
being particularly involved in essential hypertension pathogenesis. 
 
V a. Renin-angiotensin-aldosterone system (RAAS) 
Angiotensin II (Ang II) is the major peptide hormone of the RAAS having a critical role in 
the control of cardiovascular homeostasis, including mediation of peripheral artery 
resistance, vasodilation, contraction, and vascular tone. Ang II function is mediated by the 
AT1 and AT2 receptors, the first type activating several cytoplasmic signalling pathways, 
which contribute to vascular remodeling by inducing hypertrophy, hyperplasia and 
migration of vascular smooth muscle cells (SMCs) together with endothelial dysfunction 
(Touyz & Schiffrin, 2000). Ang II through the AT1 receptor activates small GTP binding 
proteins that appear to play important roles in mediating cardiovascular remodeling 
induced by Ang II, in particular RhoA which is a regulatory factor of cytoskeletal dynamics, 
transcription, cell cycle progression and cell transformation (Yamakawa et al., 2000; 
Ohtsu et al., 2006b). On the other hand, RhoA and ROCK, its downstream effector, seem 
to exert a negative regulatory effect on eNOS gene expression by inducing a 
destabilization of eNOS mRNA and a positive regulatory effect on ET-1 transcription 
favoring vascular occlusion (Barandier et al., 2003). The pair RhoA-ROCK is also involved in 
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the regulation of the endothelial barrier dysfunction and enhanced contraction of 
vascular smooth, the later due to an increase of myosin light chain phosphorylation (Lee 
et al., 2004). Ang II through AT1 receptor may, also, induce vascular smooth muscle 
hypertrophy through the trans-activation of epidermal growth factor receptor (EGFR, 
ErbB-1; HER1) leading to c-Fos induction and smooth muscle cells proliferation (Eguchi & 
Inagami, 2000; Eguchi et al., 2001; Kagiyama et al., 2002; Ohtsu et al., 2006a) (Fig. 1-4). By 
regulating several non-receptor tyrosine kinases, in particular, a proto-oncogene tyrosine-
protein kinase (Src) which is activated by reactive oxygen species as well as c-fos and c-
myc, Ang II is also able to control cell growth and proliferation (Berk & Corson, 1997).  
 
 
 
Figure 1-4. Diagram showing the general interactions between AngII and other co-factors to promote 
target organ damage in hypertension. The mechanism of EGFR transactivation involves a metalloprotease 
which when inactivated blocks Ang II-stimulated hypertrophy. Adapted from EGFR signalling pathway. 
 
 
Ang II together with aldosterone and endothelin plays a central role in the remodeling of 
extra cellular matrix (ECM) in hypertension which is characterized by a fibroblastic 
activation and increased expression of collagen, fibronectins and integrins which leads to 
an extensive myocardial fibrosis and myocardial stiffness (Booz & Baker, 1995; Berk et al.  
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 00   Mar n- arc a et al., 2011). This condition that can be facilitated by the activation of 
RAAS and the increased activation of transforming growth factor b1 (TGF-b1) by renin and 
pro-renin (Nguyen, 2006) leads to the recruitment of vascular smooth cells, monocytes, 
and fibroblasts and stimulates a genetic program of wound repair and extracellular matrix 
(ECM) deposition, leading to perivascular fibrosis and amplification of the profibrotic 
state (Iaccarino et al., 2004). In physiological conditions, Ang II promotes the association 
of scaffolding proteins leading to focal adhesion and ECM formation. Thus, changes in 
ECM leads to modification in gene expression associated with hypertrophy and 
contractile dysfunction (Iaccarino et al.   004  Mar n- arc a et al., 2011). The Ang II 
effects described above are dependent on Ang II availability, which, in turn, depends from 
a cascade of reactions and activations, which have renin as a precursor.  
Since there is a positive correlation between the angiotensinogen levels and blood 
pressure values (Dzau & Ingelfinger, 1989; Jeunemaitre et al., 1992; el-Dahr et al., 1993; 
Nakamura & Johns, 1994; Lodwick et al., 1995; Kirby et al., 1996) several studies, both in 
animals and human subjects, have suggested that abnormalities in the regulation of 
angiotensinogen gene expression may be involved in the pathogenesis of AHT 
(Jeunemaitre et al., 1992; Kimura et al., 1992; Fukamizu et al., 1993; Caulfield et al., 1994; 
Yang et al., 1994). In fact, the angiotensinogen-deficient mouse shows low values of 
arterial blood pressure, showing the impact of angiotensinogen in the maintenance of BP 
and in the development of AHT (Pratt et al., 1989; Tanimoto et al., 1994). 
Renin is mainly produced through an enzymatic activation of pro-renin at granular cells of 
the renal juxtaglomerular apparatus. There is evidence of a relation between renal 
sympathetic nerve activity and the production and release of renin which gene expression 
is increased in SHR, an animal model of hypertension (Antonaccio et al., 1984; Samani et 
al., 1989; Nakamura & Johns, 1995). In fact, renal denervation in the rat blunted the 
increase in renal renin mRNA after long-term ureteral obstruction (el-Dahr et al., 1991). 
Similarly, renal renin mRNA levels were lower in denervated than innervated kidneys 
(Page et al., 1992) showing that tonic activity in the renal nerves could elevate renin gene 
expression. To induce the conversion of angiotensinogen to angiotensin II, renin binds to 
an ATPase H(+)-transporting lysosomal accessory protein 2, or the prorenin receptor 
(Nguyen et al., 2002; Nguyen, 2006). The pro-renin receptor activation encompasses two 
types of actions: one related directly to all processes that involve the final production of 
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Ang II and another, which reveals a specific function for renin and pro-renin independent 
of Ang II production receptor (Nguyen et al., 2002; Nguyen, 2006). In the first case, pro-
renin receptor activation increases the enzymatic activity of renin accelerating the 
production of Ang I on the cell surface and induces the non-proteolytic activation of pro-
renin contributing to Ang I production. In the second case, it involves the activation of 
signalling pathways leading to induce DNA synthesis and stimulation TGF-b (Nguyen et al., 
2002; Nguyen, 2006) which participates in a biochemical cascade leading to smooth cells 
hypertrophy and fibrosis (Iaccarino et al., 2004).  
The angiotensin-converting enzyme (ACE) cleaves Ang I and bradycinin thus interacting 
simultaneously with RAAS and the kallikrein-kinin system, that is implicated in many 
physiological and pathological processes, including blood pressure regulation, sodium 
homeostasis, inflammation and cardioprotective effects of preconditioning (Campbell, 
2001). Thus, a disturbance of ACE activity may induce vasoconstriction and salt retention. 
Aldosterone is another component of the RAAS system that modulates partially the 
vascular tone by binding to a mineralocorticoid receptor promoting the upregulation of 
Ang II receptors under conditions where the availability of endothelial NO is reduced. 
Moreover, an aldosterone excess promotes collagen deposition in blood vessels, 
enhancing vascular remodelling and peripheral blood monocytes and vascular smooth 
cells are both influenced by aldosterone to produce ROS. Interestingly, is that activated 
aldosterone mineralocorticoid receptor can activate signalling pathways in vascular 
smooth cells to which the cross-activation EGFR- and Src-dependent signalling pathways 
is needed (Callera et al., 2005; Grossmann et al., 2005; Ishizawa et al., 2005). 
 
V b. Endothelial signalling 
In hypertension, endothelium suffers functional and structural modifications losing its 
normal protective function, which includes relaxation of the vascular smooth muscle and 
a number of antiatherosclerotic actions. Endothelial dysfunction is characterized by 
significance decrease of NO availability due to an increase breakdown of NO by reactive 
oxygen species (ROS) and a reduction of NO synthesis due to a decreased eNOS activity. 
These alterations elicit a impairment of endothelial function characterized, not only, by a 
decreased ability of the endothelium to vasodilate but also by an increased ability to 
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vasoconstric when activated by several contracting factors like endothelin-1, ang II, 
cyclooxygenase (COX)-derived prostanoids (thromboxane A2, prostaglandin H2) and ROS 
(Fig. 1-5; Mar n- arc a et al., 2011).  
 
 
Figure 1-5. Angiotensin II related signalling pathways involved in endothelial dysfunction. COX1 
cyclooxygenase 1, eNOS endothelial nitric oxide synthase, ICAM-1 intercellular adhesion molecule-1, VCAM-
1 vascular cell adhesion molecule-1, ONOO− peroxynitrite  ROS reactive oxygen species, eNOS endothelial 
nitric oxide synthase. Adapted from Mar n- arc a et al.   011. 
 
ROS are not only released at the endothelial level but also at smooth muscle and 
inflammatory cells within the arterial wall. All these sources of ROS concur to the 
accumulation of peroxynitrites and NO destruction and decreased bioavailability that 
could be, at least partially, restored by the administration of antioxidants like vitamin C 
(Taddei et al., 1998). 
Endothelial derived constrictors factors (EDCF) are COX-derived products released in 
response to shear stress or to acetylcholine stimulation (Lüscher & Vanhoutte, 1986; 
Huang et al., 2000; Félétou et al., 2011) and endothelin (Verhaar et al., 1998; Barton, 
2000; Félétou et al., 2011; Ohkita et al., 2012; Kaoukis et al., 2013; Moorhouse et al., 
2013). The former, with a most relevant role in the physiopathology of endothelium-
dependent contraction, are thromboxane A2 and prostaglandin H2. They diffuse to the 
vascular smooth muscle cells and by acting on thromboxane receptors (TP) (Vanhoutte et 
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al., 2005) induce vasoconstriction which can be reversed by COX inhibitors and TP 
antagonists (Taddei et al., 1993; Virdis et al., 2007; Félétou et al., 2011).  Endothelin 
presents a dual and opposite effect depending of the type of receptors to which binds as 
ET-A receptors stimulate vascular contraction whereas ET-B receptors mediate NO 
release promoting vasodilation. In the hypertensive endothelial dysfunction ET-A 
receptors are impaired thus the observed endothelial constriction is due to ET-B 
receptors activation not regulated by ET-A mediated vasodilation (Penna et al., 2006; 
Kohan et al., 2011; Ohkita et al., 2012; Kaoukis et al., 2013; Moorhouse et al., 2013) 
 
V c. Natriuretic peptides 
The major natriuretic peptides (NP) signalling effects upon blood pressure regulation are 
the relaxation of vascular smooth cells and the antagonism of renal renin-angiotensin-
aldosterone system despite can be also involved in the earlier cardiomyocite 
differentiation as well as in the hypertensive cardiac hyperthrophy (Harris et al., 1987; 
Calderone et al., 1998; Gambaryan et al., 1998; Ellmers et al., 2002; Lumsden et al., 2010; 
Hayek & Nemer, 2011; Kohan et al., 2011).  
This peptide family which acts through NPR-A, NPR-B and NPR-C receptors, includes three 
structurally related peptides: atrial natriuretic peptide (ANP) produced in the atria, a 
ventricular natriuretic peptide (BNP) produced by the ventricles and a C-type natriuretic 
peptide (CNP) which does not show direct natriuretic activity but is rather a potent 
arterial and venodilator and a chrono and inotropic agent by its selective agonism for the 
NPR-B and NPR-C receptors to which it is the sole ligand (Lumsden et al., 2010; Hayek & 
Nemer, 2011).  
There is a close association between natriuretic peptides and the geometric arrangement 
of the sarcomeres of cardiac muscle fibers under stress. Upon a response to an increase 
in systolic load, the new sarcomeres will be arranged in parallel to provide an increase of 
cardiac muscle fibre and a concentric pattern of cardiac hyperthrophy characterized by an 
increase in ventricular wall thickness and reduction of chamber volume is observed. 
However, when the load stress is persistent, like in the great majority of hypertensive 
patients, the diastolic dysfunction will induce the formation of new sarcomeres 
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rearranged in a series pattern promoting an eccentric pattern of cardiac hypertrophy 
characterized primarily by an increase in chamber volume and a modest increase in 
ventricular wall thickness. All these sarcomeric changes underline rearrangements at 
cellular and molecular level. During heart development, the proliferative ability of the 
cardiomyocites is lost and important qualitative changes in the expression of the cardiac-
specific genes will occur (Zak, 1974; Nadal-Ginard & Mahdavi, 1989). These include 
downregulation of fetal genes encoding fetal contratile proteins like skeletal -actin and 
-myosin heavy chain together with a decrease expression of ANP-mRNA in the 
myocardium (Nadal-Ginard & Mahdavi, 1989). In animal models, the rise of afterload lead 
to an increase of cardiac mass and to the expression of genes reminiscent of the 
embryonic heart which include those related to contractile proteins and ANP-mRNA 
(Mercadier et al., 1981; Schiaffino et al., 1989). Coincident with these changes is the 
downregulation of the adult specific gene sarcoplasmic reticulum Ca2+ATPase (SERCA2) 
(de la Bastie et al., 1990).  
The adaptive response which is the change from  to -myosin heavy chain leads to a 
decreased myosin ATPAse activity and contractile response for the heart (Mercadier et 
al., 1981) thus, reducing the usage of ATP in the presence of a greater work load and 
oxygen demand (Katz, 1990). The increase of ANP-mRNA observed in both types of 
cardiac hyperthrophy could represent a counter regulatory mechanism due to the anti-
hyperthrophic and antifibrotic actions of natriuretic peptides (Harris et al., 1987; 
Calderone et al., 1998; Gambaryan et al., 1998; Ellmers et al., 2002; Lumsden et al., 2010; 
Hayek & Nemer, 2011; Kohan et al., 2011). SERCA2 mRNA down-regulation is in part 
responsible for abnormal Ca2+ handling at the sarcoplasmatic reticulum and the following 
impairment of myocardial relaxation observed in concentric hyperthrophy (de la Bastie et 
al., 1990). However, if the re-expression of ANP-mRNA could be considered a conserved 
molecular event of pathological cardiac hyperthrophy, the changes between the different 
types of contractile proteins seem to depend on the hemodynamic stimulus as in animal 
studies, where the primary stimulus for hyperthrophy was increase of volume rather than 
the increase in pressure, were not observed modifications on the expression of -myosin, 
-actin or the reciprocal down-regulation of SERCA2 (Calderone et al., 1998). This 
different behaviour indicates may indicate that at mRNA level these genes can be 
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regulated differently according to the characteristics of the stimulus and that the 
expression of ANP-mRNA could be secondary and dependent on the hyperthrophic 
growth of the cardiomyocites. This contrasts with the regulation of -actin, -myosine 
and SERCA2 mRNA which seems to be less conserved events on the hypertrophic process 
and more stimuli specific. 
 
V d. Redox and mitochondrial signalling  
Reactive oxygen species (ROS) are elevated and affect the vessels by targeting several 
signalling cascades that are related to cell proliferation, differentiation and cell death 
(Ushio-Fukai et al., 1998; Touyz et al., 2001). In hypertension, their major sources are 
xanthine oxidize, uncoupled endothelial NO synthase and NAD(P)H oxidize which are 
activated by Ang II and the shear stress (Seshiah et al., 2002; Landmesser et al., 2003; 
Lassègue & Clempus, 2003). As mentioned before, the activation of redox-sensitive 
tyrosine kinases may mediate some of the vascular changes that occur in hypertension as 
ROS can mediate Ang II transactivation of EGFR. However, direct targets of ROS are 
protein tyrosine phosphatases (PTP) which together with tyrosine kinases control the 
level of phosphorylation in cells (Stoker, 2005). The redox regulated pathways are 
implicated in the arterial remodeling with the induction of the expression of pro-
inflammatory molecules leading to the recruitment of inflammatory cells like IL-6 and to 
vascular inflammation (Simon et al., 1998; Schieffer et al., 2000). In addition, 
experimental studies in vivo and in vitro showed that under pro-hypertensive conditions 
endothelial cells and fibroblasts express elevated amounts of molecules adhesive for 
inflammatory cells being this expression mediated by ROS (Cheng et al., 1998; Tummala 
et al., 1999; Pueyo et al., 2000).  
The pathogenesis of arterial hypertension correlates with mitochondrial dysfunction, 
which includes mitochondrial energy deficiency leading to a mild respiratory uncoupling 
in vascular smooth cells and calcium overload (Postnov, 2001; Bernal-Mizrachi et al., 
2005). From studies in both patients and animal models of hypertension was observed an 
association between hypertension and mitochondrial uncoupling proteins (UCP). In 
physiological conditions, these mitochondrial anionic transporters regulate mitochondrial 
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membrane potential and ROS generation (Bernal-Mizrachi et al., 2005). However, when 
the mitochondrial antioxidant defense system is impaired, ROS production is induced by 
the activity of monoamine oxidize by producing hydrogen peroxide, a major source of 
ROS (Youdim et al., 2006) and the production of the protein p66Sh which binds to 
cytochrome c and acts as oxidoreductase catalyzing electron transfer from cytochrome c 
to oxygen, thus generating ROS (Giorgio et al., 2005), (Booz & Baker, 1995; Berk et al.  
 00   Mar n- arc a et al., 2011) and leading to apoptosis, vascular wall remodeling and 
atherosclerosis (Napoli et al., 2003). 
 
VI. Diagnosis and Treatment recommendations according to the 
ESH/ESC Guidelines 
The evaluation of hypertension involves blood pressure measurements, a medical history 
and physical examination and routine laboratory studies (Katakam et al., 2008; Mancia et 
al., 2013). These steps can help determine the presence of end-organ disease, the 
possible causes of hypertension, cardiovascular risk factors, baseline values for judge 
biochemical effects of therapy (Katakam et al., 2008; Mancia et al., 2013). Other studies 
may be obtained on the basis of clinical findings or in individuals with suspected 
secondary hypertension and/or evidence of target-organ disease, such as complete blood 
count, chest radiograph, 12-lead ECG, serum uric acid, serum creatinine (with estimation 
of GFR) and urine microalbumin (Mancia et al., 2013).  
In the 2003 and 2007 ESH/ESC guidelines a large number of randomized trials of 
antihypertensive therapy were reviewed. They concluded that the main benefits of 
antihypertensive treatment are due to lowering of BP per se and are largely independent 
of the drugs employed (Cifkova et al., 2003; Mancia et al., 2007; Mancia et al., 2013).  
In the Losartan Intervention For Endpoint Reduction in Hypertensives (LIFE) study, left 
ventricular hypertrophy regression was linearly related to the treatment induced BP 
changes (the lower the better) (Okin PM, 2003). In Ongoing Telmisartan Alone and in 
Combination with Ramipril Global Endpoint Trial (ONTARGET), the lowest BP achieved by 
the ramipril-telmisartan combination was associated with reduced proteinuria, but with a 
greater risk of acute renal failure and a similar cardiovascular risk (Liebson & Amsterdam, 
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2009). Several studies have shown that the regression of asymptomatic organ damage 
occurring during treatment reflects the treatment-induced reduction of morbid and fatal 
cardiovascular events (Mancia et al., 2013). 
Drug classes recommended for first line therapy are diuretics (including thiazides, 
chlorthalidone  and indapamide)  β-adrenoceptor blockers, calcium channel blockers, 
angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers. All of 
them are suitable for the initiation and maintenance of antihypertensive therapy either as 
monotherapy or in some combinations (Mancia et al., 2013). In the JNC8 guidelines, the 
diuretics were preferred for initial therapy over other classes, and in the British 
guidelines  excluded β-blockers from first line use except in people with angina or heart 
failure (Ritchie et al., 2011; James et al., 2014). Recent data suggesting that diuretics, such 
as, chlorthalidone and indapamide have better evidence for reduced cardiovascular 
events in AHT, than conventional thiazide diuretics was not supported (Roush et al., 
2012). 
The 2013 ESH/ESC recommendations are based on consensus that resistant hypertensive 
patients should remove drugs that are shown not to lower BP; consider adding 
mineralocorticoid antagonist, amiloride, or doxazosin to the regimen; and consider renal 
denervation or baroreceptor stimulation if optimal drug therapy is ineffective (Mancia et 
al., 2013). However these procedures are not available in most centers and are not used 
as routine clinical therapeutic strategies (Jennings & Touyz, 2013).  
ESH/ESC guidelines recommend lifestyle modification for all patients with hypertension or 
prehypertension. Clinical studies show that the BP-lowering effects of targeted lifestyle 
modifications can be equivalent to drug monotherapy (Elmer et al., 2006). 
The recommended lifestyle modifications, that have been shown to be capable of 
reducing BP, are: reducing dietary sodium (5-6 g per day); cessation of smoking; 
moderation of alcohol consumption (to no more than 20–30 g of ethanol per day in men 
and to no more than 10–20 g of ethanol per day in women); increase the consumption of 
vegetables, fruits, and low-fat dairy products; weight reduction and maintenance (body-
mass index up to 25 kg/m2 and of waist circumference to <102 cm in men and <88 cm in 
CHAPTER 1 – ARTERIAL HYPERTENSION 
29 
women); and regular physical exercise (at least 30 min of moderate dynamic exercise on 5 
to 7 days per week) (Mancia et al., 2013). 
Patients with hypertension should be advised to eat fish at least twice a week and 300–
400 g/day of fruit and vegetables. Soy milk appeared to lower BP when compared with 
skimmed cows’ milk (Rivas et al., 2002). With regard to coffee consumption, a recent 
systematic review found that most of the available studies were of insufficient quality to 
allow a firm recommendation to be given for or against coffee consumption as related to 
hypertension (Steffen et al., 2012). 
In relation to these lifestyles changes and effect in BP, it has been shown that reduction in 
sodium to about 5 g/day has a modest (1–2mmHg) SBP-lowering effect in normotensive 
individuals and a somewhat more pronounced effect (4–5mmHg) in hypertensive 
individuals (Dickinson et al., 2006; Pimenta et al., 2009; Graudal et al., 2012). The 
Prevention And Treatment of Hypertension Study (PATHS) investigated the effects of 
alcohol reduction on BP and the intervention group had a 1.2/0.7mmHg greater reduction 
in BP than the control group at the end of the 6-month period (Cushman et al., 1998). In a 
meta-analysis, the mean SBP and DBP reductions associated with an average weight loss 
of 5.1 kg were 4.4 and 3.6 mmHg, respectively (Neter et al., 2003). Another meta-analysis 
of randomized controlled trials has shown that aerobic endurance training reduces 
resting SBP and DBP by 3.0/2.4mmHg overall and even by 6.9/ 4.9mmHg in hypertensive 
participants (Cornelissen & Fagard, 2005). 
Alternative treatments such as vitamin C, coenzyme Q10, magnesium, and omega-3 fatty 
acids have been suggested for managing hypertension, but evidence for their 
effectiveness is lacking.  
 
VII. Animal models of hypertension 
The difficulty in studying a disease process such as hypertension begins with the fact that 
the aetiology of AHT is heterogeneous and involves complex interactions between 
genetically mechanisms and environmental factors (Takahashi & Smithies, 2004; Lerman 
et al., 2005; Sarikonda et al., 2009). Therefore, several experimental models have been 
developed to mimic the many facets of human AHT. The ideal animal model for AHT 
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research should have human-like cardiovascular anatomy, hemodynamics, and 
physiology; develop the human AHT characteristics and complications; allow studies in 
chronic stable AHT; and allow measurement of relevant hemodynamic and biochemical 
parameters (Doggrell & Brown, 1998; Lerman et al., 2005). Inevitably, no species can 
consistently answer all of these needs, and experimental design and other constraints 
often dictate the choice of animal models for specific research applications. 
There are several animal models of hypertension including renal (Goldblatt model), 
pharmacological or endocrine (deoxycorticosterone (DOCA)-salt rat) and genetic (SHR or 
Dahl salt sensitive rat) hypertension (Pinto et al., 1998; Sun & Zhang, 2005) as shown in 
table 1.4. In this thesis, it was chosen the most common animal model of essential AHT, 
that is the spontaneously hypertensive rat (SHR), taking into account their characteristics 
and advantages over other models (Pinto et al., 1998). 
 
Table 1.4.  Animal models of hypertension: renal, pharmacological or endocrine and genetic 
hypertension. 
Animal model Type of AHT Description 
Goldblatt 
Renovascular 
hypertension 
Clipping of the renal artery of one kidney with the other 
kidney removed (one kidney one clip) or retained (two 
kidney one clip).  Can be carried out in different species 
including dog and rat. 
DOCA-salt 
Endocrine or 
pharmacological 
hypertension 
Large doses of deoxycorticosterone (DOCA) along with 
salt and often removal of one kidney are used to induce 
hypertension 
Ren2 
over expression 
Transgenic 
hypertension 
Over expression of the mouse Ren2 gene in the rat 
causing an increase in renin and is related to severe 
hypertension 
Sinoaortic 
denervation (SAD) 
Neurological 
hypertension 
SAD results in chronic hypertension in several species, 
including dog, cat, baboon and rabbit. 
Dahl salt sensitive 
rats 
Dietary/genetic 
hypertension 
Genetic predisposition to develop severe hypertension 
following high salt intake 
SHR 
Genetic 
hypertension 
Hypertension develops with age (see text for further 
details) 
Stroke prone SHR 
Genetic 
hypertension and 
cardiovascular 
disease 
Related to the SHR, but with higher BP and 
predisposition for stroke (Nabika et al., 2004) 
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The SHR strain was derived from the Wistar-Kyoto (WKY) rats and their WKY inbred non-
hypertensive controls (Okamoto & Aoki, 1963). However it is important to focus that the 
SHR is not strictly an inbred strain, so there is still some genetic variability between 
breeding colonies from different establishments (Nabika et al., 1991) and not all SHR 
necessarily develop hypertension. The SHR does not require surgical or pharmacological 
intervention to develop hypertension (unlike the Goldblatt or DOCA-salt models) (Zicha & 
Kunes, 1999) and is recognized as an excellent model of experimental AHT that can be 
used in clinical studies as a model of human essential AHT (Trippodo & Frohlich, 1981). 
The SHR is born normotensive and systolic blood pressure (SBP) gradually increases from 
three weeks of age, becoming hypertensive by six weeks of age compared to age-
matched normotensive controls (Dickhout & Lee, 1998). At 12 weeks of age, SBP is 
maintained at 180-200 mmHg in the SHR, whereas, the age-matched WKY has a SBP of 
115-130 mmHg (Pinto et al., 1998). According to Pinto et al., the SHRs older than 12 
weeks of age reached a plateau phase (Pinto et al., 1998). In the early stages of 
hypertension, SHR have an increased cardiac output, with normal total peripheral 
resistance (TPR). Since the SHR progresses into the established hypertension state, the 
cardiac output returns to normal values and the hypertrophied blood vessels induce a 
TPR increase (Smith & Hutchins, 1979). The SHR also displayed increased heart rate (HR) 
from two weeks old, reduced baroreflex sensitivity and increased chemoreflex sensitivity 
(Przybylski, 1981; Hayward et al., 1999). With the progress of hypertension, the SHR 
progressively develops (between 6 and 24 months of age) structural alterations in the 
heart, which are associated with progressive cardiac hypertrophy (Engelmann et al., 
1987). As this is not a strictly inbred strain, individual variations in the genetic background 
of both SHR and particularly of their control strain may significantly influence the 
resulting end-organ changes (Pinto et al., 1998). 
This animal model has the advantage of being commercially available and has been 
extensively studied, so it is physiologically well characterized. Moreover, it is a chronic 
stable model, producing symptoms which are predictable and controllable (Doggrell & 
Brown, 1998). For presenting a relative short life (the normal life spans of SHR is 1.5–2.5 
years vs 2.5–3 years of WKY), being small, have relatively low cost and easy maintenance 
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in animal houses, the SHR are frequently used to study the genetic determinants and the 
pathophysiological changes in the essential hypertension (Folkow & Svanborg, 1993). 
Another advantage of the SHR is that it follows the same progression of hypertension as 
human hypertension with pre-hypertensive, developing and sustained hypertensive 
phases, with each phase lasting at least several weeks (Folkow, 1993). However the SHR 
differs from human hypertension in that SHR reproducibly develop hypertension in young 
adulthood rather than in middle age as in humans (Doggrell & Brown, 1998). The SHR also 
have other similarities to human essential hypertension: the AHT is multi-factorial, 
involving a neurogenic component (increased sympathetic nerve activity and total 
peripheral resistance) and responds to anti-hypertensive drugs prescribed to human 
patients (Pinto et al., 1998).  As in humans, hypertension develops more rapidly and 
becomes more severe in male than female SHR (Iams et al., 1979; Maris et al., 2005). So 
the male SHR is more commonly used as a model of established human hypertension 
(Doggrell & Brown, 1998).  
Moreover, the slow onset of disease in SHR allows the investigation of these animals 
before the onset of hypertension. This allows researchers to differentiate between 
changes that are the cause and those that are secondary to the onset of hypertension. It 
also allows the study of therapeutic agents to prevent the development of hypertension 
in the SHR, as well, as investigations of possible drugs that can minimize or reverse 
established hypertension in adult SHR.  
The common criticism of the SHR model is the doubt about the cause of the onset of the 
disease. However, the genetic mechanisms of hypertension in SHR have been frequently 
attributed to both neural and vascular alterations observed in these animals (Lerman et 
al., 2005). 
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1.2  PATHOPHYSIOLOGY OF NEUROGENIC HYPERTENSION 
 
I. Hypertension and Sympathetic Nervous System 
I a.  "Neurogenic" Essential Hypertension: Historical Antecedents 
The historical antecedents help us to understanding the importance of sympathetic 
nervous system (SNS) pathophysiology in the pathogenesis of essential hypertension: 1st) 
the anatomical description of sympathetic nerves and ganglia and their identification as 
pressor nerves; 2nd) surgical sympathectomy as an antihypertensive therapy; 3rd) 
identification of noradrenaline as a sympathetic transmitter; 4th) development of anti-
adrenergic antipertensive drugs; 5th) techniques developed for measuring human 
sympathetic activity and 6th) SNS activation demonstrated in AHT (Parati & Esler, 2012). 
Thomas Willis discovered the workings of the sympathetic nervous system and presented 
the findings in “The Anatomy of the Brain and Nerves” (Zimmer, 2004). They identified 
these as blood pressure-raising "pressor nerves", suggesting, for the first time, that they 
might cause AHT. 
In the early decades of the twentieth century, with the high mortality of severe AHT and 
with no effective pharmacological treatment, a number of operations on the sympathetic 
nervous system were devised in order to lower BP. The radical lumbodorsal 
splanchnicectomy, developed in 1938 by Smithwick and co-workers (Smithwick et al., 
1956), which incorporated surgical section of accessible nerves in the thorax and 
abdomen and transaction and clipping of the sympathetic chain, lowered the BP and 
reduced the mortality, but at the cost of often incapacitating side effects, particularly 
disabling postural hypotension.  
By the late 1960s, it had been demonstrated that in the developmental phase of essential 
hypertension, cardiac output and heart rate were commonly elevated, intimating the 
presence of probable sympathetic nervous system activation (Julius & Conway, 1968). 
Another study demonstrated that this increase of cardiac output in the early phases of 
essential hypertension is gradually converted, over the course of many years, to the 
hemodynamic pattern of normal cardiac output and high vascular resistance, considered 
typical of the hypertensive condition (Lund-Johansen, 1989).  
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Therefore the idea of neurogenically mediated hypertension has emerged. So the 
majority of antihypertensive drugs entering clinical practice that antagonized the 
autonomic nervous system were ganglionic blockers or drugs that specifically antagonized 
its sympathetic division, like central sympathetic inhibitors, such as methyldopa and 
clonidine, sympathetic neuronal blockers, such as guanethidine, and alpha- and beta-
adrenergic blockers (Parati & Esler, 2012). The effectiveness of these drugs showed that 
the SNS was important in the pathogenesis of essential hypertension. 
The antihypertensive drugs used most widely, ranking highest in international treatment 
guidelines, include the angiotensin receptor blockers, angiotensin-converting enzyme 
inhibitors, calcium channel blockers, and diuretics. Antiadrenergic drugs are not 
prominent in the guidelines, because the currently available antiadrenergic drugs produce 
frequent metabolic and other adverse effects and are less effective, since they tend to 
reduce rates of myocardial infarction and stroke less than the first-line drugs. 
 
I b. Activation of the Sympathetic Nervous System in Essential 
Hypertension 
The role of the SNS in the pathogenesis of AHT only became clear in the last few years. 
Until a few decades ago it was thought that the SNS acted mainly in the control of BP in 
the short term, having almost no influence on their long term control, being exercised 
primarily by control of salt and water balance, through the renin-angiotensin-aldosterone 
system.  
However, in the last 20 years due to the refinement of the assessment of sympathetic 
cardiovascular function, the concepts regarding the role of the SNS in the regulation of BP 
were drastically altered (Mark, 1996).  
At present, it is known that overactivity of the SNS contributes to the onset, development 
and maintenance of hypertension (Guyenet, 2006; Tsioufis et al., 2011). In fact, studies in 
humans and animals clearly demonstrate an increased sympathetic nerve activity in the 
hypertensive state (Grassi, 2004b; Guyenet, 2006; Fisher & Paton, 2012). The same was 
not observed in subjects with secondary hypertension (Grassi et al., 1998; Grassi, 2004a, 
2009). 
CHAPTER 1 – ARTERIAL HYPERTENSION 
35 
The increase of sympathetic outflow to the heart results in increased cardiac output and 
neurally mediated vasoconstriction leading to elevated blood pressure values (Schlaich et 
al., 2012). Excessive sympathetic activity may also contribute to vascular smooth and 
cardiac muscle hypertrophy, organ hypoperfusion and inflammation (Zubcevic et al., 
2011).   
In white coat and borderline hypertensive patients, the sympathetic nerve activity to the 
arterioles supplying skeletal muscle is already raised compared to healthy individuals 
(Grassi, 2004a; Smith et al., 2004). Also in normotensive subjects with family history of 
AHT the activity of the SNS is increased (Yamada et al., 1988). These data seem to suggest 
that the excitation of the sympathetic nervous system precedes the onset of 
hypertension and that may be the cause of this condition.  
Furthermore, it is established, after several studies, that the activity of the SNS increases 
progressively and in parallel with the stages of AHT (Smith et al., 2004; Tsioufis et al., 
2011). 
The sympathetic fibres’ recording from the renal plexus and the measurement of the 
spillover of norepinephrine demonstrated that the efferent SNS to the kidneys, heart and 
vasculature of skeletal muscle duplicate in individuals with essential AHT compared to 
normotensive individuals (Esler et al., 1988; Grassi et al., 1998; Petersson et al., 2002; 
Schlaich et al., 2004; Lambert et al., 2007). 
Studies in obese patients showed that there is renal sympathetic activation with a 
minimal involvement of sympathetic outflow to the heart. In fact, in many obese 
hypertensive patients cardiac norepinephrine is reduced (Rumantir et al., 1999).  On the 
other hand, in normal-weight patients with hypertension, both cardiac and renal 
sympathetic outflows are activated (Esler et al., 1985; Esler et al., 1988; Rumantir et al., 
1999). 
Single-fibre sympathetic recording demonstrates increased CNS sympathetic outflow, 
with increased fibre-firing frequencies and multiple firings within a cardiac cycle, not seen 
in health conditions (Greenwood et al., 1999; Lambert et al., 2007). 
It is estimated that the AHT with neurogenic cause is no less than 50% of all cases of 
essential AHT. This is based the proportion of untreated patients with essential 
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hypertension who have demonstrable sympathetic excitation, and in the number in 
whom substantial BP lowering is achieved, as well as the extent of this lowering with anti-
adrenergic drugs (Parati & Esler, 2012). 
Recent evidence also suggests that afferent sensory nerves from the kidneys that project 
to the brain are an important source of sympathetic activation. In fact, in patients with 
resistant hypertension that respond inadequately to concurrent treatment with multiple 
antihypertensive drug classes, ablation of the renal sympathetic nerves with an 
endovascular radiofrequency technique lowered blood pressure remarkably (Krum et al., 
2009; Esler et al., 2010).  
Activation of the renal sympathetic nerves has been seen to be pivotal. The introduction 
of radiofrequency renal sympathetic nerve ablation as an effective treatment for patients 
with essential hypertension now adds compelling empirical evidence (Krum et al., 2009; 
Esler et al., 2010).  
So, the reduction of the enhanced sympathetic activity has been considered as an 
antihypertensive strategy (Del Colle et al., 2007; Biaggioni, 2008; Signolet et al., 2008; 
Fisher & Fadel, 2010; Grassi et al., 2010). However, the mechanism of sympathetic 
activation in AHT is not well known.  
The specific causes of the increased sympathetic activity in essential AHT remain 
enigmatic, although it is known that the interaction of genetic influences with behavioural 
and lifestyle factors are important.  
Genetic influence on sympathetic activity in essential AHT may be polygenetic and thus 
more difficult to identify, perhaps involving interactions of overweight, mental stress and 
dietary sodium intake with the SNS (Chandola et al., 2006). However, there is evidence 
that essential AHT is approximately 30%-40% heritable (Longini et al., 1984).  
Physical inactivity also appears to be important in AHT. In fact the observation that 
aerobic exercise training in sedentary people reduces sympathetic nervous activity and 
preferentially renal sympathetic outflow supports this concept (Somers et al., 1995). 
Recent experience with radiofrequency renal nerve ablation in patients with resistant 
hypertension, in which the denervation procedure reduces whole-body sympathetic 
activity, indicates that a "renal injury" signal from the kidneys to the brain must exist also 
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in these patients, contributing to the chronic sympathetic activation evident in these 
patients (Shibao et al., 2007; Schlaich et al., 2009). 
Adipokines, O2 and CO2 blood concentration, endothelial factors, aldosterone, 
angiotensin II, insulin resistance and baroreflex impairment, have also been implicated in 
sympathoexcitation. 
The hypothesis, which is the basis of this thesis, is that the hyperactivity of the SNS can be 
caused by inappropriate increase in the activity of the brain centres. Hence the 
importance of whether the silencing and/or decreased activity of central nuclei that 
coordinate sympathetic activity and that are potentially deregulated in AHT may be 
sufficient to cause changes at the peripheral level. 
In experiments that were initially designed to produce analgesia in patients with chronic 
neuropathic pain, Green et al. (2006) demonstrated that electrical stimulation of midbrain 
structures produces depressor responses. Whether these would be both powerful enough 
to off- set the high blood pressure in a hypertensive patient and persist chronically for 
effective treatment remains to be determined (Green et al., 2006).  
 
II. Hypertension and Central Nervous System 
The Central Nervous System (CNS) plays an important role in the short term control of BP, 
but its contribution to the chronic control of BP is not yet clear. In fact, research in the 
past years has been directed to essential hypertension with possible neurogenic cause. 
As mentioned above, several studies suggest that the SNS is a predominant factor for the 
development, maintenance and progression of essential hypertension. The SNS 
hyperactivity found in individuals with essential hypertension can be caused by 
inappropriate increase in the activity of sympathetic-excitatory regions of the CNS. The 
most mentioned sympathetic excitatory regions are the Paraventricular Nucleus of the 
Hypothalamus (PVN) and the Rostral Ventrolateral Medulla (RVLM), which will be 
described below. 
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II a. Paraventricular nucleus of the hypothalamus or PVN 
The paraventricular nucleus (PVN) is a major sympatoexcitatory area, that becomes more 
active under conditions of hypertension such as in the spontaneously hypertensive rat 
(SHR) model (Allen, 2002). Some authors have referred to this region as a command 
nucleus providing feed forward excitatory synaptic drives to coordinate lower brainstem 
cardiovascular and respiratory motor activity and where there is an integration of 
autonomic and neuroendocrine responses (Swanson & Sawchenko, 1980, 1983; Dampney 
et al., 2005).  
The PVN is also a critical component in the pathways that control the blood volume, since 
this nucleus receives afferent information from receptors located in the right atrium and 
in the inferior vena cava, which are sensitive to small (8-10%) volume changes (Lovick & 
Coote, 1988) van Giersbergen, 1992). 
The PVN is located in the forebrain and can be divided into several distinct subnuclei 
(Benarroch, 2005). In the rat, the PVN has approximately 21500 neurones arranged into 
eight subnuclei (Swanson & Kuypers, 1980; Kiss et al., 1991). It contains two different 
types of neurones: the magnocellular and parvocellular. The magnocellular neurons 
(arranged into three subnuclei) are large cells that project to the posterior pituitary where 
they synthesize and release oxytocin (OT) and vasopressin (VP) into the circulation 
(Armstrong & Hatton, 1980; Sawchenko & Swanson, 1982; Kiss et al., 1991; Benarroch, 
2005). 
VP acts upon the kidney to promote antidiuresis and upon the blood vessels to cause 
vasoconstriction. In addition, baroreceptor unloading stimulates VP release. OT is best 
known in association with reproductive functions in the female animal, such as 
parturition and milk ejection, although it is co-secreted with VP in response to osmotic 
and blood volume challenges (Hatton, 1990). It also contract blood vessels when present 
in relatively larger amounts and hence can cause increases in BP (Petty, 1987; Richard et 
al., 1991). 
Plasma OT have been shown to increase kidney sodium excretion in the conscious rats 
(Verbalis et al., 1991).  OT acts as a neuromodulator within the brainstem; when 
microinjected into the NTS, OT caused hypertension and tachycardia (Vela et al., 2010).  
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In addition, OT knockout mice were slightly hypotensive suggesting that OT plays a role in 
tonic MBP maintenance (Michelini et al., 2003).  
Smaller neurones form the parvocellular division of the PVN and can be divided into five 
subnuclei (Swanson & Kuypers, 1980). It is from amongst these neurones that projections 
arise to innervate different groups of autonomic neurones in the brainstem and spinal 
cord (Fig.1-6).  
The projections in the PVN have been identified using retrograde and anti-retrograde 
markers microinjected into the PVN, rostral ventrolateral medulla (RVLM) and/or in the 
intermediolateral (IML) cell column of the spinal cord (Ranson et al., 1998; Shafton et al., 
1998; Motawei et al., 1999; Pyner & Coote, 1999, 2000; Pyner et al., 2001). In the end, 
these projections synapse on their effector organs - the heart, blood vessels and kidneys. 
The PVN project to regions such as the nucleus tractus solitari (NTS), dorsal motor nucleus 
of the vagus (DMNV), periaqueductal gray (PAG), parabrachial nucleus (PBN), RVLM, 
caudal ventrolateral medulla (CVLM) and intermediolateral (IML) cell column (Fig. 1-6) 
(Swanson & Kuypers, 1980; Luiten et al., 1985; Holstege, 1987; Michelini & Morris, 1999; 
Pyner, 2009).  
The parvocellular cells secrete vasopressin and corticotropin-releasing hormone (or 
corticotrophin releasing factor, CRF) (Engelmann et al., 2004). These hormones are 
released in pulses into the hypophyseal portal system by the parvocellular neurones 
approximately every 30 minutes (Engelmann et al., 2004; Benarroch, 2005). The release 
of CRF also promotes the release of adrenocortico tropic hormone (ACTH) from the 
adenohypophysis (Sawchenko, 1987b, a). 
The parvocellular neurones seem to form three separate projections that modulate the 
activity of the SNS (Pyner, 2009). There are direct projections from the PVN to the RVLM 
and from the PVN to the IML and an indirect projection, which goes to RVLM and the IML, 
both critical regions in the control of the SNS (Dampney, 1994; Badoer et al., 1997; 
Badoer, 2001). 
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Fig. 1-6. Diagram illustrating the principal autonomic efferent projections from the PVN (A, B) and the 
autonomic afferent inputs to the PVN (C). PVN, paraventricular nucleus; LH, lateral hypothalamus; Arc, 
arcuate nucleus; AV3V, anteroventrolateral region of 3
rd
 ventricle; LPBN, lateral parabrachial nucleus; 
RVLM, rostral ventrolateral medulla; CVLM, caudal ventrolateral medulla; Sp Cord, , thoraco-lumbar spinal 
cord; PAG, periaqueductal grey; NTS, nucleus tractus solitari; DMNV, dorsal motor nucleus of the vagus; NA, 
nucleus ambiguous; VP, vasopressin; CRF, corticotrophin releasing factor; Ang II, Angiotensin II; GLU, 
glutamate; OT, oxytocin; DA, dopamine; ORX, orexin; NPY, neuropeptide Y; AGRP, agouti related protein. 
Adapted from John Coote, Neural mechanisms of cardiovascular regulation, 2004.    
 
Hence the PVN is considered one of the five major groups of sympathetic premotor 
neuronal cells (Strack et al., 1989; Dampney, 1994) and due to its connections with RVLM 
also influences the vasomotor sympathetic nerve discharge (Shafton et al., 1998; Yang & 
Coote, 1998). 
In fact the PVN appears to be involved in the regulation of sympathetic activity (Coote, 
2005). For example, electrolytic lesions of the PVN in SHR causes a decrease in BP, and 
this decrease was associated with reduced SNS activity which occurred without changes 
in the secretion of VP (Takeda et al., 1991). 
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In addition, microinjection of muscimol in the PVN in SHR and in Dahl salt-sensitive rats 
resulted in a decrease in MBP and caused a reduction in the SNS activity without affecting 
the MBP of their control animals (Allen, 2002; Ito et al., 2003). However, there are 
conflicting results regarding the BP observed in conscious and anesthetized rats (Badoer 
et al., 2002; Li et al., 2007). Other studies show that GABAergic synaptic inputs to the PVN 
inhibit the sympathetic tone and BP (Decavel & Van den Pol, 1990; Zhang & Patel, 1998; 
Zhang et al., 2002). In contrast, PVN microinjection of bicuculline (a GABAA receptor 
antagonist) or glutamate elevated sympathetic nerve activity causing hypertension in 
anesthetized and conscious rats (Kannan et al., 1989; Zhang et al., 2002). 
PVN lesions or the transection of the brain caudal to the hypothalamus promotes a 
decrease in blood pressure in SHR but not in WKY rats (Yamori & Okamoto, 1969; Goto et 
al., 1981; Ciriello et al., 1984; Herzig et al., 1991; Takeda et al., 1991).  
In the PVN-spinal sympathetic pathway there is now convincing evidence that VP and OT 
act as neurotransmitters, since both peptides depolarise sympathetic preganglionic 
neurones recorded in vitro in slices of spinal cord (Ma & Dun, 1985; Sermasi & Coote, 
1994; Desaulles et al., 1995; Kolaj & Renaud, 1998). Also, VP or OT applied 
iontophoretically alter the firing rate of cardiovascular-like sympathetic preganglionic 
neurones (Gilbey et al., 1982; Backman & Henry, 1984). Furthermore, VP or OT given 
intrathecally to the thoracic cord increase activity in renal sympathetic nerves (Porter & 
Brody, 1986; Tan & Tsou, 1986; Riphagen & Pittman, 1989a; Malpas & Coote, 1994; Yang 
et al., 2002). It has also been shown that pressor responses or increases in renal 
sympathetic nerve activity elicited by PVN stimulation can be selectively blocked by 
intrathecally applied V1a antagonist (Riphagen & Pittman, 1989b; Malpas & Coote, 1994; 
Yang et al., 2002). However, it was not possible to show the PVN-OT dependent effect on 
renal sympathetic outflow (Yang et al., 2002). One hypothesis is that the OT pathway 
terminates on different target specified sympathetic neurones compared to the VP 
pathway. In fact, there also appears to be a difference in the sensitivity of sympathetic 
neurones to the peptides: some neurones in the upper thoracic segments display 
selective action to OT, whereas on neurones in the lower thoracic segments wich are 
especially sensitive to VP (Sermasi & Coote, 1994; Desaulles et al., 1995).    
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The PVN-NTS pathway is involved in homeostasis and responses to stressful situations 
(Engelmann et al., 2004). Stimulation of this pathway causes the synthesis and release of 
VP and OT into the blood stream (Loewy & Spyer, 1990b). There is also persuasive 
evidence that part of the PVN-NTS projection inhibits arterial baroreceptor reflex 
transmission, since microinjection of the VP or OT peptides causes an increase in BP and 
HR (Matsuguchi et al., 1982). Also, lesions of the PVN increase a baroreceptor-induced 
inhibition of lumbar sympathetic nerve activity (Darlington et al., 1988; Patel & Schmid, 
1988). 
Relative to the PVN-RVLM pathway it has been shown that the activation of PVN 
neurones induce sympathoexcitatory and pressor responses via excitatory connections 
with RVLM (Coote et al., 1998; Yang & Coote, 1998). It also appears that glutamate (GLU) 
and VP neurons, as well as other PVN neuronal phenotypes are important in the RVLM 
(Gómez et al., 1993; Yang et al., 2001). Terminals of PVN neurones containing CRF have 
been demonstrated in the RVLM region and bilateral microinjection of CRF into this 
region increases BP (Milner et al., 1993). There is also evidence that the PVN can excite 
neurones in the RVLM by activation of angiotensin receptors, but is not clear how direct 
this pathway is (Tagawa & Dampney, 1999; Tagawa et al., 2000). 
The PVN also receives projections from the caudal ventrolateral medulla (CVLM) - the 
PVN-CVLM pathway - and the neurons in this area also receive inputs from neurones in 
the NTS (Kawano & Masuko, 1996). This suggests that the NTS has a direct and an indirect 
(which includes CVLM) projection to the PVN (Kawano & Masuko, 1996). In a study that 
experimentally induced hypotension resulted in c-fos expression in the PVN neurones 
that project to the NTS and to the CVLM, indicating that these connections are reciprocal 
(Krukoff et al., 1997).  
Similarly, distinct descending projections to the dorsal motor vagus (DMV), the nucleus 
ambiguous (NA) and the NTS provide the anatomical substrate for PVN influences on 
parasympathetic activity and baroreflex control, respectively (Armstrong et al., 1980; 
Swanson & Kuypers, 1980; Ranson et al., 1998). 
It is well established that the parvocellular neurones in the PVN influence food intake and 
energy expenditure (Woods & D'Alessio, 2008) and these same neurones also express 
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receptors of Ang II type1 (AT1) (Lenkei et al., 1997). It is known that these receptors play 
an important role in AHT, however, the central mechanisms by which these receptors 
contribute to sympathetic-excitation remain unclear. 
Results of one study indicated that the increased activity of AT1 receptors in the PVN 
contributes to the increase of afferent sympathetic reflex and the cardiac sympathetic-
excitation in rats with renovascular hypertension (Chen et al., 2011). Another study shows 
that blockade of AT1 receptors in the PVN reduces renal sympathetic excitation induced 
by central hyperosmolality (Chen & Toney, 2001). 
Thus, through modulatory actions on the baroreceptor reflex, sympathetic and 
parasympathetic nerve activity, the PVN is in a pivotal position to contribute to the short 
and long-term control of the cardiovascular system. 
 
II b. Rostral Ventrolateral Medulla or RVLM 
The RVLM lies ventral to the rostral part of the nucleus ambiguous (NA) and to the 
Bötzinger complex and caudal to the facial nucleus (Dampney, 1994; Janig, 2006b).  
The RVLM neurons project to the sympathetic preganglionic neurones in the 
intermediolateral (IML) cell column of the spinal cord (Guertzenstein & Silver, 1974; 
Dampney, 1994; Leman et al., 2000; Card et al., 2006b) and receive a direct glutamatergic 
projection from the NTS, believed to be part of the peripheral chemoreflex (Ross et al., 
1985; Koshiya & Guyenet, 1996b; Nosjean et al., 1998).  There are also projections from 
the PVN to the RVLM (Kantzides & Badoer, 2005; Pyner, 2009) (see IIa).   
The RVLM plays an important role in BP control. In fact it has been shown that electrical 
or chemical stimulation (with glutamate) causes an increase in BP and HR in the cat 
(Guertzenstein & Silver, 1974) and in the rat (Ross et al., 1984). On the other hand, 
inhibition of RVLM in the conscious rat causes a chronic decrease in BP, HR and in the SNS 
activity (Dampney, 1994; Kishi et al., 2001).  
Previous studies suggested that in SHRs there is an increased excitatory drive from RVLM 
neurons that is associated with an elevated sympathetic outflow (Bergamaschi et al., 
1995; Ito et al., 2000, 2001; Ito et al., 2002; Ito et al., 2003). It was also shown that the 
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RVLM of SHR has a higher density of AT1 receptors (Hu et al., 2002) and the blockade of 
these receptors in this area causes an increase in baroreflex sensitivity (Gao et al., 2004) 
and a reduction in BP (Ito et al., 2002) in SHR rats but not in WKY controls.  
The RVLM of rats shows some viscerotopic organization according to the type of 
sympathetic preganglionic neurons it projects to (Beluli & Weaver, 1991; Dampney, 1994; 
McAllen & May, 1994). Sympathetic renal vasoconstrictors premotor neurones are 
located in the rostral area of the RVLM and the sympathetic visceral vasoconstrictive 
premotor neurones are more caudal (Janig, 2006a). This RVLM connection with the 
sympathetic preganglionic neurones is vital in maintaining the basal BP. In anesthetized 
animals, acute bilateral lesions of the RVLM result in a decrease in BP (Guertzenstein & 
Silver, 1974; Dampney & Moon, 1980). Little is known about the role of RVLM after 
chronic lesions in conscious rats. 
Figure 1-7 illustrates the neurons responsible for maintaining BP. There is a small nucleus 
in the rostral part of the RVLM in rats that are important, since any intervention that 
decreases or eliminates its normal function causes an acute decrease in sympathetic 
activity, all sympathetic reflex activity is eliminated and BP decreases to a level similar to 
that seen after high spinal cord transection (Schreihofer et al., 2005; Braga et al., 2007). 
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Figure 1-7. A diagram of pathways in the regulation of the cardiorespiratory system. (a) all pathways 
overlapped. The bulbospinal red pathways are in the RVLM and integrate information from the centre and 
the periphery. The output from this nucleus is crucial for maintaining normal sympathetic tone. PBN, 
parabrachial nucleus; DMH, dorsomedial hypothalamus; CVLM, caudal ventrolateral medulla; VLM, 
ventrolateral medulla; rVRG, rostral ventral respiratory group; CPA, caudal pressor area; MCPA, medullo 
cervical pressor area; IML, intermediolateral cell column; RVMM, rostral ventromedial medulla; VII, facial 
nucleus; RTN, retrotrapezoid nucleus; preBöt, preBötzinger neurons; VN, vestibular nucleus. (b) The 
baroreflex pathway is shown on its own. Stretch receptor afferent neurons from the aortic arch and carotid 
sinus and the neurons synapse in the nucleus tractus solitarius (NTS). Neurons in the NTS then activate 
inhibitory neurons (blue) in the caudal ventrolateral medulla, which in turn inhibit the neurons in the RVLM; 
this intense gamma-aminobutyric acid (GABA)-mediated inhibition inhibits sympathetic outflow, causing 
blood pressure and sympathetic nerve activity to fall. Note also the yellow respiratory neurons that 
modulate the activity of the cardiovascular neurons (also in c). (c) The pathways for peripheral and central 
chemoreceptors are shown. Peripheral chemoreception emanates from the carotid body. Neurons 
terminate in the medial NTS (like the baroreceptors). From here, the excitatory information passes to both 
respiratory and cardiovascular neurons. (d) The somatosympathetic pathway is shown in an abbreviated 
form. Afferent nociceptive pathways enter the spinal cord in the dorsal roots, activate circuits locally, and at 
several stations throughout the neuraxis including the RVLM. This pathway is excitatory and results in the 
appearance of a variable number of peaks in sympathetic nerve activity, depending on which nerve is 
recorded from. In the case of the greater splanchnic nerve, this is generally two peaks. Adapted from 
Pilowsky PM, Differential regulation of the central neural cardiorespiratory system by metabotropic 
neurotransmitters, 2009. 
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About 50-70% of the neurons of RVLM are part of the C1 catecholaminergic group (Sved 
et al., 1994; Schreihofer & Guyenet, 1997; Madden & Sved, 2003a). The C1 cells are 
excitatory neurons whose ongoing discharges are essential to maintain resting 
sympathetic tone and BP.  
These neurons are highly active at rest and powerfully inhibited by activation of arterial 
baroreceptors. However, it should be noted that both C1 and non C1-catecholaminergic 
neurones expressed mouse C-fos in response to hypotension, suggesting that both cell 
types are barosensitive (Chan & Sawchenko, 1994; Sved et al., 1994).  
Furthermore, in most instances, the C1 cells display a discharge pattern that is highly 
correlated with that of the sympathetic efferents that innervate the heart, kidney or 
blood vessels of the skeletal muscles and splanchnic area (Sun & Reis, 1996).   
Initially, it was believed that C1 neurons were responsible for regulating sympathetic 
vasomotor pathways through the release of adrenaline in the spinal cord (Goodchild et 
al., 1984; Ross et al., 1984), but it became clear that both C1 and non-C1 neurons also 
release glutamate (Phillips et al., 2001; Stornetta et al., 2002; Morrison, 2003).  
Glutamate is expressed in most of the barosensitive sympathetic preganglionic neurones 
that project to RVLM. The release of glutamate agonists as well as electrical stimulation of 
the RVLM caused excitation of sympathetic preganglionic neurons and this excitation 
could be blocked with glutamate antagonists (Morrison, 2003). 
The actual role of adrenaline released at the level of sympathetic preganglionic neurons 
still remains unclear (Bolme et al., 1974). The possibility is that it exerts complex effects 
depending on the post-synaptic receptor present and if an inhibitory interneuron is 
interposed (Shi et al., 1988; Coote & Lewis, 1995). 
The specific contribution of bulbospinal C1 cells to the generation of sympathetic 
vasomotor tone was showed in the anesthetized rat by a selective destruction (using an 
anti-DßH antibody) of over 80% of the C1 cells. It promoted a slight but significant (~ 10 
mmHg) BP reduction and also attenuated the sympathetic tonus involved in baroreflex 
(determined by reflex change in HR in response to a decrease in mean BP) with little 
effect on the parasympathetic tonus (Guyenet et al., 2001; Madden & Sved, 2003a, b).  
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The C1 cells project into central regions involved in cardiovascular control, including the 
PVN and the ventrolateral column of the PAG (Guyenet et al., 2001; Card et al., 2006a). 
Furthermore, some of the C1 cells of the RVLM project into chromaffin cells which control 
the release of adrenaline, whereas the barosensitive non-C1 RVLM cells control the 
release of noradrenaline by chromaffin cells (Morrison & Cao, 2000). 
The RVLM displays a tonic activity in sympathetic preganglionic neurones. The 
"pacemaker hypothesis" proposed by Guyenet was based on studies using intracellular 
recording of the RVLM in medullary slices. However, the source of this pacemaker activity 
is unknown. There are two hypotheses: 1) there are pacemaker neurones within the 
RVLM or 2) the tonic input comes from a network of other brain regions (Guyenet, 2006).  
The pacemaker properties are voltage dependent and not dependent on synaptic input. 
The pacemaker properties were attributed to the presence of a persistent sodium current 
(Kangrga & Loewy, 1995). 
The pacemaker theory is based on the observation made in brain slices of the RVLM area, 
where there were some spontaneously active cells (Sun et al., 1988a) that did not belong 
to C1 group (Sun et al., 1988b). On the other hand, other authors reported technical 
difficulties when trying to identify pacemaker and non-pacemaker C1 cells within the 
RVLM (Kangrga & Loewy, 1995). However, in vivo, it has not been possible to identify 
spontaneously active pacemaker cells in the RVLM (Lipski et al., 1996; Sved et al., 2001). 
So, based mainly on anaesthetized animals, the RVLM has been shown to be a pivotal 
area regulating cardiovascular sympathetic tone. Therefore, the increased activity of 
RVLM neurons is suspected to contribute to the increased sympathetic tone associated 
with AHT. 
 
II c. Medulla Cervical Pressure Area or MCPA 
The medullo-cervical pressor area (MCPA) is recently discovered sympathoexcitatory 
region that is located in the most ventrolateral medulla that extends caudally from the 
medulla at the level of the caudal pole of the inferior olive to the fourth cervical segment 
and contains spinally projecting neurons (which are neurochemically heterogeneous) that 
directly innervate the sympathetic preganglionic neurons (Seyedabadi et al., 2006).  
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This pressor area is distinct from the caudal pressor area (CPA), because it is not 
dependent on the integrity of the RVLM and does not appear to mediate its effects via 
suprabulbar regions but via bulbospinal sympathetic neurons in the region.  
Using retrograde tracing it was showed that MCPA neurons project to thoracic levels 
(which are neurochemically heterogeneous) that directly innervate the sympathetic 
preganglionic neurons (Seyedabadi et al., 2006). On the other hand, another study 
suggested the possibility of a projection from the MCPA to the RVLM, since chemical 
stimulation in a region in the very caudal medulla activated bulbospinal barosensitive 
neurons of the RVLM (Campos & McAllen, 1999). 
Other studies have demonstrated that bilateral RVLM blockade eliminates the 
responsiveness of the more rostrally located CPA (Gordon & McCann, 1988; Possas et al., 
1994; Natarajan & Morrison, 2000). In contrast, responses evoked from the MCPA are 
unaffected by bilateral RVLM blockade (Seyedabadi et al., 2006). Thus, it seems that the 
MCPA does not appear to play a role in maintaining vasomotor tone after RVLM blockade 
and is distinct in both location and axonal trajectory to the CPA. The role of this novel 
descending sympathoexcitatory region in central cardiovascular regulation remains to be 
elucidated. 
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CHAPTER 2 
BLOOD PRESSURE REGULATION 
 
I. Autonomic reflexes 
The autonomic reflexes are the mechanisms that regulate BP in the short term. These 
reflexes act moment to moment, in seconds or minutes. They resulted from activation of 
peripheral receptors whose afferents projecting to the central nervous system via the 
glossopharyngeal and vagus nerves (Dampney, 1994). The processing of this afferent 
information, in the CNS, produces a consequent regulation of the autonomic efferent 
pathways leading to an adjustment of the cardiovascular parameters (heart rate, stroke 
volume, and vascular resistance) (Colombari et al., 2001).  
Central control of BP involves both the sympathetic and parasympathetic nervous system 
continuously controlling BP. The BP is controlled by the action of total peripheral 
resistance (TPR) and cardiac output (CO), and this depends on heart rate (HR) and stroke 
volume (SV) [BP = COxTPR, BP = HRxSVxTPR] (Loewy & Spyer, 1990a). The sympathetic 
nervous system increases stroke volume, heart rate and total peripheral resistance which 
promote an increase in BP. The parasympathetic nervous system acts mainly on heart 
rate decreasing it, but also acts on the contraction strength of the heart, decreasing 
stroke volume, which leads to a decrease in BP (Berne, 2004). 
There are several reflexes involved in the modulation of sympathetic and 
parasympathetic activity, such as, the arterial baroreceptors, cardiopulmonary receptors 
and arterial chemoreceptors (Spyer, 1990; Sleight, 1991; Chalmers et al., 1992; Dampney, 
1994; Marshall, 1994; Vasquez, 1994; Machado et al., 1997).  
Reflexes are immediate and automatic responses of the body to an appropriate stimulus, 
without the intervention of consciousness or will. The basic unit of integrated reflex 
activity is the reflex arc (Ganong, 2005). This arc consists in 5 components: a sense organ, 
an afferent neuron, one or more synapses in a central integrating station or sympathetic 
ganglion, an efferent neuron, and an effector (Fig. 2-1; Ganong, 2005). 
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Figure 2-1. General components of a reflex arc that functions as a negative feedback control system. The 
response of the system has the effect of counteracting or eliminating the stimulus (negative feedback). 
Adapted from Vander, Sherman, & Luciano's human physiology: the mechanism of body function, 2004. 
 
The simplest reflex arc is one with a single synapse between the afferent and the efferent 
neurons. Such arcs are monosynaptic, and reflexes occurring in them are monosynaptic 
reflexes. Reflex arcs in which one or more interneurons are interposed between the 
afferent and efferent neurons are polysynaptic, the number of synapses in the arcs 
varying from two to many hundreds (Ganong, 2005).  
A stimulus is defined as a detectable change in the internal or external environment, such 
as a change in temperature, plasma potassium concentration, or blood pressure. A 
receptor detects the environmental change. A stimulus acts upon a receptor to produce a 
signal that is relayed to an integrating center. The pathway traveled by the signal 
between the receptor and the integrating center is known as the afferent pathway 
(Widmaier et al., 2004). 
An integrating center often receives signals from many receptors, some of which may 
respond to quite types of stimuli. Thus, the output of an integrating center reflects the 
net effect of the total afferent input; that is, it represents an integration of numerous bits 
of information. The output of an integrated center is sent to the last component of the 
system, a device whose change in activity constitutes the overall response of the system. 
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This component is known as an effector. The information going from an integrated center 
to an effector is like a command directing the effector to alter its activity. The pathway 
along which this information travels is known as the efferent pathway (Widmaier et al., 
2004). If the response produced by the effector causes a decrease in the magnitude of the 
stimulus that triggered the sequence of events, then the reflex leads to negative feedback 
and we have the typical homeostatic control system (Widmaier et al., 2004). 
 
The baroreceptor reflex is the main mechanism for adjusting blood pressure. The reflex is 
initiated by stimulation of baroreceptors that are nerve endings sensitive to stretching of 
the artery in each cardiac cycle. These receptors are found in reflexogenic areas along the 
high and low pressure vascular system and in the cardiac pump. In the vessels, the most 
relevant for blood pressure control are located in the carotid sinus at the bifurcation of 
common carotid artery, the aortic arch and mesenteric circulation (Fig. 2-2) (Agnoletti et 
al., 1989). The communication between the aortic arch and the cardiovascular centers of 
the medulla is made via the vagus nerve and the carotid sinus communications is 
performed through the nerve of Hering, a branch of the glossopharyngeal nerve 
(Tresguerres, 2005). The arterial baroreceptors play a key role in the short-term 
adjustments of BP and are known to maintain BP in a normal range by actions on cardiac 
output and peripheral resistance as well as cardiac inotropism (Mancia et al., 1979; 
deBoer et al., 1987). 
Also referred to as mechanoreceptors, the baroreceptors respond to distension and 
deformation that is imposed on the vessel, through local BP changes elicited by the 
phases of the cardiac cycle. This deformation causes, as an end result, a change in the 
frequency of nerve impulses that are carried to the nucleus tractus solitarius (NTS) 
(Donoghue et al., 1984; Spyer et al., 1984). The NTS located in the caudal dorsal medulla 
presents a functional and a viscerotopic organization and plays an important role in the 
modulation of autonomic efferent activity to the cardiovascular system (Paton, 1998; 
Silva-Carvalho et al., 1998). 
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Figure 2-2. Location of the most prominent arterial baroreceptors. The arterial baroreceptors are 
strategically located for monitoring the blood pressure in the arteries that supply blood to brain (carotid 
sinus baroreceptor) and the rest of the body (the aortic arch baroreceptor, mesenteric baroreceptors and 
heart). Adapted from Ross et al., 1985. 
 
NTS is the primary central station for the reception of sensory information with origin in 
peripheral reflexogenic areas including the heart and vessels (Miura & Reis, 1969, 1972) 
and it is richly innervated by fibers arising from different brain nuclei belonging or not to 
the central autonomic network that are known to have an important role in 
cardiovascular control, including the parabrachial nucleus, the medial hypothalamus, and 
the amygdala (Crill & Reis, 1968; Miura & Reis, 1972; Loewy & McKellar, 1980; Colombari 
et al., 2001). NTS neurones project into two groups of cells in the ventrolateral medulla 
located almost at the same antero-posterior level: 1) inhibitory neurons in the caudal 
ventrolateral medulla (CVLM), which project to premotor neurons in the rostral 
ventrolateral medulla (RVLM, sympathetic-excitatory neurons) which then project to the 
sympathetic preganglionic neurons of the intermediolateral (IML) cell column of the 
spinal cord, origin of pre-ganglionic sympathetic neurons) and; 2) neurons located in the 
nucleus ambiguous (NA) and dorsal motor nucleus of the vagus (DMNV), which contain 
the cell bodies of preganglionic neurons of the parasympathetic nervous system (PNS) 
(Krieger, 1964; Spyer, 1981) (Fig. 2-3). 
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Figure 2-3  The general pattern of the baroreceptor reflex pathway, showing the relationship between 
the sensory receptors, the integrative brainstem regions and the motor innervations to the heart and 
blood vessels. AP; area postrema, CVLM; caudal ventrolateral medulla, DMNV; dorsal motor nucleus of the 
vagus, NA; nucleus ambiguous, NTS; nucleus tractus solitari, RVLM; rostroventrolateral medulla. Adapted 
from Loewy A and Spyer KM, 1990. 
Changes in baroreceptor activity also affect breathing. As an example, in vivo studies on 
anesthetized vagotomized dogs, showed the carotid body chemoreceptor reflex response 
was eliminated by surgically excluding the carotid bodies from the carotid sinus 
baroreceptor area (Brunner et al., 1982). These data showed that baroreceptor 
stimulation (by increasing carotid sinus pressure, whilst maintaining constant SBP) 
decreased respiration rate and increased end-tidal volume (Brunner et al., 1982).  Other 
studies have shown similar results (Grunstein et al., 1975; Dove & Katona, 1985; Maass-
Moreno & Katona, 1989). It has been suggested that changes in respiration in response to 
changes in carotid sinus pressure are due to increased/decreased firing of the type 1 large 
A-fibers (Hopp & Seagard, 1998).   
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Baroreceptors are also involved in vasopressin (VP) secretion (O'Donnell et al., 1992), 
particularly in response to hypotension possibly due to the neuronal projections from the 
NTS to the PVN (Kawano & Masuko, 1996). When the baroreceptor reflex is activated by a 
reduction in BP, an increase in VP secretion is observed (Blessing & Willoughby, 1985). 
This has been shown also in human studies where plasma VP increased following 
reductions in MBP induced by ganglionic blockade (Baylis, 1987). In addition, in the dog, 
during hemorrhage, intact arterial baroreceptors were essential to maintain BP and VP 
secretion (Thrasher & Keil, 1998).  Baroreceptors are vital for the reduction in the reflex 
increase in HR or renal SNA (RSNA) (in response to decreased MAP) following VP infusion 
(enhanced sympathoinhibitory effect) (Nishida & Bishop, 1992). However, in this 
situation, their action is reinforced by the facilitation of the chemoreceptor reflex at the 
NTS level due to the nature of the stimulus (Silva-Carvalho et al., 1995a).  
Several studies have discussed the role of the baroreceptor reflex in the regulation of 
long-term sympathetic activity, once a central resetting of the baroreceptor-sympathetic 
reflex may be an important component of the mechanism that causes persistent changes 
in renal sympathetic activity. However, little is known about the cellular mechanisms that 
can cause this resetting (Dampney et al., 2005). 
 
The chemoreceptors are highly specialized cells that can detect blood changes in the 
partial pressure of oxygen (pO2), partial pressure of carbon dioxide (pCO2) and blood pH. 
The peripheral chemoreceptors are more sensitive to changes in the pO2 than changes in 
pCO2 or pH whereas the central chemoreceptors respond primarily to changes in pCO2 
and pH (Berne, 2004).  
The peripheral chemoreceptors are mainly located in the aortic and carotid bodies 
despite they can also be found in the mesenteric circulation (coeliac artery). The carotid 
bodies are placed bilaterally in the neck, at the bifurcation of the common carotid artery 
while the aortic bodies are disposed between the pulmonary artery and the aortic arch 
(Fig. 2-4) (Tresguerres, 2005). Carotid bodies are more sensitive to hypoxia and 
hypercapnia and they detect changes in blood gas tensions whereas aortic baroreceptors 
are more sensitive to anaemia, carboxi- hemoglobinaemia and systemic hypotension 
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being more involved in detecting changes in O2 flow and in BP (Burgh Daly & 
Psychological, 1997). Thus, carotid bodies monitor ventilation/perfusion ratio and aortic 
bodies perform the reflex control of systemic vascular resistance.  
 
 
 
Figure 2-4. Ventromedial views of the left and right carotid bodies. EC: external carotid artery, IC: internal 
carotid artery; LV: left vagus. Adapted from Chungcharoen et al, 1953.  
 
The central chemoreception initially was localized to areas on the ventral medullary 
surface at the area prostrema, however, there is substantial evidence that many sites 
participate in central chemoreception some located at a distance from the ventral 
medulla (Nattie & Li, 2012).  
The chemoreceptor cells detect changes in the partial pressure of gases or pH, and 
through the vagus nerve or through the glossopharyngeal nerve (innervating, 
respectively, the aortic bodies and carotid bodies) send information to the nucleus tractus 
solitary (NTS) (Donoghue et al., 1982).  
The stimulation of the chemoreceptors causes at the central level, increase in the activity 
of NTS cells, some of them distinct but other similar from those activated by the 
baroreceptors. These cells simultaneously excite neurons in the NA and RVLM with 
consequent increase in sympathetic and parasympathetic tone (Fig. 2-5). The increase in 
the respiratory activity is due to various NTS neurons that when excited by 
chemoreceptor afferents have an inspiratory activity (Rocha, 1995). 
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Figure 2-5. Schematic of the chemoreflex pathway, showing brainstem regions, SNS and PNS projections 
to the heart and blood vessels. A simplified overview of the chemoreceptor reflex showing the SNS and 
PNS arms. AP; area postrema, CVLM; caudal ventrolateral medulla, DMNV; dorsal motor nucleus of the 
vagus, NA; nucleus ambiguous, NTS; nucleus tractus solitari, RVLM; rostroventrolateral medulla.  Adapted 
from Loewy A and Spyer KM, 1990. 
Excitation of these receptors increases SNA mediating tachycardia, vasoconstriction and 
increased respiration rate (Loewy & Spyer, 1990a).  
Activation of peripheral chemoreceptors results in ventilatory adjustments that are 
characterized by increased air flow volume, increased respiratory rate and increased 
breathing volume, thus playing an important role in the reflex control of ventilation 
(Heymans & Bouckaert, 1930). In addition to ventilatory responses, stimulation of the 
chemoreceptors also promotes changes in the cardiovascular system, in order to provide 
maintenance of the chemical composition of blood at optimal levels, as well as adequate 
blood perfusion to tissue. 
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Several studies suggest that peripheral chemoreceptors have a tonic excitatory influence 
on cardiovascular control, stimulate the sympathetic nervous system and thus contribute 
to the maintenance of BP levels and part of the total peripheral resistance.  
In rats submitted to carotid denervation there was a significant reduction in renal 
sympathetic nerve activity. In rats submitted to acute hyperoxia (which induces the 
inactivation of chemoreceptors), there was a transient fall in BP and sympathetic activity. 
Selective removal of the activity of carotid chemoreceptors by compressing the artery 
that irrigates the carotid body also promotes a decrease in chronic levels of BP (Franchini 
& Krieger, 1992).  
The tonic influence of chemoreceptors on the levels of BP and the primary reflex 
responses (bradycardia and hypertension) to stimulation of chemoreceptors with 
potassium cyanide were also demonstrated by Franchini and Krieger (Franchini & Krieger, 
1992). 
There are also volume (or stretch) receptors located in the right atrium and vena cava 
which respond to decreases in blood volume by reducing their firing rates and vice versa. 
The afferents of these receptors join the vagus nerve and terminate in the NTS, synapsing 
upon neurones which project from the NTS to the PVN (van Giersbergen et al., 1992).  
This pathway is activated by changes in blood volume as small as 8-10% as shown 
electrophysiologically (Lovick & Coote, 1988) and by c-fos expression (a marker of 
neuronal activation) in the anaesthetised rat (Deng & Kaufman, 1995; Pyner et al., 2002) 
and rabbit (Badoer et al., 1997). Overall, the activation of these low pressure atrial 
receptors elicits an inhibition of sympathetic vasomotor tone and an increase of 
vasopressin secretion, which affects renal function. 
Other reflexes potentially regulating blood pressure are the Bainbridge and the Bezold-
Jarisch reflex. In Bainbridge reflex, blood pressure is indirectly regulated through heart 
rate changes. Accordingly, when right atrial volume increases, low-pressure stretch 
receptors (that is, receptors responding to stretch at the low pressures typical in the atria) 
initiate a reflex that increases heart rate through sympathetic nerves (Burgh Daly & 
Psychological, 1997). The Bainbridge reflex is not always active, depending its efficacy on 
the value of heart rate, being particularly efficient at lower rather the higher values of HR. 
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In this way, the Bainbridge reflex acts in opposition to the baroreceptor reflex which 
increases heart rate when the stretch is decreased in states of hypotension or 
hypovolemia (Bainbridge, 1915).The Bezold-Jarisch reflex is a chemically-sensitive cardiac 
reflex which strong depressor cardiovascular response of bradycardia and hypotension 
being evoked as a direct consequence of chemical stimulation of receptors in the 
ventricles or coronary circulation. The decrease in blood pressure is due both to the 
bradycardia and vasodilation caused by inhibition of sympathetic vasomotor activity and 
also modulates renin release and vasopressin secretion (Bezold et al., 1867). Conversely, 
decreases in the activity of these inhibitory sensory receptors increase sympathetic 
activity, vascular resistance, plasma renin activity and vasopressin (Bezold et al., 1867). 
 
Ia. Autonomic reflexes and Hypertension  
The autonomic nervous system (ANS) plays a crucial role in the control of BP and HR and 
is an important pathophysiological factor in the development of AHT. 
In essential AHT, the cardiovascular homeostasis is partially lost or at least is maintained 
at a level of BP different from that of normotensive subjects (Sleight, 1991; Zanchetti & 
Mancia, 1991). The cause of this abnormality is not known, but the early alteration of 
baroreceptor control suggests that the ANS is deeply involved in the process (Bristow et 
al., 1969; Eckberg, 1979). In fact, normotensive rats and spontaneously hypertensive rats 
(SHR) have similar baroreflex gain (and BP) at birth. In the weeks after birth, the 
baroreflex sensitivity increases rapidly in normotensive rats, but not in the SHR (Struyker-
Boudier et al., 1982). 
One of the mechanisms associated with this autonomic imbalance is the reduced 
baroreflex sensitivity (BRS). The baroreflex is reduced or reset toward elevated blood 
pressure values in hypertension, blunting its ability to suppress the increased BP values 
promoted through the increased sympathetic activity (Mancia et al., 1999; McCubbin et 
al., 1956; Korner et al., 1974; Eckberg, 1979; Grassi et al., 1998). In the case of essential 
AHT the degree of decrease in baroreflex sensitivity for the control of heart rate is much 
higher than for the control of vascular resistance (Grassi et al., 1998). 
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Above 160 mmHg increases in the intensity of responses are becoming smaller for the 
same BP increase, and this increase does not occur when the values exceed 200 mmHg. In 
addition, during the development of hypertension the baroreceptors adapt quickly to 
each tensional level, increasing the excitation threshold and reducing the maximum 
frequency of the discharge pulses. 
Also most brainstem regions involved in controlling the baroreceptor reflex become more 
active (NTS and RVLM) or less active (CVLM) during the onset of hypertension, resulting in 
increased SNA (Smith & Barron, 1990; Grassi et al., 1998; Colombari et al., 2001). 
In addition, the severity of the baroreflex sensitivity change is correlated with the severity 
of AHT. However, is not yet well understood whether this decrease - also observed in pre-
hypertensive patients - precedes or participates in the development of AHT (Eckberg, 
1979). 
Another study showed that slow breathing reduces blood pressure and enhances 
baroreflex sensitivity in hypertensive patients, suggesting a potentially beneficial effect in 
hypertension (Joseph et al., 2005). 
The baroreflex activity can be modulated by several peptides of the RAAS (Averill & Diz, 
2000). Studies in rats, rabbits and dogs showed the inhibitory action of Ang II on the 
baroreflex in AHT after peripheral or central administration (in the medulla oblongata). 
Ang II, modulates the baroreceptor reflex by diminishing the sensitivity of the reflex and 
shifting the operating point for regulation of sympathetic outflow to higher blood 
pressures (Dampney, 1994; Phillips & Sumners, 1998; Averill & Diz, 2000). 
The central administration of angiotensin I converting enzyme (ACE) inhibitors, non-
selective peptidergic antagonists and antagonists of AT1 receptors in SHR rats produces a 
decrease in BP (Phillips & Sumners, 1998; Averill & Diz, 2000). So, the decrease in the 
central hyperactivity of the RAAS leads to a decrease in BP. The mechanisms by which the 
hyperactivity of the RAAS causes AHT are the same as those involved in the 
antihypertensive effect produced by central administration of Ang II, i.e., stimulation of 
the release of vasopressin, SNS activation and the inhibition of the baroreflex. This 
suggests that the Ang II is involved not only in shifting the operating band of the 
baroreflex (change of set point), but also in the decrease in the baroreflex gain. 
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Other studies have shown that the central infusion of a selective antagonist of Ang-(1-7), 
A-779, produces a significant decrease in baroreflex, whereas the infusion of a selective 
antagonist of the AT1 receptor improves the baroreflex sensitivity (Oliveira et al., 1996; 
Heringer-Walther et al., 2001). It was also been shown an increase in baroreflex 
sensitivity in SHR rats after intracerebroventricular administration of captopril (ACE 
inhibitor) (Phillips & Sumners, 1998; Averill & Diz, 2000). 
Furthermore, it is known that the effect of Ang II on the baroreflex is independent of the 
rise on BP caused by this peptide. Several studies have shown that even when it prevents 
the decrease in BP after central administration of angiotensin-converting enzyme (ACE) 
inhibitors, there are changes in baroreflex sensitivity towards normal values (Averill & Diz, 
2000). This observation leads to a very important suggestion: the effect of RAAS or Ang II 
on the baroreflex should be made in the central nervous system. 
Other mechanism that may be involved in the autonomic imbalance is the chemoreflex 
activation in essential hypertension, which can be an additional mechanism responsible 
for the increase in sympathetic activity (Somers et al., 1988). 
It is known that the SHR rats have an increased chemoreflex activity (Przybylski, 1981; 
Hayward et al., 1999). It has been observed that young hypertensive animals had 
increased pH, and pO2 and pCO2 reduction in blood when compared to normotensive 
animals (Hayward et al., 1999). Additionally, SHR rats have an increased respiratory 
volume than the normotensive rats (Fukuda et al., 1987; Hayward et al., 1999). This 
suggests that the changes found in the chemical composition of the blood of hypertensive 
animals would result from hyperventilation, possibly induced by the hyperactivity of the 
peripheral chemoreceptors in these animals. 
In fact there are several studies that correlate the AHT with the activity of the peripheral 
chemoreceptors (Przybylski, 1981; Habeck, 1991; Abdala et al., 2012). It has been shown 
through recordings of carotid sinus nerve activity, that SHR have an increased 
chemoreceptors sensitivity to hypoxia compared to normotensive rats (Fukuda et al., 
1987). The same was observed in humans with essential hypertension or pre-
hypertensive patients, once there was a significantly increase in ventilatory, airway 
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occlusion pressure and blood pressure response to hypoxia in the hypertensive subjects 
(Trzebski et al., 1982; Somers et al., 1988). 
Other studies have shown that hyperoxia induced deactivation of carotid body 
chemoreceptors, reduces sympathetic activity in hypertensive patients, but it does not 
affect BP (Seals et al., 1991; Seals & Reiling, 1991). The maintenance of BP values can be 
explained by the direct, vasoconstrictive effect of hyperoxia, which offsets diminished 
sympathetic activity (Sinski et al., 2014). In a recent study it was compared the effect of 
acute hyperoxia on hemodynamic parameters between hypertensive and normotensive 
subjects and they confirm that deactivation of carotid body chemoreceptors can acutely 
decrease blood pressure in humans (Sinski et al., 2014). 
Human and animal studies have also shown that in the AHT, the peripheral 
chemoreceptors (especially in the carotid bodies) exhibit morphological, biochemical and 
functional changes, which might be correlated with the genesis of hypertension (Edwards 
et al., 1971; Heath et al., 1986; Habeck, 1991; Abdala et al., 2012).  
These changes in chemoreflex sensitivity in SHR may be due to narrowing of the lumen of 
the artery to the carotid body, possibly resulting from atherosclerosis in the in the carotid 
sinus region (Habeck, 1991), changes in the capillaries of the carotid corpuscles of SHR 
(Smith et al., 1984) or due to an increase in size of the carotid body (Habeck et al., 1981; 
Alho et al., 1984). 
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II. Humoral factors 
The hormonal regulation of BP is exerted by circulating vasodilators, such as arterial 
natriuretic peptide (ANP), prostaglandins and kinins and vasoconstrictors, such as 
vasopressin, catecholamines and angiotensin.  
Bold and collaborators showed that the heart has an endocrine role in the production of 
ANP (de Bold et al., 1981). In fact, the heart release this peptide not only by atrial 
distension, but also by ventricular distension and neurohumoral stimuli (Edwards et al., 
1988). Various ANP actions contribute to the regulation of blood pressure, including its 
vasodilator, diuretic and potent natriuretic effect, as well as their action in the 
modulation of the activity of the RAAS (Maack et al., 1985; Chen, 2005). Thus, under 
normal conditions, the release of the ANP leads to an increased renal excretion of sodium 
and potassium in response to increases in BP. Moreover, in healthy subjects, the 
administration of low doses of ANP strikingly increases the urinary excretion not only of 
sodium but also of the primary solutes retained in chronic renal failure, such as urea, 
potassium, and phosphate, with no systemic effect (Richards et al., 1985; De Nicola et al., 
1993; Conte et al., 1997; De Nicola et al., 1997). The diuretic effectiveness of low-dose 
ANP in normal subjects appears to be dependent on the attainment of plasma ANP levels 
immediately above the physiological range (Richards et al., 1985; De Nicola et al., 1993; 
Conte et al., 1997; De Nicola et al., 1997).  
One of the important clinical features of increased SNS activity is sodium and water 
retention. Clonidine tends to stimulate diuresis and natriuresis by mechanisms that 
involve actions on the renal tubule to modulate the actions of vasopressin (Pettinger et 
al., 1987) or through the release of the ANP, which stimulates cGMP production in 
different target cells leading to vasodilation and natriuresis (Mukaddam-Daher & 
Gutkowska, 2000). Previous work (Baranowska, 1987; Chen et al., 1989; Gutkowska et al., 
1997; Mukaddam-Daher et al., 1997) demonstrated that in addition to 
sympathoinhibition  α -adrenergic receptors play a role in the cardiac release of ANP. In 
vivo administration of clonidine or its peripherally acting analogue induces dose-related 
increases in plasma ANP levels and results in diuresis and natriuresis (Baranowska, 1987; 
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Chen et al., 1989; Gutkowska et al., 1997; Mukaddam-Daher et al., 1997). Also ANP is 
inhibited by α -adrenergic receptor antagonists (Baranowska et al., 1987). 
Prostaglandins and kinins constitute a major blood pressure-regulating system which 
opposes the effects of circulating vasoconstrictor hormones, such as angiotensin, 
vasopressin and catecholamines, and moderate the release of norepinephrine from 
vasoconstrictor nerves (Kahn et al., 1973; McGiff & Quilley, 1980). Important interactions 
of prostaglandins and kinins that can decrease BP occur within the kidney and blood 
vessels where they contribute to the regulation of extracellular fluid volume and vascular 
reactivity (McGiff & Quilley, 1980). 
Vasopressin (arginine vasopressin, AVP or antidiuretic hormone, ADH) is a peptide 
hormone formed in the hypothalamus, then transported via axons to, and released from 
the posterior pituitary. Vasopressin has a potent vasoconstrictor effect and, in cases of 
severe bleeding, vasopressin plays a fundamental role since it markedly increases the 
reabsorption of water from renal tubules, thereby increasing the volume (Guyton & Hall, 
2006). 
Other vasoconstrictors are the catecholamines, epinephrine and norepinephrine, that are 
originated from two sources. Epinephrine is released upon activation of preganglionic 
sympathetic nerves that innervate the adrenal medulla and occurs during times of stress 
(e.g., exercise, heart failure, haemorrhage, emotional stress or excitement, pain). The 
primary source of circulating norepinephrine is spillover from sympathetic nerves 
innervating blood vessels. Therefore, at times of high sympathetic nerve activation, the 
amount of norepinephrine entering the blood increases dramatically. Both circulating 
catecholamines are released by the adrenal medulla (Klabunde, 2012).  
The RAAS plays an important role in regulating blood volume and systemic vascular 
resistance, which together influence cardiac output and BP.  Briefly, in the RAAS, the 
renin is released by the kidney into the circulation where it cleaves angiotensinogen to 
angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II 
(Ang II) (Veerasingham & Raizada, 2003).  Ang II causes vasoconstriction increasing total 
peripheral resistance, increases water retention due to aldosterone release which 
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increases kidney sodium reabsorption collectively acting to increase BP (Bader & Ganten, 
2002, 2008).   
The hormonal system is affected by the action of endothelin (ET) peptides and their 
receptors. So ET affects natriuretic peptides, aldosterone, catecholamines, and 
angiotensin, being intimately involved in the physiological control of systemic BP and 
body sodium (Na) homeostasis. ET also directly regulates cardiac output, central and 
peripheral nervous system activity, renal Na and water excretion, systemic vascular 
resistance and venous capacitance (Kohan et al., 2011). 
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CHAPTER 3  
RATIONALE, HYPOTHESIS, METHODS AND RESULTS   
 
I. Overall purpose of the present PhD thesis   
Hypertension (AHT) is a recognized and important risk factor for cardiovascular disease. 
Its prevalence has been increasing and it is estimated that about one billion people suffer 
from AHT worldwide. However, for the great majority of patients, the treatment decisions 
are just clinical and the therapeutic strategy it is only symptomatic as the aethiology of 
the disease is unknown. Among the different origins and mechanisms of deregulation that 
have been discussed, the neurogenic nature of this cardiovascular dysfunction has been 
postulated by several authors.  
The central nervous system (CNS) plays an important role in regulating blood pressure 
instant-by-instant, but its contribution to chronic blood pressure regulation is still not 
clear, in particular in allostatic conditions. Several studies suggest that sympathetic 
nervous system (SNS) is a major factor on the onset, development and maintenance of 
several cardiovascular pathologies including essential hypertension. The continuous 
sympathoexcitation observed in the hypertensive state can result firstly from a protective 
defense reaction through negative feedback mechanisms which would be transformed in 
a deleterious overprotection relying on long term neurohumoral responses with major 
maladaptive consequences. This inappropriate change and/or maintenance of activity can 
be originated at any level of the autonomic reflex arc including the brain centres which 
integrate sympathetic activity. 
Therefore, the overall purpose of this PhD thesis is to target central sympathetic nuclei to 
address the mechanisms putatively involved in the generation of sympathetic activation 
in hypertensive conditions of unknown origin. 
With the fulfilment of this goal is expected to:  
CHAPTER 3 – RATIONALE, HYPOTHESIS, METHODS AND RESULTS   
70 
i) Identify regions in the central nervous system from where a persistent 
simultaneous decrease in arterial blood pressure and sympathetic activity due to 
genetic modification of their cells excitability can be evoked;  
ii) Evaluate hypertensive target organs characteristics upon the central evoked 
decrease of arterial blood pressure and sympathetic output to conclude on their 
reverse remodelling process; 
iii) Define the relationship between cardiorespiratory reflexes regulation - 
baroreceptor and chemoreceptor reflex - hypertensive target organs condition and 
cardiovascular risk; 
iv) Outline new physiological roles in neurogenic hypertension for the target brain 
areas;  
v) Discuss autonomic modulation with particular focus on the integrative centres of 
the autonomic reflex arc, as a new therapeutic strategy for neurogenic 
hypertension. 
 
II. Specific aims of the project 
The work flow of the project was divided in 2 parts, according to the specific aim. 
In the 1st part, the aim was to decrease the sympathetic tone by affecting brain 
sympatho-excitatory regions. For that, the activity of PVN, RVLM and MPCA neurones was 
depressed by the over-expression of a potassium channel in order to reduce neuronal 
membrane excitability.  
In the 2nd part, through the elicited decrease of sympathetic activity and BP evoked by 
potassium channels overexpression, the effect of a putative autonomic therapeutic was 
evaluated on target organs. For that, through RT-PCR, gene expression changes in 
hypertensive target organs were analyzed. 
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III. Exploring the hypotheses under study 
Hypothesis 1 - Will a chronic reduction of neuronal excitability within the paraventricular 
nucleus of the hypothalamus evoke a persistent reduction of arterial blood pressure and 
sympathetic activity with impact in respiratory, baro and chemoreceptor function?  
Hypothesis 2 - What is the role of rostral ventrolateral medullary and medullar pressor 
cervical neuronal activity in the long term maintenance of high blood pressure values, 
sympathoexcitation and baroreflex blunting in the hypertensive condition? 
Hypothesis 3 – Will the chronic depression of brain sympatho-excitatory regions activity 
induce major signalling changes in hypertensive target organs condition? 
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HYPOTHESIS 1  
The paraventricular nucleus of the hypothalamus is a rather complex area composed by 
several groups of neurons including autonomic neurons which play an important role on 
cardiovascular control, both on physiological and pathological conditions. Through 
reciprocal connections with other areas of the central autonomic network, PVN is involved 
in the integration of autonomic and endocrine responses that regulate visceral functions. 
The PVN receives sensory information of neuronal and humoral origin which is sent, after 
integration, to lower autonomic centres located at the brainstem and spinal cord. In this 
way, PVN is able to exert multiple autonomic effects including influencing sympathetic 
activity. In accordance, the following working hypothesis was designed: 
Will a chronic reduction of neuronal excitability within the paraventricular nucleus of 
the hypothalamus evoke a persistent reduction of arterial blood pressure and 
sympathetic activity with impact in respiratory, baro and chemoreceptor function? 
 
1. INTRODUCTION 
Essential arterial hypertension (EHT) has now reached pandemic proportions with an 
estimated one billion sufferers worldwide. The pathogenesis of EHT is multi-factorial and 
not completely understood but there is clear evidence that chronic elevation of 
sympathetic nervous system (SNS) activity is a major contributor to the onset, 
development and maintenance of the hypertensive state (Grassi, 2004b; Guyenet, 2006; 
Fisher & Paton, 2012). In fact, the increase of sympathetic outflow to the heart results in 
increased cardiac output and neurally mediated vasoconstriction leading to elevated 
blood pressure values (Schlaich et al., 2012). In white coat and borderline hypertensive 
patients, sympathetic nerve activity to the arterioles supplying skeletal muscle is already 
raised compared to healthy individuals (Grassi, 2004a; Smith et al., 2004). Excessive 
sympathetic activity may contribute to vascular smooth and cardiac muscle hypertrophy, 
brain hypoperfusion and inflammation, and becomes a major target to control in 
neurogenic  hypertension (Zubcevic et al., 2011).   
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The evaluation of sympathetic activity can be achieved indirectly by applying 
mathematical tools such Fast Fourier Transform (FFT) to blood pressure signals (M Malik, 
1996). A power spectrum is, then, generated where the low frequencies (LF) represent 
predominantly sympathetic activity and high frequencies (HF) are related with 
parasympathetic tonus and respiration (Radaelli et al., 1994; M Malik, 1996; Furlan et al., 
2000). These mathematical results have been addressed in several studies which have 
suggested that sympathetic activity is a critical determinant of blood pressure fluctuations 
at a frequency range which is slower than the rate of respiration (Japundzic et al., 1990; 
Cerutti et al., 1991; Malliani et al., 1991).  
Located in the hypothalamus, the paraventricular nucleus (PVN) is a major 
sympatoexcitatory area, that becomes more active under conditions of hypertension such 
as in the spontaneously hypertensive rat (SHR) model (Allen, 2002). Some authors have 
referred to this region as a command nucleus providing feed forward excitatory synaptic 
drives to coordinate lower brainstem cardiovascular and respiratory motor activity 
(Dampney et al., 2005). PVN activation promotes an increase in sympathetic output and a 
pressor effect mediated via direct and indirect projections (via rostral ventrolateral 
medulla, RVLM), to the spinal cord (Caverson et al., 1984; Shafton et al., 1998; Pyner & 
Coote, 2000; Hardy, 2001).  
Both electrical stimulation and chemical manipulation of PVN neurons with bicuculline (a 
GABAA receptor antagonist) or glutamate elevated sympathetic nerve activity causing 
hypertension in anesthetized and conscious rats (Kannan et al., 1989; Zhang et al., 2002). 
In contrast, acute inhibition of the PVN with GABA or muscimol reduces the blood 
pressure and sympathetic nerve activity in SHRs (Allen, 2002). PVN lesions or the 
transection of the brain caudal to the hypothalamus promotes a decrease in blood 
pressure in SHRs but not in Wistar Kyoto (WKY) rats (Yamori & Okamoto, 1969; Goto et 
al., 1981; Ciriello et al., 1984; Herzig et al., 1991; Takeda et al., 1991).  
Long-term manipulation of neurone excitability can be performed by expressing a human 
inwardly rectifying potassium channel (hKir2.1) under the control of a selective neuronal 
promoter such as synapsin (Duale et al., 2005b; Duale et al., 2007). Inwardly rectifying 
potassium channels, like Kir2.1, are endogenously expressed in rat brain and have 
recently been over expressed as a means to reduce neuronal membrane excitability (Yu et 
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al., 2004; Duale et al., 2007; Mizuno et al., 2007; Okada & Matsuda, 2008; Yoon et al., 
2008; Howorth et al., 2009). Their long-term expression can be achieved by the use of 
lentiviral vectors (LVV) derived from human immunodeficiency virus (Coleman et al., 
2003). Therefore, using a LVV to over-express hKir2.1 channels within the PVN we asked 
what long term influence does this nucleus have on the control of blood pressure, heart 
rate, sympathetic activity and respiration in the SHRs as well as homeostatic reflex control 
mechanisms?   
 
2. METHODS 
All the experimental procedures were in accordance with the European and Portuguese 
Law on animal welfare and had the approval of the ethics committee of the Faculty of 
Medicine, University of Lisbon, Portugal. Male Wistar–Kyoto rats (n =15) and SHRs (n =15) 
were used, aged 12 weeks and weighing 363±8 g. Animals, synchronized to a 12 h–12 h 
light–dark cycle (light on at 07.00 h and light off at 19.00 h), were housed individually and 
allowed to freely move in standard plastic cages. Food and water were available ad 
libitum. 
 
2.1 Viral vector construction and validation 
Lentiviral vector construction was based on previous studies (Waki et al. 2003; Duale et 
al. 2007). Briefly, LVV-eGFP, used for the sham-treated group, was a mix of LVTREtight-
GFP 5.7×109 IU and LV-Syn-Eff-G4BS-Syn-Tetoff 6.2×109 IU in a ratio 1:4. This binary 
system expresses enhanced green fluorescent protein (eGFP). The LVV-hKir2.1 is a mix of 
LV-TREtight-Kir-cIRES-GFP 5.4×109 IU and LV-Syn-Eff-G4BS-Syn-Tetoff 6.2×109 IU in a 
ratio 1:4, which expresses eGFP and expresses human inwardly rectifying potassium 
channels (hKir2.1) in neurones. Validation of transduction efficacy and transgene 
expression was assessed as described previously by Duale et al. and included mRNA 
expression, immunocytochemical and electrophysiological data (Duale et al., 2007). 
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2.2. Microinjection sites 
Initially, we fine tuned our stereotaxic coordinates for bilateral PVN microinjections in 5 
SHR and 5 WKY rats anaesthetised with sodium pentobarbitone (60mg/Kg, IP, Hikma 
Pharmaceuticals, London, UK). Bilateral microinjections (0.05µl) of LVV-eGFP were 
performed. Using fluorescence microscopy and histological reconstruction we determined 
the correct coordinates for PVN injections and the amount of LVV-eGFP, needed to limit 
transduction to the confines of the PVN. 
 
2.3. Surgery 
SHRs were divided into 2 groups according to the microinjection content: LVV-hKir2.1 
(n=8) and LVV-eGFP (n=7). A control group of WKY rats, matching age, sex and number of 
individuals, underwent the same surgical and experimental protocol. 
 
a) Implantation of telemetry probes 
Rats were implanted with radio-telemetry probes (DSI, St. Paul, Minnesota, MN, USA) in 
the abdominal aorta under general anaesthesia (sodium pentobarbitone, 60mg kg−1, I.P., 
Hikma Pharmaceuticals).Animalswere allowed to recover for 15 days. Similar anaesthetic 
and surgical protocols were applied to WKY rats (n =15). 
 
b) Bilateral microinjection in the PVN 
Two weeks after the probes were implanted, SHRs (n =8) and WKY rats (n =8) under 
general anaesthesia (sodium pentobarbitone, 60mg kg−1  I.P. Hikma Pharmaceuticals) 
were placed in a stereotactic frame (Kopf Instruments, Tujunga, CA, USA), and a 
craniotomy was performed using our previously determined co-ordinates for LVVhKir2.1 
microinjections (0.05 μl) into the PVN (Bregma  −1.6 mm; Lateral, ±1.41 mm; Deep, 7.4 
mm; pipette angle, 10 deg to bregma; (Paxinos & Watson, 1986). Sham treated rats were 
microinjected in the same region with LVV-eGFP (SHRs, n =7; and WKY rats, n =7). All 
microinjections were performed bilaterally. Animals of all groups were allowed to recover 
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and monitored by telemetry for 60 days. Heart rate (HR) and blood pressure [BP; systolic 
(SBP), diastolic and mean] were recorded continuously. 
 
2.4. Metabolic Evaluation 
Rats were housed for 24h in metabolic cages to evaluate food and fluid intake, urine and 
feces production and body weight. Measurements were performed before and 59 days 
after each microinjection.  
 
2.5. Cardio-respiratory reflex evaluation 
At 60 days, animals were anesthetised (sodium pentobarbitone, 60mg/Kg, IP, Hikma 
Pharmaceuticals). The trachea was cannulated below the larynx to record tracheal 
pressure (TP). The femoral and carotid arteries and femoral vein were cannulated. Rectal 
temperature was maintained at 38±1°C by a servo-controlled heating blanket. The 
electrocardiogram (ECG) was recorded with the use of needle electrodes inserted into the 
limbs and HR was derived from the ECG. Baroreceptor and peripheral chemoreceptor 
reflexes were activated twice with an interval of 5 minutes between each stimulation. 
Baroreceptor reflex was stimulated by phenylephrine (0.2ml, 25µg/ml i.v.; Sigma Aldrich). 
Peripheral chemoreceptor reflex was stimulated with lobeline (0.2ml, 25µg/ml, Sigma 
Aldrich) injected retrogradely into the bifurcation of the common carotid artery. HR, BP 
(systolic, diastolic and mean) and respiratory rate (RespR) were recorded continuously 
thought the experiment. 
 
2.6. Histology and immunochemistry  
Animals were terminally anesthetized and immediately perfused transcardially with 
phosphate-buffered saline (PBS; 0.1M; pH 7.4) followed by 4% paraformaldehyde (0.1M; 
pH 7.4). The brain was removed and placed for 48 h in 15% (w/v) sucrose solution. 
Coronal sections (18 µm) were cut on a microtome and mounted on slides. The pipette tip 
location and the microinjection diffusion in the PVN were examined and documented. 
The microinjected contents (LVV-hKir2.1 or LVV-eGFP) containing e-GFP allowed an 
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estimation of virus dispersion. eGFP-labeled fluorescent regions were identified using an 
epifluorescence microscope and plotted on standardized sections from the Paxinos and 
Watson atlas (Paxinos & Watson, 1986).  
 
2.7. Western blot analysis  
The expression of hKir2.1 in the PVN was analysed by Western blot 60 days after the 
microinjection of LVV-hKir2.1 (n =8) or LVV-eGFP in SHRs (n =7). The PVN was dissected 
fromboth groups and homogenized by sonication in ice-cold RIPA buffer (Sigma, St. Louis, 
MO, USA) supplemented with a cocktail of protease inhibitors (complete mini; Roche). 
Proteins were extracted from the homogenates by centrifugation at 5000g for 10 min at 
4ºC, and protein concentration was determined with a Bio-Rad DC Protein Assay kit. 
Proteins were resolved by electrophoresis on a 10% Tris–glycine SDS-PAGE gel and 
transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, 
MA,USA).Membranes were blocked with 5% milk in Tween/Tris-buffered saline and 
incubated overnight at 4ºC with rabbit anti-hKir2.1 polyclonal antibody (Abcam, 
Cambridge, UK). After washing, membranes were incubated for 1 h at room temperature 
with HRP-conjugated goat anti-rabbit antibody (Bio-Rad, Hercules, CA, USA), and 
immunoreactive proteins were detected by Immobilon Western Chemiluminescent HRP 
Substrate (Millipore, Bedford, MA, USA) and visualized using Curix 60 (AGFA, Greenville, 
SC, USA).Membranes were stripped with 0.1 M glycine (pH 2.2) and reprobed with the α-
tubulin antibody (Santa Cruz Biotechnology, Dallas, TX, USA) for loading control. 
 
2.8. Data acquisition and analysis 
Telemetric data were acquired at 1KHz and analyzed with suitable software (LabChart6, 
Powerlab, ADInstruments). Mean values of HR, BP (systolic, diastolic and mean) and 
RespR were extracted.  
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a) Baroreceptor and chemoreceptor reflex 
The baroreceptor reflex gain (BR ) was quantified calculating ∆HR/∆BP (bpm.mmHg−1). 
Chemoreceptor (ChR) reflex was calculated through the RespR derived from the tracheal 
pressure before and after stimulation with lobeline: ΔChR = RespRlobeline - RespRbasal. BP 
and HR were also evaluated.  
 
b) Analysis of BP and HR variability  
Systolic BP and RR interval data were analyzed (period of 3 minutes) in the frequency 
domain (Fast Fourier Transform, FFT), using the in-house software Fisiosinal (Tavares, 
2011b), to evaluate sympathetic (Low Frequency band, LF, 0.15-0.6Hz of SBP) and 
parasympathetic (High Frequency band, HF, 0.6-2.0Hz of HR) activity over time. 
 
c) Circadian light/dark heart rate and blood pressure profile  
Mean BP and HR values were calculated using the continuous telemetric data and 
compared between light (07.00–19.00 h) and dark phases (19.00–07.00 h). 
 
2.9. Statistical analysis 
Comparisons between groups for the same period and also comparisons within the same 
group, before and after the microinjections were performed. For the statistical analysis, 
Student’s t test for paired data and ANOVA for comparisons between groups were used. 
All data were expressed as mean ± SEM and passed the normality test. Significance was 
taken as P < 0.05. 
 
3. RESULTS 
3.1 Effect of LVV-hKir2.1 or LVV-eGFP microinjection on 24h mean values of blood 
pressure, heart rate and respiration  
Basal BP values (recorded before microinjections) in conscious SHRs (n=15) were 158±3 
mmHg for systolic BP, 135±4 mmHg for diastolic BP and 142±3 mmHg for mean BP, being 
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significantly higher than those for WKY rats (119±3, 91±2, 101±1 mmHg respectively; 
n=15; p<0.0001). SHRs showed a higher baseline respiratory rate than WKY (77±5 vs 61±4 
cpm, p<0.05) as well as a lower HR (311±5 and 367±9 bpm, for SHR and WKY rats, 
respectively, p<0.0001).  
Thirty days after LVV-hKir2.1 microinjection, a significant BP decrease (p<0.05) was 
first observed but in order to evaluate its persistence, animals were monitored for a 
further 30 days. At the 60th day after lentiviral microinjection, SHRs values for systolic, 
diastolic and mean BP were 132±6, 113±5 and 120±5mmHg, corresponding to a 
decrease in pressure of 26mmHg, 22mmHg and 22mmHg, respectively (p<0.01, Figure 
3-1). These BP changes were accompanied by a lowering of HR (295±3 bpm, p=0.099) 
but RespR remained unchanged. The decreased BP and HR values approached those of 
normotensive animals. At the same time, SHR LVV-eGFP were showing increased 
values of systolic (174±10 mmHg, p>0.05), diastolic (149±11 mmHg, p>0.05) and mean 
BP (157±10 mmHg, p>0.05) together with a significantly HR decreased (285±6 bpm, 
p<0.01). This profile of BP and HR changes was expected and is a consequence of 
maturation. In contrast, no significant changes in BP, HR and RespR were observed in 
WKY rats during the 60 days duration of the experimental protocol.  
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Fig. 3-1 – Effect on systolic, diastolic blood pressure and heart rate before (0 days) and after 
microinjection of LVV-hKir2.1 (n=7) or LVV-eGFP (n=7). The asterisks denote statistically significant 
differences between SHR LVV-hKir2.1 and SHR LVV-eGFP groups and the cardinals denote statistically 
significant differences within the group; *,#p < 0.05; **,##p < 0.01. 
 
3.2. Effect of LVV-hKir2.1 microinjection on sympathetic output measured indirectly 
SHRs showed putative evidence for an overall decrease of cardiovascular autonomic 
outflow at 60 days after LVV-hKir2.1 microinjection when compared with basal autonomic 
output at day 0. In fact, by using FFT applied to systolic BP and RR intervals, a decrease of 
LFsBP/HFRR ratio (from 0.07±0.02 to 0.04±0.01 mmHg
2.ms-2; p>0.05) was observed, mainly 
due to a strong decrease in sympathetic output expressed by LFsBP band power (from 
0.79±0.13 to 0.42±0.09 mmHg2, p<0.05). In SHR the basal HFsBP (0.75±0.10 mmHg
2) was 
first reduced at 40 days and persisted until 60 days (0.33±0.10 mmHg2; p<0.05) after LVV-
hKir2.1 but unchanged in the LVV-eGFP group (0.82±0.38 mmHg2). Interestingly, LF SBP 
was significantly reduced by 20 days after LVV-hKir2.1 microinjection and occurred before 
the fall in SBP. In contrast, at 60 days the LFSBP/HFRR ratio for SHR LVV-eGFP was 0.08±0.03 
mmHg2 ms−2 and the LF was 0.86±0.21 mmHg2 (P >0.05). The variations of mean LFSBP and 
LFSBP/HFRR, at 10 day intervals for each SHR group, are depicted in Fig. 3-2. For WKY rats in 
basal conditions, the LFSBP and LFSBP/HFRR ratio were 3.23±0.36 mmHg
2 and 0.43±0.14 
mmHg2 ms−2, respectively. No significant changes in LF and LFSBP/HFRR ratio were 
observed for WKY LVV-hKir2.1 (3.11±0.44 mmHg2 and 0.40±0.23 mmHg2 ms−2, 
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respectively) and WKY LVVeGFP rats (2.56±0.48 mmHg2 and 0.22±0.08 mmHg2 ms−2, 
respectively). 
 
 
Fig. 3-2 – Mean (±SEM) LF and LF(BP)/HF(RR) before (0 days) and 10 days intervals after the 
microinjection of LVV-hKir2.1 or LVV-eGFP in SHR. Note that the fall in LF SBP occurred a week before the 
fall in SBP suggesting a causative association. The asterisks denote statistically significant differences 
between groups; *p < 0.05. 
 
3.3. Arterial baroreflex gain (BRG) and peripheral chemoreflex responsiveness 
The injection of phenylephrine triggered, in all animal groups, a progressive increase in 
mean BP, which was accompanied by a progressive reduction in HR. In SHR, BRG 
increased significantly after LVV-hKir2.1 microinjection approaching the values of the 
normal controls. SHR LVV-hKir2.1 group had a higher BRG in comparison to the SHR LVV-
eGFP group (0.51±0.06 vs 0.33±0.03 bpm.mmHg-1, respectively, p<0.05, Figure 3-3). 
Interestingly, BRG of WKY LVV-hKir2.1 (1.29±0.18 bpm.mmHg-1) was also increased in 
comparison to WKY LVV-eGFP group (0.41±0.02 bpm.mmHg-1, p<0.0001), despite all 
cardiovascular variables remaining unchanged.  
RespR remained unchanged throughout the full experimental protocol in all animal 
groups, before and after the lentiviral microinjection. At 60 days after microinjection, the 
baseline values of respiratory rate in the anesthetized animal were 76±3.4, 81±4.9, 
80±4.5 and 67±3.5 cpm, respectively for SHR and WKY LVV-hKir2.1, SHR and WKY LVV-
eGFP. However, peripheral chemoreceptor reflex activation with lobeline, elicited a 
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hyperventilatory reflex responses of different magnitude according to the animal group. 
In SHR LVV-hKir2.1 animals showed a decreased ventilatory response when compared 
with SHR LVV-e FP (Δ 4.4±3.4 vs Δ38.1±4.9 cpm  respectively  p<0.05) (Figure 3-3). In 
contrast, there were no differences in the ventilatory response between WKY LVV-hKir2.1 
and WKY-e FP groups (Δ 3.3±5.9 cpm for WKY LVV-hKir .1  Δ 4.8±4.  cpm for WKY LVV-
eGFP). Mean BP responses to chemoreflex activation in SHR LVV-hKir2.1 (from 140±7 to 
154±9 mmHg) were depressed compared to SHR LVV-eGFP rats. (179±9 to 193±9 mmHg; 
p<0.05) but HR responses were not different (from 337±23 to 359±12 vs 373±10 to 
362±13 bpm, respectively). For the two WKY groups changes in BP and HR to peripheral 
chemoreflex activation were not different. 
 
 
Fig. 3-3 – The histograms show the effect of bilateral microinjections of LVV-hkir2.1 or LVV-eGFP into the 
PVN on cBRG (A) and chemoreflex variation (B), 60 days pos-microinjection. In SHR-hKir2.1 there is an 
increase in the baroreflex gain and a decrease in the chemoreflex ventilatory response.  The asterisks 
denote statistically significant differences between groups; *p < 0.05. Abbreviations: cpm, cycles per 
minute. 
 
3.4. Circadian variation of BP and HR and patterns of nocturnal blood pressure profile 
In basal conditions and without any intervention, the pattern of circadian variation of BP 
and HR followed a similar trend- lower BP values during the light phase relative to the 
dark phase. During the light phase systolic, diastolic and mean BP of SHRs were 
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significantly higher than those for WKY rats (Table 3.1; p<0.0001) over the same time 
period. The same type of variation was found for the dark phase where SHRs showed 
higher values for BP parameters than WKY (p<0.0001; Table 3.1). Mean basal HR followed 
these variations in BP inversely.  The HR was significantly lower during the light and dark 
phases for SHR than for WKY rats (p<0.01; Table 3.1).  
At 60 days after the LVV-hKir2.1 microinjection, SHRs showed a significant decrease of 
systolic, diastolic and mean BP during both light and the dark phases (both p<0.01; Table 
3.1). A significant decrease of HR was observed during the light but not during the dark 
phase (p>0.05).  For the SHR LVV-eGFP rats HR, diastolic, systolic and mean BP values for 
the light phase and dark phase were expectedly increased at 60 days (Table 3.1). Finally, 
in WKY LVV-hKir2.1 as well as WKY LVV-eGFP rats there was an increase in BP during the 
dark phase without a distinct circadian rhythm. This profile was maintained after LVV-
hKir2.1 and LVV-eGFP PVN microinjections at 60 days (Table 3.1).  
 
Table 3.1 – Blood pressure and heart rate during the light and dark phases for all groups before and 59 
days after the microinjection.  
 
 
3.5. Metabolic evaluation 
A significant decrease in food intake was observed in SHR LVV-hKir2.1 at 60 days after the 
microinjection (Table 3.2). No other significant changes were found in body weight, water 
intake, feces and urine production for all groups, before and after the microinjections 
suggesting that the physical inactivity due to social isolation (only one animal per cage) 
could have an impact on food consumption. Furthermore, animals were not subjected to 
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an adaptation period to the metabolic cages, which could impact on our metabolic data, 
constituting a study limitation.   
 
Table 3.2 – Metabolic evaluation of spontaneously hypertensive rats before and 59 days pos-injection. 
 
 
3.6. Histological, immunohistochemical and Western blot analysis 
The microinjection sites were located within the PVN according to the rat atlas of Paxinos 
& Watson (1986). Enhanced green fluorescent protein was detected by fluorescence 
microscopy as fluorescence confined to a surface of 0.10–0.20mm around the injection 
site. The eGFP did not penetrate the third ventricular ependymal lining. Through 
immunohistochemical studies, it was confirmed that PVN neurones expressed eGFP (Fig. 
3-4). The overexpression of hKir2.1 in the PVN was analysed using Western blot. The PVN 
dissected from SHRs microinjected with LVV-hKir2.1 showed an increased expression of 
hKir2.1, on average about ninefold increased when compared with the LVV-eGFP group 
(Fig. 3-4). 
 
 
Fig. 3-4 – Lentiviral vector-mediated transduction of green fluorescent protein (GFP) in the 
paraventricular nucleus (PVN); confocal microscope images of GFP-expressing cells in the PVN (bar:  (A) 
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20 µm, (B) 10 µm) following injection of lentiviral vector into this site. (C) Western blot analysis of sham 
SHR (1,2) and LVV-hKir2.1 microinjected SHR (3,4). Results show an over expression of hKir2.1 in LVV-
hKir .1 microinjected SHR. α-tubulin was used as house keeping gene. 
 
4. DISCUSSION 
In the present study, we investigated the effect of over expressing a potassium inwardly 
rectifying channel in the PVN to lower neuronal activity while measuring BP chronically 
and its reflex control in a rat model of hypertension. Our study is the first to demonstrate 
that chronic suppression of PVN neuronal activity in freely moving SHRs causes a 
sustained reduction in arterial blood pressure (>60 days) together with a decrease of 
sympathetic activity, a down-regulation of peripheral chemoreflex responsiveness and an 
improvement of baroreflex gain. No such changes were found in the control groups of 
both rat strains that underwent comparable experimental protocols. 
The PVN nucleus of the hypothalamus is well known for its importance in autonomic 
control and, in particular, for cardiovascular regulation. Several anatomical and 
electrophysiological studies have shown that PVN neurones project either directly to the 
spinal cord or to the RVLM (Coote, 2007) thereby accessing sympathetic neurones to 
modulate blood pressure (Hosoya et al., 1991; Loewy, 1991; Coote, 1995; Ranson et al., 
1998; Motawei et al., 1999; Pyner & Coote, 1999, 2000; Badoer, 2001; Coote, 2005). As 
an example, electrolytic lesions of the PVN in SHR elicited an acute reduction of 
sympathetic activity together with a decrease of blood pressure (Takeda et al., 1991). 
Other acute studies, performed under general anesthesia, showed that PVN muscimol 
injections lowered BP and renal sympathetic nerve activity both in SHR and WKY rats, 
indicating that this region was tonically active in both animal strains to control BP and 
peripheral sympathetic activity (Allen, 2002).  
In the SHR, sympathetic activity is known to be over-activated even before hypertension 
develops (Simms et al., 2009). Several studies have pointed out that the persistent 
increase in sympathetic tone is a major contributor to both the initiation and 
maintenance of the hypertensive condition (Yamada et al., 1988; Grassi, 2004b; Smith et 
al., 2004; Guyenet, 2006; Fisher & Paton, 2012). In fact, increased sympathetic activity 
has been detected in normotensive individuals with a family history of hypertension and 
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in individuals with essential hypertension but not in those with secondary hypertension 
(Yamada et al., 1988; Grassi et al., 1998; Grassi, 2004a, 2009). Likewise, high plasmatic 
nor-epinephrine levels have also been associated with essential hypertension being 
consistently increased in younger hypertensive patients (Grassi, 1998) and increased 
peripheral sympathetic nervous activity has been detected by microneurography 
techniques in hypertensive patients (Anderson et al., 1989; Grassi, 1998; Greenwood et 
al., 1999; Mano, 2012). 
Several studies both in human subjects and animal models have demonstrated an 
association between the circadian variation of BP values, the hypertensive condition, the 
sympathetic activation, the end-organ damage and the worsening of cardiovascular 
outcome (White, 2000; Pickering & Kario, 2001; Weber, 2002). Thus, the idea of a long 
term modulation of the level of sympathetic activity, at its central origin, as a way to 
control, and treat, high blood pressure and increasing cardiovascular compliance is very 
appealing. In particular, the manipulation of sympathetic cell excitability by modulation 
one of K+ channel expression, to hyperpolarize neuronal resting membrane potential, is 
an attractive hypothetical therapeutic strategy (Duale et al., 2007).  
In the present work, our purpose was to depress chronically the activity of PVN neurones 
by the over-expression of K+ channels in PVN neurones exclusively to evaluate its 
consequences upon long term blood pressure regulation in an animal model of 
hypertension.   
We overexpressed a human inwardly rectifying potassium channel (hKir2.1) under the 
control of a synapsin promoter that was neurone specific (Duale et al., 2005a; Duale et 
al., 2005b). Lentivirus was used because its expression has been shown to be sustained 
within PVN neurones in the long term (Coleman et al., 2003). In previous studies, Duale et 
al. (2007) and Howorth et al. (2009) showed that hKir2.1 overexpression hyperpolarized 
the membrane potential of cultured cathecolaminergic PC12 cells by ∼10 mV, which is 
expected to result in ‘electrical silencing’ of PVN neurones (Duale et al., 2007; Howorth et 
al., 2009). Similar overexpression strategies have been used to reveal that electrical 
silencing of neurones affected development in ovo (Yoon et al. 2008), neuronal activity in 
vivo (Okada & Matsuda, 2008) and the ability of neurons to make and maintain 
connections in vivo (Yu et al., 2004; Mizuno et al., 2007; Hendy, 2010). This virus 
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mediated approach has the advantage of being site specific and enabling overexpression 
in adulthood, which avoids the development of putative compensatory mechanisms 
associated with transgenic animals (Hendy, 2010).  
Our results show that LVV-hKir2.1 treatment of the PVN in SHRs lowered SBP by ∼15% 
(>20 mmHg). This decline of SBP, which was accompanied by a decrease in HR, was 
statistically confirmed at 30 days after the lentiviral microinjection and persisted until the 
animals were killed 60 days postinjection. Interestingly, the LF spectra of SBP (indicative 
of sympathoinhibition) occurred before the fall in SBP (i.e. 20 versus 30 days), suggesting 
a putative association between the changes in both variables.  
Furthermore, the fall in HF SBP is indicative of reduced respiratory modulation of arterial 
pressure and could include reduced respiratory–sympathetic coupling, a phenomenon 
known to raise total peripheral resistance in the SHR (Simms et al., 2009). In contrast, 
changes in diastolic BP were significant only after 50 days, suggesting the involvement of 
an additional mechanism. This reveals novel insight into the long-term control of arterial 
pressure in hypertension by the PVN. It also indicates that the system does not adapt. 
This could be explained by the associated improvement of baroreflex gain and/or a 
downregulation of peripheral chemoreflex responsiveness to stabilize lower levels of 
blood pressure, as we observed. We propose that these changes were a result of reduced 
electrical excitability of PVN premotor sympathetic neurones, but we cannot rule out 
reduced release of vasopressin and oxytocin.  
This is consistent with our neuroanatomical Western blot analysis confirming that hKir2.1 
protein overexpression was within the PVN region. Interestingly, respiratory rate 
remained unchanged in all experimental groups, suggesting that there is no tonic 
excitatory drive from the PVN affecting this variable in hypertensive or normotensive rats. 
Additionally, we saw no tonic influence from the PVN on the resting arterial pressure level 
in normotensive rats, which contrasts with a previous acute in vivo study (Allen, 2002). 
It is well accepted that neurogenic hypertension is accompanied by an impairment of the 
baroreceptor reflex (Grassi et al., 1998).Our data showed that depressing PVN neuronal 
activity improved baroreflex gain. Previous work from several authors has shown that 
during the course of an alerting reaction there is a decrease in baroreflex efficacy and a 
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facilitation of the carotid chemoreceptor reflex due to modifications of synaptic 
integration at the level of the nucleus tractus solitarii; this might include mechanisms 
involving GABA and angiotensin II release within the nucleus tractus solitarii (Jordan et al., 
1988; KM, 1990; Silva-Carvalho et al., 1995a; Silva-Carvalho et al., 1995b; Kasparov et al., 
1998; Kasparov & Paton, 1999; Head & Mayorov, 2001; Rocha et al., 2003). Such an 
angiotensinogenic mechanism seems to be particularly active in pathophysiological 
conditions such asmyocardial ischaemia and hypertension (Rocha et al., 2003; Rosário et 
al., 2003; Maximino et al., 2006), and its behaviour can be modulated by intervening 
pharmacologically on AT1 receptors within the nucleus tractus solitarii (Kasparov et al., 
1998; Kasparov & Paton, 1999; Rocha et al., 2003; Rosário et al., 2003). In fact, during 
myocardial ischaemia, AT1 blockade reversed the remodelling of baroreceptor and 
chemoreceptor reflex function in a way similar to that elicited upon the overexpression of 
hKir2.1 in PVN neuronal cells  (Rocha et al., 2003; Rosário et al., 2003). 
The demonstration of a non-dipper blood pressure profile in animal models remains 
difficult, mainly due to the failure to establish a clear distinction between day and night 
values. This was confirmed in our study, because through PVN-induced sympathetic 
manipulations, we were only able to modify BP light–dark values of SHRs which 
approached those of WKY rats. However, we were unable to modify the day and night 
profile of BP value variations in both strains. This inability to define a light–dark profile in 
rats similar to the one set for human subjects may be due to the intermittent behaviour 
rats, with alternating awake and sleep periods in both the light and the dark phase. It is 
likely that the only way to define the light and dark phase profiles of rats better would be 
by monitoring of cerebral activity through EEG, which was outside the scope of the 
present work.  
In conclusion, the present work shows that the intervention on central 
sympathoexcitatory neurone excitability through the genetic manipulation of expression 
of K+ channels is able to alter peripheral blood pressure in the long term. This occurs by 
remodelling of the sympathetic outflow and restores the imbalance of peripheral reflex 
mechanisms that maintain cardiovascular homeostasis. Our data, from an animal model, 
give insights into the pathophysiological mechanisms involved in the aetiology of 
neurogenic hypertension and provide novel hypothetical therapeutic interventions at 
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both the central and the peripheral level of the autonomic nervous system to control 
sympatoexcitation. 
 
New findings and their importance under working hypothesis 1 
We are able to show, for the first time, that overexpression of an inwardly rectifying 
potassium channel in the paraventricular nucleus provided a long-term (>60 days) 
antihypertensive response in conscious spontaneously hypertensive rats that was 
associated with a reduction in neurohumorally mediated vasoconstriction, enhanced 
baroreflex sensitivity and reduced peripheral chemosensitivity; no such response was 
observed in normotensive rats.  Our results support the paraventricular nucleus as a 
therapeutic target for the chronic control of blood pressure in neurogenic hypertension 
under the concept of autonomic therapeutics. 
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HYPOTHESIS 2  
The excitation of PVN neurons elicits sympathoexcitation and pressor responses through 
excitatory connections with the rostro ventrolateral medulla. RVLM is a key area of the 
brainstem that regulates the rate and pattern of discharge of sympathetic pre-ganglionic 
neurons which are the major determinants of the sympathetic output to the heart and 
vessels as well as to the kidney. Despite receiving inputs from several central autonomic 
nuclei, a direct angiotensinogenic pathway from PVN to RVLM involved in cardiovascular 
reflexes regulation was described. Sympathetically mediated pressor responses have also 
been evoked from the medullo-cervical pressor area, an area that extends till the third 
cervical segment. These responses are not relayed through rostroventrolateral medulla 
and can be elicited when the brainstem is transacted. MCPA cells project to spinal neurons 
that directly innervate sympathetic preganglionic neurons. In accordance, the following 
working hypothesis was built: 
What is the role of rostral ventrolateral medullary activity in the long term maintenance 
of high blood pressure values, sympathoexcitation and baroreflex blunting? 
 
1. INTRODUCTION 
Hyperactivity of the sympathetic nervous system has for a long time been hypothesized 
as a mechanism for the initiation, development and maintenance of elevated blood 
pressure (BP) in human hypertensive patients and animal models (Bourjeili et al., 1995; 
Esler, 1995; Johansson et al., 1999; Mancia et al., 1999; Carlson et al., 2000; Grassi, 
2004b; Fisher & Paton, 2012). Recently, the development of non-pharmacological 
therapeutics through medical devices for the treatment of resistant hypertension has 
further emphasized the association between sympathetic hyperactivity and the 
generation of high blood pressure.  The findings that baroreflex impairment has been 
associated with a higher risk of developing hypertension in normotensive children with a 
family history of hypertension (Yamada et al., 1988) suggests a neurogenic component 
could be causal. This interpretation is consistent with increased levels of sympathetic 
activity and plasma noradrenaline in white coat and borderline hypertensive individuals 
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(Grassi, 1998, 2004a; Smith et al., 2004; Grassi, 2009). These studies imply that sympatho-
excitation precedes hypertension and may be a cause for this condition (Lucini et al., 
2002; Guyenet, 2006). The increase of sympathetic drive to the heart and peripheral 
circulation not only increases cardiac output and vascular resistance, causing elevated BP 
values (Schlaich et al., 2012), but also to end organ damage (Zubcevic et al., 2011), which 
worsens patient prognosis. 
Based mainly on anaesthetized animals, the rostroventrolateral medulla (RVLM) has been 
shown to be a pivotal area regulating cardiovascular sympathetic tone. The RVLM lies 
ventral to the rostral part of the nucleus ambiguous (NA), caudal to the facial nucleus and 
ventral to the Bötzinger complex (Dampney, 1994; Janig, 2006b). The RVLM neurones 
project to the sympathetic preganglionic neurones in the intermediolateral (IML) cell 
column of the spinal cord (Guertzenstein & Silver, 1974; Dampney, 1994; Leman et al., 
2000; Card et al., 2006b) and receives a direct glutamatergic projection from the NTS, 
believed to be part of the peripheral chemoreflex (Ross et al., 1985; Koshiya & Guyenet, 
1996b; Nosjean et al., 1998). There are also projections from the PVN to the RVLM 
(Kantzides & Badoer, 2005; Pyner, 2009). Functionally, electrical or chemical activation of 
RVLM evokes a pressor response which is blocked by adrenoreceptor antagonists (Ross et 
al., 1984; Kuo & Yang, 2000). In contrast, inhibition of the RVLM caused a decrease in BP, 
HR and sympathetic nerve activity in the conscious normotensive rat, from day 5 to day 
10 (Dampney, 1994; Kishi et al., 2001).  In acute studies, in chloralose-anesthetized SHR, 
bilateral injection of excitatory amino acid  antagonist kynurenic acid (KYN) into the RVLM 
reduced mean arterial pressure by ≈40 mmHg  however in WKY similar injections did not 
alter BP (Ito et al., 2000). 
Overexpression of MnSOD (Kishi et al., 2004; Nishihara et al., 2012), or microinjection of 
tempol (Kishi et al., 2004; Koga et al., 2008; Konno et al., 2012) decreased blood pressure, 
heart rate (HR) and urinary norepinephrine excretion in stroke-prone spontaneously 
hypertensive rats, but not in normotensive rats. Furthermore, other studies 
demonstrated that overexpression of inducible NO synthase (iNOS) in the RVLM elicited 
blood pressure elevation and sympathoexcitation in normotensive rats via increase in 
oxidative stress (Kimura et al., 2005) and a significant reduction in the molecular synthesis 
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and functional expression of iNOS in the RVLM produces the opposite effects (Chan et al., 
2001a; Chan et al., 2001b).  
In chloralose-anesthetized SHR, bilateral injection of excitatory amino acid  antagonist 
kynurenic acid (KYN) into the RVLM reduced mean arterial pressure by ≈40 mmHg  
however in WKY similar injections did not alter BP (Ito et al., 2000).  
It is under powerful baroreceptor reflex control, which provides profound inhibition to 
these neurons (Cravo et al., 1991; McAllen & May, 1994; Lipski et al., 1996; Guyenet, 
2006). This inhibition originates from GABA-ergic neurons located within the caudal 
ventrolateral medulla (CVLM) that are driven by glutamatergic neurons from the nucleus 
tractus solitarius (NTS) receiving baroreceptor inputs (Guyenet, 2006; Janig, 2006a). 
Bilateral lesions of the RVLM in anaesthetised animals results in a decrease in BP to levels 
comparable to those seen after spinal cord transection (Guertzenstein & Silver, 1974; 
Dampney & Moon, 1980).  Less is known about the role of the RVLM after chronic lesions 
in conscious rats. 
In the hypertensive state the role of RVLM neurons in the regulation of SNA and BP in 
conscious animals is not completely understood. To date, most of our knowledge of the 
RVLM for BP control in hypertension is restricted to anaesthetized animals. The central 
processing of baroreceptor reflexes in spontaneously hypertensive rats (SHR) appears 
normal, but CVLM-mediated inhibition of the RVLM sympathoexcitatory neurons seems 
to be attenuated, suggesting that it is specifically a baroreceptor-independent mechanism 
of cardiovascular regulation in SHR that is altered (Sved et al., 2000). It has also been 
reported that RVLM neurons in SHR are over-activated and possibly this mechanism may 
lead to increased BP and peripheral sympathetic nerve activity (Matsuura et al., 2002). 
The recent work of Moraes et al. indicates that the firing frequency of RVLM neurones, 
through there respiratory modulation, is exacerbated in the SHR  (Moraes et al., 2014).  
Our aim was to understand the importance of the RVLM for the maintenance of 
hypertension in conscious unrestrained adult SHR. Given the inevitable compensation 
that follows electrolytic and chemically induced lesions, we have used a virus to express a 
potassium channel to depress the electrically excitability of neurons. In previous studies, 
we have shown that lentiviral vectors (LVV) over expression of inward rectifying 
potassium channels hKir2.1 depressed the electrical excitability of NTS neurons (Duale et 
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al., 2005b; H et al., 2005). More recently, we showed a long term decrease in arterial 
pressure and sympathetic activity following LVV over expression of hKir2.1 channels in 
the paraventricular nucleus of the hypothalamus (Geraldes et al., 2013). Using this 
approach we have studied the chronic effect of depressing the intrinsic excitability of 
RVLM neurons on blood pressure and sympathetic activity in SHR.  We have compared 
the importance of the RVLM with another more recently described sympathoexcitatory 
region – the medullo-cervical pressor area (MCPA).  This pressor and sympathoexcitatory 
region is not dependent on the integrity of the RVLM (Seyedabadi et al., 2006). It extends 
caudally from the medulla at the level of the caudal pole of the inferior olive to the fourth 
cervical segment and contains spinally projecting neurons (which are neurochemically 
heterogeneous) that directly innervate the sympathetic preganglionic neurons 
(Seyedabadi et al., 2006). It is distinct from the caudal pressor area, because blockade of 
the RVLM with muscimol inhibited this pressor response but not that evoked from the 
MCPA (Seyedabadi et al., 2006). The role of this novel descending sympathoexcitatory 
region in central cardiovascular regulation remains to be elucidated. 
Here we show that expression of hKV1.2 channels in RVLM neurons causes a long lasting 
reduction in arterial pressure in SH rats but that no such chronic response was obtained 
from the MCPA.  
 
2. MATERIALS AND METHODS 
All the experimental procedures were in accordance with the European and Portuguese 
Law on animal welfare and had the approval of the ethic committee of the Faculty of 
Medicine, University of Lisbon, Portugal. Spontaneous Hypertensive Rats (SHR), males, 
aged 12 weeks and weighing 351±10g, were from Charles River Laboratory. Animals, 
synchronized for a 12:12h light-dark cycle (light on at 7am, light off at 7pm), were housed 
individually and allowed to freely move in standard plastic cages in a climate-controlled 
room (22±1ºC). Food and water were provided ad libitum. 
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2.1 Animal model of hypertension 
We have used the SHR that is a well established model of hypertension characterized by 
increased plasma catecholamine levels (Nagaoka & Lovenberg, 1976), increased 
sympathetic nerve activity (Judy et al., 1976), sympathetic hyperreactivity to stressful 
stimuli (Lundin & Thorén, 1982) and a faster firing rate of RVLM neurons (Chan et al., 
1991; Matsuura et al., 2002; Matsuura et al., 2005) when compared with its 
normotensive control, the Wistar-Kyoto rat (WKY).  
 
2.2. Viral vector construction and validation 
Lentiviral vector (LVV) construction was based on previous studies (Waki et al., 2003; 
Duale et al., 2007; Geraldes et al., 2013). The LVV-eGFP, used for the sham group, was a 
mix of LVV-TREtight-GFP 5.7x10E9 and LVV-Syn-Eff-G4BS-Syn-Tetoff 6.2x10E9 in a ratio 
1:4. These binary systems express enhanced Green Fluorescent Protein (eGFP). The LVV-
hKir2.1 is mix of LVV-TREtight-Kir-cIRES-GFP 5.4x10E9 and LVV-Syn-Eff-G4BS-Syn-Tetoff 
6.2x10E9 in a ratio 1:4, that expresses eGFP and human inwardly rectifying potassium 
channels (hKir2.1) in neurones. Validation of transduction efficacy and transgene 
expression was assessed as described previously by us (Duale et al., 2007; Geraldes et al., 
2013) and included mRNA expression, immunocytochemical and electrophysiological 
data.  
 
2.3. Microinjection sites 
Initially, we fine-tuned our stereotaxic coordinates for bilateral RVLM and MCPA 
microinjections in 10 SHR anaesthetised with sodium pentobarbitone (60mg/Kg, IP). 
Bilateral microinjections (0.05µl) of LVV-eGFP were performed. Using fluorescence 
microscopy and histological reconstruction, we determined the correct coordinates for 
RVLM and MCPA microinjections and the amount of LVV-eGFP needed to limit 
transduction to the confines of the RVLM and MCPA.  
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2.4. Surgery 
SHR were divided into 4 groups according to the region and microinjection content: RVLM 
LVV-hKir2.1 (n=6), MCPA LVV-hKir2.1 (n=6) and RVLM LVV-eGFP (n=6), MCPA LVV-eGFP 
(n=5).  
 
a) Implantation of radio-telemetry probes 
SHR were anaesthetised (sodium pentobarbitone, 60mg/kg, i.p.) and a medial laparotomy 
was performed to allow the insertion of the telemetry sensor catheter (ca. 0.7 mm, thin-
walled thermoplastic membrane) into the root of the abdominal aorta, below the renal 
artery, using a binocular microscope. Before implantation, the aorta was clamped 
proximally and the catheter was inserted and secured with medical glue (Vetbond 3M, 
Saint Paul, MN, USA). Radiotelemetric pressure transducers (Data Sciences International, 
St. Paul, Minnesota, MN, USA) consisting of a fluid-filled catheter connected to a PA-C40 
transmitter was sutured in the abdominal wall to allow the transmission of blood 
pressure (BP) values over months. Antibiotics (Baytril, 5 mg/kg) and analgesics (Rimadyl, 4 
mg/kg) were subcutaneous injected at the end of the surgery. The animals were allowed 
to recover for two weeks before viral gene transfer and blood pressure (BP) and heart 
rate (HR) were continuously monitored by telemetry.  
 
b) Bilateral microinjection into RVLM and MCPA 
Two weeks after the probes were implanted, SHR rats were placed in a stereotactic frame 
(Kopf Instruments) and a craniotomy performed using our previously determined 
coordinates for LVV-hKir2.1 microinjections (0.05µl) into the RVLM (B: -12.5mm, L: 
2.1mm, D: 8mm) or MCPA (B: -14,8mm, L: 2mm, D: 4,5mm)(Paxinos & Watson, 1986). 
Sham rats were microinjected in the same region with LVV-eGFP. All microinjections were 
performed bilaterally. Animals of all groups were allowed to recover and monitored by 
telemetry for 60 days. Heart rate (HR) and blood pressure (BP; systolic, diastolic and 
mean) were recorded continuously.  
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2.5. Metabolic Evaluation 
Rats were housed individually for 24h in metabolic cages to evaluate food and fluid 
intake, urine and faeces production and body weight, before and 59 days after the 
microinjections.  
 
2.6. Cardio-respiratory reflexes evaluation 
At 60 days, the SHR were anesthetised (sodium pentobarbitone, 60mg/Kg, IP). The 
trachea was cannulated below the larynx to record tracheal pressure (TP). The femoral 
and carotid artery (for arterial pressure monitoring) and femoral vein were cannulated. 
Rectal temperature was maintained at 38±1°C by a servo-controlled heating blanket. The 
electrocardiogram (ECG) was recorded with the use of needle electrodes inserted into the 
limbs and HR is derived from the ECG. The respiratory rate (RespR) was obtained though 
the TP recording. Baroreceptor and peripheral chemoreceptor reflexes were activated 
twice with an interval of 5 minutes between each stimulation. The baroreceptor reflex 
was stimulated using phenylephrine (0.2ml, 25µg/ml i.v.; Sigma Aldrich). Peripheral 
chemoreceptor reflex was stimulated with lobeline (0.2ml, 25µg/ml, Sigma Aldrich) 
injected retrogradely via the external carotid artery into the bifurcation of the common 
carotid artery. HR, BP (systolic, diastolic and mean) and RespR were recorded 
continuously thought the experiment. 
 
2.7. Histology and immunochemistry  
Animals were terminally anesthetized with an overdose of sodium pentobarbitone 
(60mg/Kg, iv) and immediately perfused transcardially with phosphate-buffered saline 
(PBS; 0.1M; pH 7.4) followed by 4% paraformaldehyde (0.1M; pH 7.4). The brain was 
removed and placed for 48 h in 15% (w/v) sucrose solution. Coronal sections (18 µm) 
were cut on a microtome and mounted on slides. The pipette tip location and the 
microinjection diffusion in the RVLM were examined and documented. The microinjected 
contents (LVV-hKir2.1 or LVV-eGFP) containing e-GFP allowed an estimation of virus 
dispersion. eGFP-labeled fluorescent regions were identified using an epifluorescence 
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microscope and plotted on standardized sections from the Paxinos and Watson atlas 
(Paxinos & Watson, 1986).  
 
2.8. Western blot analysis  
The expression of hKir2.1 protein in RVLM and MCPA was analysed by western blot 
following 60 days after the microinjection of LVV-hKir2.1 (n=6) and LVV-eGFP in SHR 
(n=5). The RVLM and MCPA were dissected from both groups and homogenized by 
sonication in ice cold RIPA buffer (Sigma) supplemented with a cocktail of protease 
inhibitors (complete mini, Roche). Proteins were extracted from the homogenates by 
centrifugation at 5000g for 10 minutes at 4ºC and protein concentration was determined 
with Bio-Rad DC Protein Assay kit. Proteins were resolved by electrophoresis on a 10% 
Tris-Glycine SDS-PAGE gel and transferred to a polyvinylidene fluoride (PVDF) membrane 
(Millipore). Membranes were blocked with 5% milk in Tween/Tris Buffered Saline (TBST) 
and incubated overnight at 4ºC with rabbit anti-hKir2.1 polyclonal antibody (Abcam). 
After washing, membranes were incubated for 1 hour at room temperature with Goat 
anti-rabbit HRP conjugated (Bio-Rad) and immunoreactive proteins were detected by 
Immobilon Western Chemiluminescent HRP Substrate (Millipore) and visualized using 
Curix 60 (AGFA). Membranes were stripped with 0.1M Glycine pH2.2 and reprobed with 
the α-tubulin antibody (Santa Cruz Biotechnology) for loading control. 
 
2.9. Analysis of BP and HR variability 
Telemetric pulsatile blood pressure data were acquired continuously at 1KHz and 
analyzed with suitable software (LabChart6, Powerlab, ADInstruments). Mean values of 
HR, BP (systolic, diastolic and mean) and RespR were extracted.  
 
a) Baroreceptor and chemoreceptor reflex 
The baroreceptor reflex gain (BR ) was quantified calculating ∆HR/∆BP (bpm.mmHg−1). 
Chemoreceptor (ChR) reflex was calculated through the RespR derived from the tracheal 
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pressure before and after stimulation with lobeline: ΔChR = RespRlobeline - RespRbasal. BP 
and HR were also evaluated.  
 
b) Analysis of BP and HR variability  
Systolic BP and RR interval data were analyzed (period of 3 minutes) in the frequency 
domain (Fast Fourier Transform, FFT), using the in-house software Fisiosinal (Tavares, 
2011a), to evaluate sympathetic (Low Frequency band, LF, 0.15-0.6Hz of SBP) and 
parasympathetic (High Frequency band, HF, 0.6-2.0Hz of HR) activity over time (M Malik, 
1996; Marques-Neves et al., 2004). 
 
c) Circadian light/dark heart rate and blood pressure profile  
Mean BP and HR values were calculated using the continuous telemetric data and 
compared between light (7am-7pm) and dark phases (7pm-7am). 
 
2.10. Statistical analysis 
Comparisons between groups for the same period and also comparisons within the same 
group, before and after the microinjections were performed. For the statistical analysis, 
Student’s t test for paired data and ANOVA (with Tukey's range test used as post hoc test) 
for comparisons between inter-groups were used. All data were expressed as mean±SEM 
and passed the normality test. Significance was taken as P < 0.05. 
 
3. RESULTS 
3.1 Effect of LVV-hKir2.1 or LVV-eGFP microinjection on 24h mean values of blood 
pressure, heart rate and respiration  
Basal BP values in conscious SHR (n=23) were 155±3 mmHg (systolic), 130±3 mmHg 
(diastolic) and mean BP was 138±3 mmHg. HR was 310±4 bpm (Table 3.3). There was a 
continuous downward trend in BP after RVLM microinjection of LVV-hKir2.1 in with a 
significant decrease (p<0.05) by day 30.  To evaluate its persistence, animals were 
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monitored for a further 30 days. At 60 days post microinjection of LVV-hKir2.1 values for 
systolic, diastolic and mean BP were 116±8 mmHg, 90±12 mmHg and 98±10 mmHg, 
respectively. This corresponded to decreases of 39 mmHg, 40 mmHg and 40 mmHg in 
systolic, diastolic and mean BP, respectively (p<0.0001, Figures 3-5). These BP changes in 
the RVLM SHR LVV-hKir2.1 group were accompanied by a lowering of HR to 293±6 bpm 
(p>0.05), but RespR remained unchanged at all time points. At 60 days after 
microinjection, the RespR values for RVLM LVV-hKir2.1 group was 72±3 cpm (p>0.05). 
The RVLM SHR LVV-eGFP group showed increased values of systolic (168±9 mmHg, 
p>0.05), diastolic (148±9 mmHg, p>0.05) and mean BP (155±9 mmHg, p>0.05) together 
with a decrease in HR (292±4 bpm, p>0.05, Figure 3-5). This profile of BP and HR changes 
was expected and consistent with their developmental trend (Dickhout & Lee, 1998) .  
In the MCPA group, at the 60th day after lentiviral microinjection, BP and HR in SHR LVV-
hKir2.1 remained unchanged (Table 3.3, Figure 3-5). Also, RespR didn´t change between 
the two groups, the RespR values for MCPA SHR LVV-hKir2.1 was 63±3 cpm and for MCPA 
SHR LVV-eGFP was 63±3 cpm (p>0.05). 
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Fig. 3-5 – Effect on systolic, diastolic blood pressure and heart rate in SHR before (0 days) and after 
microinjection of LVV-hKir2.1 in RVLM (n=6) and in MCPA (n=6) or LVV-eGFP in RVLM (n=6) and in MCPA 
(n=5). The asterisks denote statistically significant differences between LVV-hKir2.1 and LVV-eGFP groups; 
*p < 0.05; **p < 0.01.  
3.2. Effect of LVV-hKir2.1 microinjection on sympathetic output measured indirectly 
SHR showed an overall decrease of cardiovascular autonomic outflow at 60 days after 
LVV-hKir2.1 microinjection in the RVLM when compared with basal autonomic output at 
day 0.  By using FFT applied to systolic BP and interpulse intervals, a decrease in 
sympathetic output expressed by LFsBP band power was observed (from 0.69±0.11 to 
0.42±0.10 mmHg2, p<0.05). The LFsBP/HFRR ratio for RVLM hKir2.1 was from 0.09±0.02 at 
the baseline to 0.05±0.01 mmHg2.ms-2 at 60 days; p>0.05. In contrast, the LFsBP/HFRR ratio 
for RVLM LVV-eGFP (from 0.08±0.02 to 0.09±0.03, p>0.05) and the LF (from 0.74±0.13 to 
0.86±0.16,p>0.05) remain unchanged. The LFsBP and LFsBP/HFRR ratio was unchanged in 
MCPA LVV-hKir2.1 (from 1.02±0.23 to 1.03 ± 0.23 mmHg2 and from 0.067±0.03 to 
0.05±0.02 mmHg2.ms-2; p>0.05). Also in MCPA LVV-eGFP the LF/HF ratio (from 0.099±0.02 
to 0.10±0.03 mmHg2.ms-2; p>0.05) and the LF (from 1.12±0.10 to0.90 ± 0.18 mmHg2; 
p>0.05) remain unchanged. The variations of mean LFsBP and LFsBP/HFRR, at 10-days 
intervals for each SHR group, are depicted in figure 3-6.  
CHAPTER 3 – RATIONALE, HYPOTHESIS, METHODS AND RESULTS   
101 
 
 
Fig. 3-6 – Mean (±SEM) LF and LF(BP)/HF(RR) before (0 days) and 10 days intervals after the 
microinjection of LVV-hKir2.1 or LVV-eGFP in RVLM (above) and in MCPA (below). The asterisks denote 
statistically significant differences between groups; *p < 0.05. 
 
3.3. Arterial baroreflex gain (BRG) and peripheral chemoreflex responsiveness 
Injection of phenylephrine (PHE) triggered a progressive increase in mean BP, which was 
accompanied by a progressive reduction in HR. No changes in the BRG were found in all 
groups evaluated: in RVLM LVV-hKir2.1 was 0.45±0.07 bpm.mmHg-1, in RVLM LVV-eGFP 
group was 0.42±0.05 bpm.mmHg-1, in MCPA LVV-hKir2.1 was 0.40±0.05 bpm.mmHg-1 and 
in MCPA LVV-eGFP group was 0.36±0.06 bpm.mmHg-1, p>0.05, Figure 3-7). In RVLM the 
BP changes to PHE injection in SHR LVV-hKir2.1 was 52±4 mmHg and in SHR LVV-eGFP 
was 62±5 mmHg (p>0.05). In SHR LVV-hKir2.1 MCPA was 82±7 mmHg and in SHR LVV-
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eGFP MCPA was 67±6 mmHg (p>0.05). Between the SHR LVV-hKir2.1 RVLM and SHR LVV-
hKir2.1 MCPA groups there were extremely significant differences in the pressor response 
to PHE injection (p<0.0001). 
Peripheral chemoreceptor reflex activation with lobeline, elicited a hyperventilatory 
reflex responses of different magnitude according to the animal group. In RVLM SHR LVV-
hKir2.1 animals the ventilatory response remained unchanged when compared with 
RVLM SHR LVV-e FP (Δ24.8±3.0 vs Δ28.9±3.9 cpm, respectively, p>0.05). The same 
happened to MCPA SHR LVV-hKir2.1 group when compared with MCPA SHR LVV-eGFP 
(Δ37.7±5.0 vs Δ29.0±4.2 cpm, respectively, p>0.05) (Figure 3-7). Pressor responses to 
chemoreflex activation in RVLM SHR LVV-hKir2.1 (from 157±8 to 173±10 mmHg) were 
similar compared to RVLM SHR LVV-eGFP rats (192±9 to 211±9 mmHg; p>0.05) and also 
HR responses were not different (from 318±14 to 317±16 vs 372±12 to 371±17 bpm, 
respectively). In MCPA the mean BP and HR responses to chemoreflex activation were 
unchanged in SHR LVV-hKir2.1 (from 146±9 to 164±7 mmHg and from 341±11 to 343±10 
bpm, p>0.05) and in SHR LVV-eGFP (from 178±8 to 195±6 mmHg and from 352±13 to 
347±3 bpm). 
Fig. 3-7 – The histograms show the effect of bilateral microinjections of LVV-hkir2.1 or LVV-eGFP into the 
RVLM or MCPA on cBRG and chemoreflex variation, 60 days post-microinjection.  Abbreviations: cpm, 
cycles per minute. 
 
3.4. Circadian variation of BP and HR  
In basal conditions and without any intervention, the pattern of circadian variation of BP 
and HR followed a similar trend- lower BP values during the light phase relative to the 
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dark phase and there were no significant changes between all groups evaluated (Figure 3-
8).  At 60 days after the LVV-hKir2.1 microinjection, RVLM SHR showed a significant 
decrease of systolic, diastolic and mean BP during both light and the dark phases (both 
p<0.001; Table 3.3). A significant decrease of HR was observed during the light (p<0.01) 
but not during the dark phase (p>0.05).  For the RVLM SHR LVV-eGFP rats HR, diastolic, 
systolic and mean BP values for the light phase and dark phase were expectedly increased 
at 60 days (Table 3.3). There were no changes in BP values in MCPA SHR LVV-hKir2.1 
group (Table 3.3). In MCPA SHR LVV-eGFP rats there was an increase in BP during the 
both phases (Table 3.3). HR didn´t change in both MCPA groups (table 3.3). 
 
Fig. 3-8 – Raw data showing blood pressure and heart rate: (A) SHR before and (B) 60 days after 
microinjection of LVV-hKir2.1; (C) another SHR at 60 days after microinjection of LVV-eGFP in RVLM 
during light (white) and dark (gray) phases.  
 
 
CHAPTER 3 – RATIONALE, HYPOTHESIS, METHODS AND RESULTS   
104 
Table 3.3 – Blood pressure (sBP: systolic Blood Pressure, dBP: diastolic Blood Pressure and mBP: mean 
Blood Pressure; mmHg) and Heart Rate (HR; bpm) during the light and dark phases for all SHR groups 
before and 59 days after the microinjection. Values are expressed as mean±SEM.  The asterisks denote 
statistically significant differences between basal and day 59; 
a
p<0.05; 
b
p<0.01; 
c
p<0.001. 
 
Basal 
Light phase Dark phase 
sBP dBP mBP HR sBP dBP mBP HR 
RVLM 
LVV-hKir2.1 
152±5 123±5 133±4 284±4 154±5 127±6 136±5 322±6 
RVLM 
LVV-eGFP 
158±4 134±5 142±5 290±6 160±4 138±6 146±5 315±6 
MCPA 
LVV-hKir2.1 
147±12 121±5 130±7 305±10 153±13 127±6 136±9 354±11 
MCPA 
LVV-eGFP 
156±6 131±6 139±6 298±3 158±6 133±7 142±6 318±6 
 
 59 days after microinjection 
Light phase Dark phase 
sBP dBP mBP HR sBP dBP mBP HR 
RVLM 
LVV-hKir2.1 
115±7
c
 88±12
c
 97±10
c
 267±3
b
 117±8
c
 92±12
c
 100±11
c
 320±10 
RVLM 
LVV-eGFP 
166±9 145±10 152±9 272±4
a
 170±8 150±10 157±9 312±4 
MCPA 
LVV-hKir2.1 
141±12 120±6 127±8 295±12 147±13 125±7 132±9 336±7 
MCPA 
LVV-eGFP 
166±9 144±12 151±11 274±4 167±9 146±12 153±11 311±5 
 
3.5. Metabolic evaluation 
No significant changes were found in body weight, food and water intake or in feces and 
urine production in all four groups before and after microinjections (Table 3.4). Body 
weights of all groups of animals (hKir2.1 and eGFP) were not significantly different before 
LVV microinjections. However, all increased at the end of the experience. 
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Table 3.4 – Metabolic evaluation of SHR before and 59 days pos-injection in RVLM. Values are expressed 
as mean±SEM.  The asterisks denote statistically significant differences between basal and day 59; *p < 
0.05. 
 
 Before microinjection – Basal condition 
ΔWeight (g) Food (g) Water(mL) Faeces (g) Urine (mL) 
SHR LVV-eGFP 5.0±6.2 29.0±4.3 30.0±5.0 9.7±3.1 10.3±3.1 
SHR LVV-hkir2.1 0.14±5.9 25.6±2.1 41.6±11.8 17.0±5.0 17.1±9.2 
 
 After microinjection (60dpi) 
ΔWeight (g) Food (g) Water(mL) Faeces (g) Urine (mL) 
SHR LVV-eGFP 0.3±2.1 27.0±2.0 32.7±13.7 16.0±3.5 12.3±3.8 
SHR LVV-hkir2.1 -4.1±2.1 22.1±3.6 37.9±10.7 13.3±4.1 14.6±3.5 
 
 
3.6. Immunohistochemical and Western blot analysis 
The microinjection sites were located within the RVLM and MCPA according to Paxinos 
and Watson rat atlas (Paxinos & Watson, 1986). e-GFP was detected by fluorescence 
microscopy being fluorescence confined to a surface of 0.10 to 0.20 mm around the 
injection site (Figures 3-9 and 3-10). Through immunohistochemical studies it was 
confirmed that RVLM and MCPA neurones expressed eGFP (Figures 3-9 and 3-10). The 
over expression of hKir2.1 in RVLM and MCPA was analyzed using western blot. The 
RVLM and the MCPA dissected from SHR microinjected with LVV-hKir2.1 showed an 
increased expression of hkir2.1, on average about 3 times increased in RVLM and 2 times 
increased in MCPA when compared to LVV-eGFP groups (Figure 3-11).  
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Fig. 3-9 – Localization of the RVLM microinjection sites (black circles) and lentiviral vector-mediated 
transduction of green fluorescent protein (GFP) in the RVLM; confocal microscope images of GFP-
expressing cells in the RVLM (bar: 50 µm) following injection of lentiviral vector into this site. Amb, 
nucleus ambiguous; Py, pyramidal tract; Sp5, spinal trigemina nucleus; 4V, 4th ventricle. 
 
Fig. 3-10 – Localization of the MCPA microinjection sites (black circles) and lentiviral vector-mediated 
transduction of green fluorescent protein (GFP) in the MCPA; confocal microscope images of GFP-
expressing cells in the MCPA (bar: 50 µm) following injection of lentiviral vector into this site. RAmb, 
nucleus retroambiguous; Py, pyramidal tract; Sp5, spinal trigemina nucleus. 
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Fig. 3-11 - Western blot analysis of sham SHR (1, 4) and LVV-hKir2.1 microinjected SHR (2, 3, 5, 6) in RVLM 
and in MCPA. Results show an over expression of hKir2.1 in LVV-hKir .1 microinjected SHR. α-tubulin was 
used as house keeping gene. 
 
4. DISCUSSION 
In the present work, our purpose was to depress chronically the activity of RVLM and 
MCPA neurones by the over-expression of K+ channels to evaluate its consequences upon 
long term blood pressure regulation in conscious unrestrained SHR. For that, we over-
expressed a human inward rectifying potassium channel (hKir2.1) under the control of a 
synapsin promoter that was neuron specific (Duale et al., 2005a; Duale et al., 2005b). 
Lentivirus was used as it induces sustained protein expression within neurones for 
months (Coleman et al., 2003). In previous studies, Duale et al (2007) and Howorth et al 
(2009) showed that hKir2.1 over-expression hyperpolarized the membrane potential of 
cultured cathecolaminergic PC12 cells by ~10mV  which is expected to “electrically 
silence” neurones (Duale et al., 2007; Howorth et al., 2009). Similar over-expression 
strategies have been used to electrically silence  neurones affecting development in ovo 
(Yoon et al., 2008), neuronal discharge in vivo (Okada & Matsuda, 2008) and the ability of 
neurones to make and maintain connections in vivo (Yu et al., 2004; Mizuno et al., 2007; 
Hendy, 2010). This viral mediated approach has the advantage of being site specific and 
enabling over-expression in adulthood, avoiding the development of putative 
compensatory mechanisms associated with transgenic animals (Hendy, 2010). 
Our results show that LVV-hKir2.1 microinjection in RVLM of conscious SHR lowered the 
frequency power of systolic blood pressure indicative of a reduction in sympathetic 
activity, however our interpretations of changes in SNA are indirect and based on spectral 
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analysis. This occurred coincident with a decrease in systolic (-39 mmHg), diastolic (-40 
mmHg) and mean BP (-40 mmHg) at 60 days post-microinjection. Sham rats did not show 
decreases in BP during the recorded period. In contrast to the RVLM, LVV-hKir2.1 
injection in the MCPA   was without effect on arterial pressure over the same time frame.  
This might be explained by the fact that the MCPA is not dependent on the integrity of 
the RVLM as described above. This explanation also assumes that the MCPA does not 
contribute tonic activity to sympathetic motor outflow at rest in conscious rats.   Thus, 
the physiological role that this cell group plays in circulatory control of normotensive and 
hypertensive animals remains to be fully determined.  
Following all LVV microinjections into the RVLM and MCPA heart rate decreased. Since 
this was observed in all rat groups this change appears to be a function of time.   
Despite the fall in arterial pressure in the SHR, LVV-hKir2.1 microinjection had no effect 
on the peripheral chemoreflex evoked cardiovascular and respiratory responses. This 
result was unexpected given the importance of the RVLM in mediating the peripheral 
chemoreceptor reflex evoked sympathoexcitation in acute anaesthetized rats (Koshiya & 
Guyenet, 1996a). We can hypothesize that the chronic depression of RVLM excitability 
could lead to neuronal plasticity and enhanced functional expression of peripheral 
chemoreflex pathways that bypass RVLM, such as those routing via the PVN, the lateral 
hypothalamus or the pre-limbic cortex (Owens & Verberne, 1996; Olivan et al., 2001; 
Gabbott et al., 2005).   
The microinjection of the lentiviral vector (LVV-hKir2.1) in the RVLM did not evoke any 
change in the baroreflex sensitivity (BRS) in the SHR. This is already impaired in the SHR 
compared to normotensive rats, indicating a deficit in the vagal capacity to reduce heart 
rate (Verberne et al., 1988; Widdop et al., 1990; Minami & Head, 1993). However, 
impairment of BRS controlling heart rate was not associated with impairment of BRS 
controlling efferent sympathetic nerve activity in human hypertension (Grassi et al., 1998) 
suggesting distinct reflex pathways. So, the impairment of BRS in the SHR is related to the 
efferent parasympathetic, vagal pathway. Due to these facts, we were not surprised that 
there are no changes in baroreflex gain, since this reflects cardiac reflex gain that is 
mainly determined by the activity of cardiac vagal motoneurons and these were not 
targeted in the present study.  
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Given that the peripheral chemoreflex and the baroreflex were tested under anesthesia 
the depressant effect of the agent cannot be neglected as it may exacerbate the reduced 
excitability of RVLM neurons and might alter the normal pattern of cardiovascular control 
(Korner, 1971). In particular, by stimulating the GABA-ergic system barbiturates will 
enhances the inhibitory pathway between the caudal ventrolateral medulla and the 
RVLM, further decreasing RVLM excitability. Future studies should focus on the baroreflex 
sympathetic vasomotor gain in SHR before and after LVV-hKir2.1 in the RVLM.  
In summary, our data show that chronic expression of Kir2.1 in the RVLM of conscious 
unrestrained SHR caused a marked and sustained decrease in blood pressure without 
changes in the baro- and peripheral chemoreceptor reflex evoked responses in 
cardiovascular and respiratory parameters. This decrease was mostly due to a reduction 
in sympathetic output as revealed indirectly by a decrease in the power density of the LF 
band of SBP and by the decrease in LF/HF SBP balance. Our data is amongst the first to 
demonstrate the role of the RVLM in maintaining levels of arterial pressure in 
hypertension in conscious SHR. We suggest that a decrease in RVLM neuronal activity is 
an effective anti-hypertensive treatment strategy. Thus, the RVLM remains an area for 
novel therapeutic intervention for controlling BP long-term.  
 
New findings and its importance under working hypothesis 2 
Our data are amongst the first to demonstrate the role of the RVLM in maintaining levels 
of arterial pressure in hypertension in conscious SHR. Our results show that LVV-hKir2.1 
expression of RVLM neurons caused a substantial and sustained decrease of blood 
pressure (SBP ~ 25 mmHg) reflecting a reduction in sympathetic output, as evidenced by 
the indirect decrease of the LF band. In contrast to the RVLM, LVV-hKir2.1 injection in the 
MCPA was without effect on arterial pressure and sympathetic output over the same time 
frame. These data strongly show that not all central sympathetic areas are involved in the 
sympathoexcitation observed under pathological conditions and that RVLM is a key area 
for the relay of sympathetic information. In accordance, the decrease of RVLM neuronal 
activity could be an effective anti-hypertensive treatment strategy, remaining RVLM as an 
area for novel therapeutic intervention to long-term control of BP. 
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HYPOTHESIS 3 
Hypertensive disease runs with modifications on peripheral organs, the most important 
being the highly vascular ones like the brain, kidney and heart and vessels. Despite the 
earliest changes in these hypertensive target organs are largely compensatory in nature 
with time, in particular if the patient is not treated, they lead to functional compromises 
like left ventricular hypertension, stroke or renal failure. Recent studies have shown that 
pharmacological therapeutics with ACE inhibitors or beta blockers is able not only to delay 
the progression of target organs damage but to evoke reverse remodelling. In accordance, 
the following working hypothesis was built: 
Will the chronic depression of brain sympatho-excitatory regions activity induce major 
signalling changes in hypertensive target organs condition? 
 
1. INTRODUCTION 
Arterial Hypertension (AHT) and its development are associated with structural, 
functional, genomic and transcriptomic alterations in several organs, in particular in the 
hypertensive target organs like brain, heart, kidney and vasculature, all of them 
contributing to cardiovascular risk. In conditions when AHT is uncontrolled, genomic 
expression and transcriptomic alterations can evoke changes in different signal-
transducing cascades, thus, accelerating organ damage which ultimately results in organ 
failure and secondary disease such as stroke, cardiac ischemia and nephropathy. It is well 
recognised that elevated blood pressure can also cause left ventricular hypertrophy, 
aortic stiffness, atherosclerotic plaques and microvascular disease that may render AHT 
more difficult to control (Muiesan ML, 2013; Raizada, 1993; Schork, 1995). 
Significant progress in molecular biology has demonstrated that AHT develops as a 
complex pathological state with a genetic background involving various hormonal and 
neuronal systems. 
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In normal cardiovascular function, angiotensin II and endothelin are implicated in the 
regulation of normal cardiovascular function, including regulation of peripheral artery 
resistance, vasodilation, vasoconstriction and vascular tone. These functions are exerted 
by signaling pathways through G protein-coupled receptors being well established that 
changes in these signaling pathways are contributory factors for hypertension. 
In particular, to angiotensin II and the renin-angiotensin system, it is well established that 
this hormonal system is elevated in several experimental models of AHT, as well as 
human essential AHT (Cowley 1992; Reinhart et al. 1995; Lenkei et al. 1997; Weir and 
Dzau 1999; de Gasparo et al. 2000; Lifton et al. 2001; Doris 2002). An elevated RAAS 
impacts blood pressure directly via vasoconstriction and sodium retention, through 
generation of angiotensin II (Ang II), as well as indirectly through increased reactive 
oxygen species (ROS), altering redox signaling and increased sympathetic outflow (Collett 
J, 2013). 
More recently the existence of the local or tissue RAAS has been established and is 
thought to participate in cardiovascular regulation (Shan et al., 2004; Klett C, 1993; Nyui 
N, 1997, Tamura K, 1995; Griendling KK, 1993; Dzau VJ, 1994). This local RAAS may play an 
important role in hypertension and may exist and function in the heart, brain, adrenal 
gland, kidney, blood vessel wall, and adipose tissue (Nyui N, 1997; Tamura K, 1996). 
However, the exact role of this local system is not clear, since there are doubts about the 
physiologically relevance of some components of the RAAS, but it is interesting to 
speculate that a local RAAS may increase the effects of Ang II on a specific tissue in a 
particular physiological and pathophysiological processes, such AHT (Tamura K, 1996). 
Angiotensin-converting enzyme (ACE) inhibitors can lower the blood pressure in 
spontaneously hypertensive rats (SHR) mainly by reducing production of Ang II and 
decreasing bradykinin degradation (Gohlke P, 1994; Johnson CI, 1994). In fact, a 4-week 
period of ACE inhibitor treatment in young SHR is sufficient to prevent the full expression 
of genetic hypertension and cardiovascular hypertrophy and that Ang II might be 
important in the development of hypertension in this animal model of AHT (Harrap SB, 
1990). 
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Endothelial cells are also involved in blood pressure control by releasing vasoactive and 
trophic factors that regulate vascular tone being nitric oxide (NO) and endothelin 1 (ET-1), 
two endothelial factors that are particularly involved in this regulation. Endothelial NO 
produced through the interference of eNOS is the main vasodilator factor that causes 
relaxation of the vascular smooth muscle. In hypertension, endothelial dysfunction has 
been related to an increased NO breakdown by reactive oxygen species (ROS) and a 
reduced NO production by eNOS resulting in a reduced vasodilator capacity of vessels 
(Mar n- arc a et al.   011). Together with these changes on NO availability  the 
dysfunctional endothelial cells also produce a series of vasoconstrictor factors which 
include endothelin 1. At vascular level, ET-1 binds to two types of endothelin receptors, 
type A and B. The type A receptors are mainly located in the smooth muscle cells and 
stimulate vascular contraction; on the other hand, ETB-receptors are abundant on 
endothelial cells and mediate NO release facilitating vasodilation. In hypertension, the 
ETB-receptors fail to increase NO-mediated vasodilation being the overall effect effect, an 
increase of vessels constriction due to the stimulation of ET-A receptors by ET-1 (Penna et 
al., 2006; Kohan et al., 2011; Ohkita et al., 2012; Kaoukis et al., 2013; Moorhouse et al., 
2013). 
Studies from our laboratory have shown that reducing the neuronal activity in either the 
paraventricular nucleus of the hypothalamus (PVN) or rostral ventrolateral medulla 
(RVLM) via chronic over expression of an inwardly rectifying potassium channel (hKir2.1) 
of SHR resulted in a long term and persistent decrease of blood pressure and sympathetic 
activity (Geraldes et al., 2014a; Geraldes et al, 2014b). 
Since the aetiology of the signalling changes in hypertensive target organs is not yet fully 
understood, in the present work, we studied tissue-specific mRNA expression genes of 
hypertensive target organs following the persistent decrease of blood pressure and 
sympathetic output to clarify the causal relationship between the decrease of blood 
pressure values and the reverse signalling phenomena in hypertensive target organs 
tissue. 
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2. MATERIALS AND METHODS 
All the experimental procedures were in accordance with the European and Portuguese 
Law on animal welfare and had the approval of the ethic committee of the Faculty of 
Medicine, University of Lisbon, Portugal. WKY rats (n=7) and SHRs (n=14), males, aged 12 
weeks and weighing 363±8g, were used. Animals, synchronized for a 12:12h light-dark 
cycle (light on at 7am, light off at 7pm), were housed individually and allowed to freely 
move in standard plastic cages. Food and water were available ad libitum. 
 
2.1. Lentiviral treatment 
SHRs were divided into 2 groups according to the content of the microinjection: LVV-
hKir2.1 (n=7) and LVV-eGFP (n=7). Rats were implanted with radio-telemetry probes (DSI) 
in the abdominal aorta under anaesthesia (sodium pentobarbitone, 60mg/Kg, IP) and 
were allowed to recover for 15 days.  
Two weeks after the probes were implanted, SHR rats were placed in a stereotactic frame 
(Kopf Instruments) and a craniotomy performed using our previously determined 
coordinates for LVV-hKir2.1 (LV-TREtight-Kir-cIRES-GFP 5.4x10E9 and LV-Syn-Eff-G4BS-
Syn-Tetoff 6.2x10E9 in a ratio 1:4) bilateral microinjections (0.05µl) into the PVN (B: -
1.6mm, L: -/+1.41mm, D: 7.4mm; pipette angle: 10°) or RVLM (B: -12.5mm, L: 2.1mm, D: 
8mm) (G & C, 1986). Sham rats were microinjected in the same region with LVV-eGFP 
(LVV-TREtight-GFP 5.7x10E9 and LVV-Syn-Eff-G4BS-Syn-Tetoff 6.2x10E9 in a ratio 1:4). 
Animals were allowed to recover and monitored by telemetry for 60 days. Heart rate (HR) 
and blood pressure (BP; systolic, diastolic and mean) were recorded continuously. The 
microinjection was not applied to WKY rats. 
 
2.2. Organ tissue processing, RNA isolation and cDNA Synthesis 
At the end of the experimental protocol described above, animals were killed with an 
overdosis of anesthesia (pentobarbital, 50 mg/kg, i.v.). The target organs (heart, vessel 
and kidney) were excised, immediately frozen separately in liquid nitrogen and stored at 
−80 ◦C for subsequent RNA isolation. 
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The heart, carotid artery and kidney samples of individual LV-treated SHR, Sham SHR and 
WKY rats were grinded with a mortar and pestle in liquid nitrogen and approximately 
50mg of powdered tissue was homogenized in Tri Reagent® Solution (Ambion) for total 
RNA isolation according to the manufacturer’s instructions. RNA concentration was 
estimated by measuring the absorbance at 260nm and its purity assessed by determining 
the 260/280nm absorbance ratio using NanoDrop 1000A (Thermo Scientific). 
First strand cDNA was synthesized from 1µg of total RNA using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems)  according to the manufacturer’s 
instructions. 
 
2.3. Quantitative real-time PCR analysis 
Oligonucleotide primers were designed with Primer Express ® Software Version 3.0 
(Applied Biosystems) according to the recommended parameters for quantitative assays, 
based on the mRNA sequences obtained from the Rat Genome Database. Gene ID and 
oligonucleotide sequences are listed in Table 3.5. The chosen genes are known to be 
involved in various processes including blood pressure regulation, renin-angiotensin 
system, nitric oxide metabolism and signalling, vasoconstriction/vasodilatation, osmotic 
shock, ion transport, nitric oxide metabolism, hypoxia response and vasotone. 
Real-time PCR reactions were performed on a 7500 Fast Real-Time PCR System (Applied 
Biosystems) using Fast SYBR®  reen Master Mix reagents  following the manufacturer’s 
protocol. Immediately after amplification, melt curve analysis was performed in order to 
check PCR reactions for primer-dimer artifacts and to ensure specificity.  
 
Table 3.5 - Primers and respective sequences designed for Real Time PCR 
Gene name (Symbol) 
Accession number  
Primer sequence 
Forward/Reverse 
Angiotensinogen (Agt) 
NM_134432 
CCCTGAGCAGTCCGTTCCT 
AAAGTGCAGCGCACCTGAGT 
Angiotensin II receptor, type 1a (AT1a) 
NM_030985 
GCCAGGGCAGCCTCTGA 
TCCTGAGGCAGGGTGAATG 
Angiotensin II receptor, type 1b (AT1b) CCTCCGCCGCACGAT 
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NM_ 112271 CCATTAGCCAGATGATGATGCA 
Angiotensin II receptor, type 2 (AT2) 
NM_012494 
TGCTGTTGTGTTGGCATTCA 
ATCCAAGAAGGTCAGAACATGGA 
ATPase, Ca++ transporting, type 2C, member 1 
(Atp2c1) 
NM_131907 
TGGAACCCTGACGAAGAATGA 
GCATGCAGGCCGTCTGA 
Endothelin 1 (ET-1) 
NM_012548 
TGGAGGCCATCAGCAACAG 
AGTTCCGCTTTCAACTTTGCA 
Nitric oxide synthase 3, endothelial cell (Nos3)  
NM_021838 
TCTTTCGGAAGGCGTTTGAC 
CTCTAGGGATACCACATCGTATTCATC 
Renin (Ren) 
NM_012642 
CTGCTCAGGCTGTTGATGGA 
CACCCTCTGGGAGAGAATGTG 
Troponin T type 2 (cardiac) (Tnnt2) 
NM_012676 
CAGGAAGCGCATGGAGAAG 
TCGAAGTGAGCCTCGATCAGA 
Tropomyosin 1, alpha (Tpm1) 
NM_019131 
GGCCAAGCACATTGCTGAA 
GCTTACGGGCCACCTCTTC 
Tropomyosin 2, beta (Tpm2) 
NM_001024345 
TAACCTGTCCCGGGTGCAT 
GCGAGCGGTGAAGAGTAGGTA 
myosin, heavy chain 6, cardiac muscle, alpha 
(Myh6) 
NM_017239 
ACAGAGTGCTTCGTGCCTGAT 
CAGTCACCGTCTTGCCGTTT 
myosin, heavy chain 7, cardiac muscle, beta 
(Myh7) 
NM_017240 
CAGCCTACCTCATGGGACTGA 
TGACATACTCGTTGCCCACTTT 
Actin, beta 
ActB/ NM_031144 
ACCAGTTCGCCATGGATGAC 
TGCCGGAGCCGTTGTC 
 
The relative quantification of gene expression in treated SHR, sham SHR and WKY samples 
was determined by comparative C(t) method, using the normotensive WKY group as a 
calibrator to estimate the relative amount of mRNA in both SHR groups. The mRNA level 
of all samples was normalized against an endogenous control (β-actin). The fold-change 
for the SHR samples relative to WKY was calculated by         , where        
                 ,and                                           . 
 
2.4. Physiological data acquisition and analysis 
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Telemetric data were acquired at 1KHz (Powerlab, ADInstruments). Mean values of BP 
(systolic, diastolic and mean) were directly extracted. From the interpolation of pulse 
pressure peaks were derived HR and Respiratory Rate (RespR), the last one after the 
application of Fourier analysis to the interpolated signal. 
Systolic BP and RR interval data were analyzed (period of 3 minutes) in the frequency 
domain (Fast Fourier Transform, FFT), using the in-house software Fisiosinal (Tavares, 
2011b), to evaluate sympathetic (Low Frequency band, LF, 0.15-0.6Hz of SBP) and 
parasympathetic (High Frequency band, HF, 0.6-2.0Hz of HR) activity over time (M Malik, 
1996; Marques-Neves et al., 2004). 
 
2.5. Statistical analysis 
Comparisons between groups for the same period and also comparisons within the same 
group, before and after the microinjections were performed. For the statistical analysis, 
Student’s t test for paired data and ANOVA for comparisons between inter-groups were 
used. All data were expressed as mean±SEM and passed the normality test. Significance 
was taken as P < 0.05. 
 
3. RESULTS 
3.1 Effect on blood pressure, heart rate and sympathetic output of potassium channels 
overexpression in the PVN and RVLM 
At 60 days post-injection, LVV-hKir2.1 expression in PVN produced a time-dependent and 
significant decreases in systolic (158±3 to 132±6 mmHg p<0.05) and diastolic (135±4 to 
113±5 mmHg p<0.05) and mean BP (142±3 to 120±5mmHg, p<0.05). These BP changes 
were accompanied by a lowering of HR (295±3 bpm, p=0.099).  
LVV-hKir2.1 expression in RVLM produced a time dependent decrease in of systolic 
(155±3 to 116±8 mmHg; SBP), diastolic (130±3 to 90±12 mmHg), mean (138±3 to 98±10 
mmHg) BP and HR (310±4 to 293±6) 60 days post-injection (p<0.01).  
At the same time, PVN SHR LVV-eGFP group were showing increased values of systolic 
(174±10 mmHg, p>0.05), diastolic (149±11 mmHg, p>0.05) and mean BP (157±10 mmHg, 
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p>0.05) together with a significantly HR decreased (285±6 bpm, p<0.01). The RVLM SHR 
LVV-eGFP group showed increased values of systolic (168±9 mmHg, p>0.05), diastolic 
(148±9 mmHg, p>0.05) and mean BP (155±9 mmHg, p>0.05) together with a decrease in 
HR (292±4 bpm, p>0.05). This profile of BP and HR changes in SHR sham was expected 
and consistent with their developmental trend (Dickhout & Lee, 1998) .  
SHRs showed putative evidence for an overall decrease of cardiovascular autonomic 
outflow at 60 days after the treatment. Indeed, a strong decrease in sympathetic output 
expressed by LFsBP band power (from 0.79±0.13 to 0.42±0.09 mmHg
2, p<0.05), was 
observed suggesting a reduced sympathetic vasomotor tone. Low frequency spectra of 
SBP in RVLM LVV-hKir2.1 SHR decreased from 0.72±0.09 to 0.42±0.10 mmHg2.  
In contrast, at 60 days the LFsBP for PVN SHR LVV-eGFP was 0.86±0.21 (p>0.05) and for 
RVLM SHR LVV-eGFP was 0.86±0.16 (p>0.05). 
No significant changes in BP, HR, RespR and autonomic outflow were observed in WKY 
rats during the 60 days duration of the experimental protocol.  
 
3.2. Gene expression changes in heart, vessels and kidney and tissue induced by LVV-
hKir2.1 treatment  
The present study was designed to extensively identify ‘signature’ genes that could be 
altered by LVV-hKir2.1 treatment in individual end-organs.  
Using RT-PCR, the expression profile of 17 genes was analyzed in the heart, vessels and 
kidneys in treated SHR, Sham SHR and sham WKY rats. The genes quantified for each 
target organ sample are shown in table 3.6. The results are shown as below separately for 
each gene, tissue and microinjected area (Figure 3-12, to 3-17; Table 3.7, 3.8 and 3.9).  
 
Table 3.6 - Selected genes and samples analyzed 
Gene Target Organ Sample 
angiotensinogen (Agt) Kidney 
angiotensin II receptor, type 1a (AT1a) Kidney 
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angiotensin II receptor, type 1b 
(AT1b) 
Kidney, Heart 
angiotensin II receptor, type 2 (AT2) Kidney 
ATPase, Ca++ transporting, type 2C, 
member 1 (Atp2c1) 
Kidney, Heart 
endothelin converting enzyme 1 
(Ece1) 
Carotid 
endothelin 1 (ET-1) Kidney, Heart, Carotid 
endothelin 2 (ET-2) Carotid 
endothelin receptor type A (Ednra) Carotid 
endothelin receptor type B (Ednrb) Carotid 
nitric oxide synthase 3, endothelial 
cell (Nos3) 
Kidney, Heart 
renin (Ren) Kidney 
troponin T type 2 (cardiac) (Tnnt2) Heart 
tropomyosin 1, alpha (Tpm1) Heart 
tropomyosin 2, beta (Tpm2) Heart 
myosin, heavy chain 6, cardiac 
muscle, alpha (Myh6) 
Heart 
myosin, heavy chain 7, cardiac 
muscle, beta (Myh7) 
Heart 
actin, beta (Actb) Kidney, Heart, Carotid 
 
 
3.2.1. Expression changes in the heart 
Comparing the mRNA expression in treated SHR with the WKY rats: among the 9 genes 
studied only 1 was down-regulated – myosin 7 (3,6 fold) in RVLM treated SHR (Figure 3-
12, table 3.7).  
Comparing the mRNA expression in treated SHR with the SHR sham: AT1 (3,9 fold and 3,8 
fold), ATP2C1 (2,6 fold and 2,5 fold) and Tnnt2 (2,7 fold and 2,0 fold) were down-
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regulated in treated PVN SHR and in treated RVLM SHR, respectively. Also, Tpm2 was 
down-regulated (3,0 fold) in treated RVLM SHRs (Figure 3-13, table 3.7). 
 
 
 
Table 3.7 - mRNAs Expression in the heart of SHR after the treatment with LVV-hKir2.1 in the PVN and in 
the RVLM relative to WKY group or to SHR SHAM group. *p<0.05; **p<0.01. 
PVN SHR 
Genes 
Fold change 
relative to WKY 
Fold change 
relative to SHAM 
RVLM SHR 
Genes 
Fold change  
relative to WKY 
Fold change 
relative to SHAM 
AT1 1,36 0,26* AT1 1,38 0,26
*
 
Atp2C1 0,74 0,38
**
 Atp2C1 0,78 0,40
**
 
ET-1 1,25 2,05 ET-1 1,65 2,35 
Myh6 0,62 0,85 Myh6 0,49 0,68 
Myh7 0,43 0,76 Myh7 0,28
* 
0,72 
NOS3 0,57 1,19 NOS3 0,98 2,05 
Tnnt2 0,70 0,36
*
 Tnnt2 0,76 0,50
*
 
Tpm1 0,78 0,43 Tpm1 0,77 0,42 
Tpm2 1,34 0,99 Tpm2 1,08 0,34
*
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Figure 3-12 – mRNA expression in the heart of treated PVN and RVLM SHR and SHR SHAM relative to 
WKY rats. AT1, angiotensin II receptor type 1; Atp2C1, ATPase, Ca++ transporting, type 2C, member 1; ET-1, 
endothelin 1; Myh6, Myosin 6; Myh7, Myosin 7; Nos3, Nitric oxide synthase 3, endothelial cell; Tnnt2, 
Troponin T type 2; Tpm1, Tropomyosin 1, alpha; Tpm2, Tropomyosin 2, beta. *p<0.05. 
 
Figure 3-13 – mRNA expression in the heart of treated PVN and RVLM SHR relative to SHR SHAM group. 
AT1, angiotensin II receptor type 1; Atp2C1, ATPase, Ca++ transporting, type 2C, member 1; ET-1, 
endothelin 1; Myh6, Myosin 6; Myh7, Myosin 7; Nos3, Nitric oxide synthase 3, endothelial cell; Tnnt2, 
Troponin T type 2; Tpm1, Tropomyosin 1, alpha; Tpm2, Tropomyosin 2, beta. *p<0.05; **p<0.01. 
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3.2.2. Expression changes in the kidney 
Comparing the mRNA expression in treated SHR with the WKY rats: in the PVN and in the 
RVLM, between the 8 genes studied only 2 were up-regulated – endothelin 1 (3,0 fold and 
5,3 fold) and AT2 (2,2 fold and 8,3 fold), respectively (Figure 3-14, table 3.8).  
Comparing the mRNA expression in treated SHR with sham SHR rats: 3 genes were up-
regulated – Angiotensinogen (1,9 fold and 2,7 fold), AT2 (11,1 fold and 42,1 fold) and ET-1 
(8,5 fold and 14,7 fold) in treated PVN SHR and in treated RVLM SHR, respectively (Figure 
3-15, table 3.8). 
 
 
 
 
 
 
Table 3.8 - mRNAs Expression in the kidney of SHR after the treatment with LVV-hKir2.1 in the PVN and in 
the RVLM, relative to WKY group or to SHR SHAM group.  *p<0.05; **p<0.01; ***p<0.001 
PVN SHR 
Genes 
Fold change  
relative to WKY 
Fold change 
relative to SHAM 
RVLM SHR 
Genes 
Fold change 
relative to WKY 
Fold change 
relative to SHAM 
Agt 1,09 1,91** Agt 1,51 2,67** 
AT1a 1,10 0,80 AT1a 1,16 0,85 
AT1b 0,85 0,59 AT1b 1,60 1,10 
AT2 2,20
*
 11,10* AT2 8,34
*
 42,10
***
 
Atp2C1 1,20 1,55 Atp2C1 1,01 1,31 
ET-1 3,06
***
 8,47
***
 ET-1 5,30
***
 14,69
***
 
NOS3 0,62 0,50 NOS3 0,83 0,66 
Ren 1,21 0,71 Ren 1,52 0,89 
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Figure 3-14 – mRNA expression in the kidney of treated PVN and RVLM SHR and SHR SHAM relative to 
WKY rats. Agt, Angiotensinogen; AT1a, angiotensin II receptor type 1a; AT1b, angiotensin II receptor type 
1b; AT2, angiotensin II receptor type 2; Atp2C1, ATPase, Ca++ transporting, type 2C, member 1; ET-1, 
endothelin 1; Nos3, Nitric oxide synthase 3, endothelial cell; Ren, Renin. *p<0.05; **p<0.01; ***p<0.001. 
 
Figure 3-15 – mRNA expression in the kidney of treated PVN and RVLM SHR relative to SHR SHAM group. 
Agt, Angiotensinogen; AT1a, angiotensin II receptor type 1a; AT1b, angiotensin II receptor type 1b; AT2, 
angiotensin II receptor type 2; Atp2C1, ATPase, Ca++ transporting, type 2C, member 1; ET-1, endothelin 1; 
Nos3, Nitric oxide synthase 3, endothelial cell; Ren, Renin. *p<0.05; **p<0.01; ***p<0.001. 
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3.2.3. Expression changes in the carotid artery 
In treated PVN SHR, among the 5 genes studied only 1 was up-regulated (1,7 fold) - 
endothelin receptor type A (Ednra) –compared with WKY rats (Figure 3-16, table 3.9). 
Comparing the mRNA expression in treated PVN SHR with sham SHR rats, 1 gene was a 
down-regulated - endothelin converting enzyme 1 (3,0 fold) - and 1 gene was up-
regulated - endothelin-2 (ET-2) (4,8 fold) (Figure 3-17, table 3.9). 
In treated RVLM SHR, 2 genes were up-regulated – endothelin converting enzyme 1 
(Ece1; 2,1 fold) and endothelin receptor type A (Ednra; 1,5 fold) - compared with WKY 
rats (Figure 3-16, table 3.9). Comparing with sham SHR group there was an up-regulation 
of Ece1 (2,0 fold) and ET-2 (3,0 fold) in RVLM treated SHR (Figure 3-17, table 4).  
 
 
 
 
Table 3.9 - mRNAs Expression in the carotid artery of SHR after the treatment with LVV-hKir2.1 in the PVN 
and in the RVLM. relative to WKY group or to SHR SHAM group.  *p<0.05 
 
PVN SHR 
Genes 
Fold change 
relative to WKY 
Fold change 
relative to SHAM 
RVLM SHR 
Genes 
Fold change 
relative to WKY 
Fold change 
relative to SHAM 
Ece1 0,35 0,33 Ece1 2,10
*
 1,98
*
 
ET-1 1,54 1,09 ET-1 1,38 0,97 
ET-2 3,29 4,76
*
 ET-2 2,06 2,99
*
 
Ednra 1,70
*
 2,55 Ednra 1,49
*
 1,75 
Ednrb 2,26 2,94 Ednrb 1,75 2,27 
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Figure 3-16 – mRNA expression in the carotid artery of treated PVN and RVLM SHR and SHR SHAM 
relative to WKY rats. Ece1, endothelin converting enzyme 1; ET-1, endothelin 1; ET-2, endothelin 2; Ednra, 
endothelin receptor type A; Ednrb, endothelin receptor type B. *p<0.05;***p<0.001. 
 
 
 
Figure 3-17 – mRNA expression in the carotid artery of treated PVN and RVLM SHR relative to SHR SHAM 
group. Ece1, endothelin converting enzyme 1; ET-1, endothelin 1; ET-2, endothelin 2; Ednra, endothelin 
receptor type A; Ednrb, endothelin receptor type B. *p<0.05. 
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4. DISCUSSION 
We previously showed that a decrease in PVN and RVLM neuronal excitability of SHR 
caused a sustained decrease in blood pressure and sympathetic output (Geraldes et al., 
2013). In order to determine if the decrease in cell excitability induced by the chronic 
overexpression of hKir2.1 channels in the PVN and RVLM induced reverse remodeling in 
target organs, we evaluated gene expression changes in the heart, vessel and kidneys, the 
major end-organs associated with arterial hypertension (HTA).  
Our main finding of the present study was that treatment of LVV-hKir2.1 promotes the 
remodeling process in target organs, as showed by the different regulation of gene 
expressions in cardiac and renal tissues of treated SHR. 
a) Heart and vessel 
Cardiac hypertrophy is one of the major hypertension-induced pathological 
consequences. Taking in to account the 9 genes evaluated in the present study, only 1 
was different from WKY rats – the myosin heavy chain β (β-MHC). The β-MHC 7 (V3 
cardiac myosin) was downregulated (3,6 fold) in treated RVLM SHR and are involved in 
regulation of contractility or hypertrophy. In normal cardiac tissue the myosin heavy chain 
α (α-MHC; v1 cardiac myosin)  is expressed predominantly, but in models of cardiac 
hypertrophy  the β-MHC has a higher expression than the α-MHC (Mercadier et al., 1981; 
Compagno et al., 2001) showed that the β-MHC was markedly expressed in the ventricle 
of 15-week old SHR vs WKY. Hence, our results showed that the LVV-treatment decreased 
the β-MHC expression in RVLM SHR in comparison to the WKY rats, similar to Ang II 
receptor type 1 antagonist that promotes the decrease in BP and downregulate MHC in 
the aorta of SHR (Fujii et al., 1999).  
There was no significant difference between treated SHR and WKY rats in the expression 
of AT1 receptor, ATPase Ca2+, Endothelin-1, Myosin 6, Nitric oxide synthase 3, Troponin 
T   Tropomyosin 1 (α) and Tropomyosin   (β) in the heart. There are several studies 
showing differences in gene expression in SHR vs WKY rats, which mean that there is a 
remodeling process in the heart of treated SHR. In fact, AT1 receptor is up-regulated and 
there is evidence that indicate that the decrease in Ca2+ ATPase expression occur in 
prominent hypertrophy and in the failured heart, however it was shown that the 
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expression of SR Ca2+-ATPase was not down-regulated in the heart of 11 week old SHR 
(Ohta et al., 1995). In addition, Troponin is up-regulated and NO synthase is 
downregulated in SHR in comparison with the WKY rats (Bauersachs et al., 1998; Piech et 
al., 2003).  
Both treated SHR had a down-regulation of AT1 (3,9 fold and 3,8 fold), ATP2C1 (2,6 fold 
and 2,5 fold) and Tnnt2 (2,7 fold and 2,0 fold) in the heart. The RVLM SHR group has also 
showed a down-regulation of Tpm2 when compared to the SHR sham group. Thus, it 
seems that there is a remodeling process in the hypertrophied heart of this animal model, 
since there is a continued improvement in gene expression in the heart of these animals, 
approaching the normality.  
However in our study we did not include a measurement of wall stress, which is 
influenced by pressure, chamber radius and wall thickness. 
In the carotid artery, there is an up-regulation of endothelin receptor type A (Ednra) in 
treated PVN and RVLM SHR in comparison to WKY rats (1,7 fold and 1,5 fold, 
respectively). We have also found an up-regulation (2,1 fold) of endothelin converting 
enzyme 1 (Ece1) - in treated RVLM SHR compared with WKY rats.  
When compared to the sham group, the treated PVN and RVLM SHR showed an up-
regulation (4,7 fold and 3,0 fold, respectively) of endothelin-2 (ET-2). In the PVN SHR 
group there is also a down-regulation of Ece1 (3 fold) and in the RVLM SHR group there is 
an up-regulation of Ece1 (2,0 fold). So it seems that the vasculature is trying to 
compensate the decrease in blood pressure values obtained by central manipulation 
though the up-regulation of Edrna (in the PVN and RVLM SHR group) and Ece1 (in the 
RVLM SHR group) .   
b) Kidney 
In the kidneys of PVN and RVLM treated SHR for the 8 genes studied only  2 were up-
regulated -ET-1 and AT2 - with a fold change of 3,0 and 2,2 for PVN SHR and 5,3 fold and 
8,3 fold for RVLM SHR, respectively, when compared to WKY rats. In the rest of the genes 
analyzed there were no differences between the two groups: Angiotensinogen, AT1a, 
AT1b, ATPase Ca2+, Nitric oxide synthase 3 (Nos3) and Renin.  
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ET-1 is a potent vasoconstrictor but the role of ET-1 in SHR remains unclear. Hughes et al 
found that SHR and aged-matched WKY rats had no difference in renal ET-1 levels until 
AHT appeared. After the development of AHT the SHR had a significantly reduced ET-1 in 
the urine and in the outer and inner medulla of the kidney (Hughes et al., 1992; Largo et 
al., 1997). Hence, the up-regulation of ET-1 found in the kidneys of treated SHR relative to 
normotensive rats (WKY) and to Sham SHR seems not to participate in the progression of 
AHT in this animal model. 
(Wu et al., 1994), observed in the kidneys of SHR an up-regulation in Ang II receptor AT-1 
in comparison to WKY rats. Therefore, we can assume that the LVV-treatment in SHR can 
reduce the mRNA levels of AT-1 in the kidneys, since these are similar to the mRNA AT-1 
levels in WKY rats, thus close to normality, which is also a limitation to the 
vasoconstrictive effect of Ang II. 
Ang-(1–7) has been shown to directly downregulate another RAS component, the AT-1 
receptor, in cultured vascular smooth muscle cells (Clark et al., 2001). Our results showed 
an up-regulation in AT-2 receptor in the treated SHR, thus contradicting the biological 
effects of AT1 receptor activation, promoting vasodilation, growth inhibition and cell 
differentiation (Suzanne Oparil, 2003). In the present study we didn´t analyze the Ang-(1-
7) expression, so, we can not speculate about the vasodilatation action of Ang-(1-7).   
Cosentino et al. showed that long-term treatment with the AT1R antagonist, losartan, in 
SHR promotes a significantly increase in AT2R mRNA in thoracic aortas, supporting our 
finding about the beneficial up-regulation of AT2R mRNA in the kidney of treated SHR 
(Cosentino et al., 2005).  
An increased expression of AT2 by LVV-treatment may be a possible way to normalize or 
improve the peripheral chemosensitivity and result in decrease of sympathetic activation 
and blood pressure in SHR (Geraldes et al., 2013). In patients with systemic arterial 
hypertension, the statin therapy has the same effect though the down-regulation of AT-1 
receptors. There are studies showing the increase in NO synthase in SHR in comparison to 
WKY rats (Vaziri et al., 1998; Fernández et al., 2003), so it seems that the LVV-treatment 
tends to decrease NO synthase expression in the kidney of treated SHR similar to WKY 
rats. 
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According to several studies, there is an increase in renin mRNA expression in the kidneys 
of SHR (Antonaccio et al., 1984; Samani et al., 1989; Nakamura & Johns, 1995). The renin-
angiotensin system in the kidney plays an important role in the regulation of 
hemodynamic and tubular functions and it is established that renin, angiotensinogen, and 
angiotensin converting enzyme can produce angiotensin II locally (Johns, 1989). In the 
kidney, the renin release is regulated by the renal sympathetic nerves (mediated by β1-
adrenoceptors); by the pressure-sensitive renal baroreceptor; and by the macula densa, 
which is responsive to tubular fluid composition (Skøtt & Jensen, 1993).  
There is evidence of a relation between renal sympathetic nerve activity and the 
production and release of renin. In fact, renal denervation in the rat blunted the increase 
in renal renin mRNA after long-term ureteral obstruction (el-Dahr et al., 1991). Similarly, 
renal renin mRNA levels were lower in denervated than innervated kidneys (Page et al., 
1992). These studies showed that tonic activity in the renal nerves could elevate renin 
gene expression. Therefore, we can speculate that the decrease in sympathetic nerve 
activity promoted through the LVV-treatment can decrease the renin expression in the 
kidneys of treated SHR, since mRNA levels of renin are similar to WKY rats. 
There is a positive correlation between the angiotensinogen levels and the blood pressure 
found in rats and in humans (Dzau VJ, 1989, El-Dahr SS, 1991, Page WV, 1992, Nakamura 
A, 1994; Bruna RD, 1993). Other studies using the rat and human angiotensinogen genes 
have suggested that the transcriptional mechanism of the angiotensinogen gene is 
involved in the pathogenesis of AHT (Ingelfinger et al., 1986; Ingelfinger et al., 1990; 
Nakamura & Johns, 1995). In addition, the angiotensinogen-deficient mice doesn´t 
produce angiotensinogen and are hypotensive, what shows the impact of 
angiotensinogen in the maintenance of BP and in the development of AHT (Pratt et al., 
1989; Tanimoto et al., 1994).  
The kidneys of the SHR contain lower levels of angiotensinogen mRNA compared with the 
WKY rats (Pratt et al., 1989). There is also evidence that low levels of renal sympathetic 
activity may increase angiotensinogen gene expression (Nakamura & Johns, 1994). In our 
study, the LVV-treatment decreased the sympathetic activity and increased the 
angiotensinogen mRNA in the kidneys of treated PVN and RVLM SHR compared to sham 
SHR (1,9 fold and 2,7 fold) and to similar levels found in WKY rats. One hypothesis is that 
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the decrease in sympathetic activity found after the LVV-treatment could be the cause for 
the increase in angiotensinogen gene expression found in the kidney of treated SHR. 
In conclusion, the central manipulation that promoted the decrease in the blood pressure 
values and sympathetic activity also affected the expression in the target organs, mainly 
through the up-regulation of angiotensinogen and AT-2 genes in the kidney and down-
regulation of AT-1 in the heart. 
Therefore, our data suggests that a decrease in SNS activity through reduction in the 
activity of sympatho-excitatory regions, can be one possible way to control BP and PVN 
and RVLM could constitute areas for novel therapeutic interventions to long-term control 
of BP and end-organ protection in AHT. However, it is important to consider that the 
balance between components of RAS is not linear; therefore any final functional result 
from modification of RAS components expressions can only be proved by comprehensive 
studies. 
 
New findings and its importance under working hypothesis 3 
Our main finding was that treatment of LVV-hKir2.1 promotes the remodeling process in 
target organs, as showed by the different regulation of gene expressions in cardiac and 
renal tissues of treated SHR. Among the 9 genes studied in the heart we did not found 
differences between the PVN treated SHR group and the WKY group. In the heart RVLM 
treated SHR, only one gene was downregulated – myosin 7 (3,6 fold) - in relation to WKY 
group. In relation to the sham SHR there was a downregulation of AT1 (3,9 fold and 3,8 
fold), ATP2C1 (2,6 fold and 2,5 fold) and Tnnt2 (2,7 fold and 2,0 fold) in treated PVN SHR 
and in treated RVLM SHR, respectively. Also, Tpm2 was down-regulated (3,0 fold) in 
treated RVLM SHR.  
In the kidney of treated PVN and RVLM SHR, between the 8 genes studied only 2 were up-
regulated – endothelin 1 (3,0 fold and 5,3 fold) and AT2 (2,2 fold and 8,3 fold), 
respectively, in comparison with the WKY rats. Comparing the mRNA expression in 
treated SHR with sham SHR rats: 3 genes were up-regulated – Angiotensinogen (1,9 fold 
and 2,7 fold), AT2 (11,1 fold and 42,1 fold) and ET-1 (8,5 fold and 14,7 fold) in treated PVN 
SHR and in treated RVLM SHR, respectively.  
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In the carotid artery, in the PVN SHR, among the five genes studied only one was up-
regulated (1,7 fold) - endothelin receptor type A (Ednra) – compared with WKY rats. 
Comparing the mRNA expression in treated PVN SHR with sham SHR rats 1 gene was a 
down-regulated  - endothelin converting enzyme 1 (3,0 fold) - and 1 gene was up-
regulated - endothelin-2 (ET-2) (4,8 fold). In RVLM SHR group, two were up-regulated – 
endothelin converting enzyme 1 (Ece1; 2,1 fold) and endothelin receptor type A (Ednra; 
1,5 fold) - compared with WKY rats. Comparing with the sham SHR group there was an 
up-regulation of Ece1 (2,0 fold) and ET-2 (3,0 fold) in RVLM treated SHR. 
Therefore, the central manipulation that promoted the decrease in the blood pressure 
values and sympathetic activity also affected the expression in the target organs, mainly 
through the up-regulation of angiotensinogen and AT-2 genes in the kidney and down-
regulation of AT-1 in the heart. These results provide new insights into the molecular 
mechanisms underlying the potential efficacy of chronic overexpression of hKir2.1 
channels in central sympathoexcitatory areas in protecting against end-organ damage in 
essential AHT and thus lay the basis for future mechanistic studies. 
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CHAPTER 4  
DISCUSSION 
I. Discussion of the hypotheses under study   
 
Several studies have pointed out that the persistent increase in sympathetic tone is a 
major contributor to both the initiation and maintenance of the hypertensive condition 
(Yamada et al., 1988; Grassi, 2004b; Smith et al., 2004; Guyenet, 2006; Fisher & Paton, 
2012). In fact, increased sympathetic activity has been detected in normotensive 
individuals with a family history of hypertension and in individuals with essential 
hypertension but not in those with secondary hypertension (Yamada et al., 1988; Grassi 
et al., 1998; Grassi, 2004a, 2009).  
Likewise, high plasmatic nor-epinephrine levels have also been associated with essential 
hypertension being consistently increased in younger hypertensive patients (Grassi, 1998) 
and increased peripheral sympathetic nervous activity has been detected by 
microneurography techniques in patients with hypertension (Anderson et al., 1989; 
Grassi, 1998; Greenwood et al., 1999; Mano, 2012).  
Therefore, it is well established, that augmented sympathetic nervous system (SNS) 
activity is related with hypertensive conditions. From experimental models of 
hypertension and hypertensive patients data using microneurography and 
norepinephrine spillover techniques, there is evidence that the sympathetic influence 
upon the cardiovascular system is often increased when blood pressure is chronically 
elevated. But, the precise mechanisms leading to sympathetic activation in essential 
hypertension remain to be elucidated despite having been suggested that the increased 
sympathetic activity is due to alterations of autonomic reflex pathways and/or in brain 
sites (Fisher et al., 2009).  
In the present work, we investigated the effect of over expressing a potassium inwardly 
rectifying channel in the PVN and in RVLM to lower their neuronal activity examining its 
consequences upon long term blood pressure regulation in an animal model of 
hypertension. For that, a human inward rectifying potassium channel (hKir2.1) was over-
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expressed under the control of a synapsin promoter, that was neurone specific (Duale et 
al., 2005a; Duale et al., 2005b).  
Results show that chronic overexpression of potassium channels in the PVN and RVLM of 
conscious unrestrained SHR caused a marked and sustained decrease in blood pressure 
and sympathetic output as revealed indirectly by a decrease in the power density of the 
Low frequency (LF) band of systolic blood pressure (SBP). In the PVN, in particular, there is 
a reversal remodeling of the baro- and chemoreceptor function that approached the 
normal physiological function. Interestingly, no changes in the baro- and chemoreceptor 
function were observed with intervention in RVLM, where the sympathetic efferent 
response is primarily generated. Signalling changes also occurred in hypertensive target 
organs, heart, kidney and vessels. In fact, the central manipulation of neuronal cells 
excitability that promoted a decrease in blood pressure and sympathetic activity also 
affected gene and molecular expression in hypertensive target organs, mainly through 
the up-regulation of angiotensinogen and AT-2 genes in the kidney and down-regulation 
of AT-1 receptors in the heart.  
Effects on arterial blood pressure: A strong decrease of blood pressure, systolic (26 
mmHg, 39 mmHg), diastolic (22 mmHg, 40 mmHg) and mean BP (22 mmHg; 40 mmHg) 
was observed after the modulation of cells excitability in PVN and RVLM, respectively at 
60 days post-microinjection. This decline of SBP and, which were accompanied by a 
decrease in HR, was statistically confirmed at 30 and 40 days after the lentiviral 
microinjection on both regions, and persisted until the animals were humanely sacrificed. 
Sham rats did not show decreases in BP during the recorded period. In contrast to the 
RVLM, LVV-hKir .1 injection in the MCPA didn’t evoke any changes on blood pressure and 
heart rate over the same time frame. This different behavior of MCPA might be explained 
by the fact that the MCPA neurons do not depend on the integrity of the RVLM or 
suprabulbar regions as described before (Seyedabadi et al., 2006). 
MCPA consists in a group of neurons in cervical spinal cord white matter located in the 
ventrolateral region of the medullo-cervical junction, from the most caudal levels of the 
medulla into the upper cervical spinal cord thus. These neurons project to the spinal cord 
and pregnaglionic sympathetic neurons. Despite, when stimulated large pressor 
responses are evoked, its role on cardiovascular regulation is not yet determined. In our 
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study, MCPA was used as a control sympathoexcitatory area due to the apparent lack of 
neuronal relay to the RVLM and PVN. In this way, our results may suggest that not all the 
sympathoexcitatory areas, even if they to evoke changes on blood pressure and/or affect 
preganglionic sympathetic neurons tone, intervene on the sympathoexcitation observed 
in hypertension. This assumption is in line with observations in previous studies of our 
lab, which revealed that lentiviral injection at periacqueductal gray matter (PAG) was 
unable to induce blood pressure and heart rate changes despite this area coordinates 
specific patterns of cardiovascular modulatory responses related to stressful stimulus. 
Due to its anatomical location interfacing the forebrain and the lower brainstem, PAG, in 
opposition to MCPA, receives selective inputs from the prefrontal cortex, amygdala, 
hypothalamus and nociceptive pathways and has neuronal connections with several 
brainstem nucleus involved in the generation of behavior specific patterns of motor and 
autonomic responses.  
 
Is SHR the best animal model for studying neurogenic hypertension? 
The animal model used in this study was the spontaneously hypertensive rat (SHR). In the 
SHR, the contribution of SNS to the maintenance of elevated blood pressure values is 
described by several authors (Yamori et al., 1969; Aoki et al., 1973; Judy et al., 1979; 
Webb et al., 1981; Abboud, 1982; Folkow, 1982; Smith et al., 1984; Simms et al., 2009; 
Geraldes et al., 2013). Also, in this animal model, the sympathetic activity is known to be 
over-activated even before hypertension develops (Simms et al., 2009). Previous studies 
suggested that in SHR there is an increased excitatory drive from PVN and RVLM neurons 
that is associated with an elevated sympathetic outflow (Allen, 2002, Bergamaschi et al., 
1995; Ito et al., 2000, 2001; Ito et al., 2002; Ito et al., 2003). 
 
On the choice of the target regions of PVN, RVLM and MPCA 
Although several regions of the central nervous system contribute to sympathetic tone, 
we chose these two regions, since the RVLM is a major source of sympathetic activity 
(Ross et al., 1984; Dampney, 1994; AM, 2001) and the PVN is well known for its 
importance in autonomic control and, in particular, for cardiovascular regulation. As a 
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control area was used the medullo-cervical pressor area (MCPA) located in the 
ventrolateral region of the medullo-cervical junction. 
The PVN neurones project either directly to the spinal cord or to the RVLM (Coote, 2007) 
thereby accessing sympathetic neurones to modulate blood pressure (Hosoya et al., 1991; 
Loewy, 1991; Coote, 1995; Ranson et al., 1998; Motawei et al., 1999; Pyner & Coote, 
1999, 2000; Badoer, 2001; Coote, 2005). 
The extensive projections of the PVN to central regions (RVLM, area postrema, NTS and 
intermediolateral nucleus of the spinal cord) indicate that PVN plays a significant role in 
modulating RVLM activity and sympathetic outflow. The PVN receives input from a large 
number of regions in the brain, including those associated with osmotic control, appetite 
and energy metabolism, stress and other areas that exert effects on BP. Thus, it is clear 
that the role of the PVN is to integrate inputs from a variety of sources and modify RVLM 
activity according (Aiyagari et al., 2011). 
Electrolytic lesions of the PVN in SHR elicited an acute reduction of sympathetic activity 
together with a decrease of blood pressure (Takeda et al., 1991). Other acute studies, 
performed under general anesthesia, showed that PVN muscimol injections lowered BP 
and renal sympathetic nerve activity both in SHR and WKY rats, indicating that this region 
was tonically active in both animal strains to control BP and peripheral sympathetic 
activity (Allen, 2002). 
RVLM is an important sympatho-excitatory region that plays a key role in controlling 
peripheral sympathetic nerve activity and blood pressure and in mediating baroreflex 
sympatho-inhibition (Loewy & Spyer, 1990a; Chalmers & Pilowsky, 1991; Dampney, 1994; 
Bergamaschi et al., 1995; Ito et al., 2000, 2001). In fact, the RVLM is the final major brain 
region that controls sympathetic nervous system activity, since it contains motor neurons 
that provide tonic drive to the spinal cord preganglionic motor neurons that directly 
regulate SNS activity (Izzo et al., 2008). 
Specific activation of RVLM neurons causes an increase in arterial blood pressure 
mediated by an increase in total peripheral resistance, cardiac output, and secretion of 
catecholamine’s (Feldberg & Guertzenstein, 1972; Campos Júnior & Guertzenstein, 1989; 
Colombari et al., 2001). Previous studies suggested that in SHR there is an increased 
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descending excitatory drive from RVLM neurons that is associated with an elevated 
sympathetic outflow (Bergamaschi et al., 1995; Ito et al., 2000, 2001; Ito et al., 2002; Ito 
et al., 2003). Most recently, part of the enhanced RVLM activity was shown to be of pre-
synaptic origin and based on elevated synaptic drives from pre-inspiratory and post-
inspiratory neurons (Moraes et al., 2014).  
Moreover, the increased activity of PVN and RVLM neurons are associated with the 
maintenance of high blood pressure values (Matsuura et al., 2002; Guyenet, 2006; Nassar 
et al., 2011; Kumagai et al., 2012; Moraes et al., 2014). Therefore, the relation of PVN and 
RVLM neurons to sympathetic control suggests that the spontaneous discharge can be 
modified through either changes to the intrinsic rate of depolarization or alterations in 
the balance of excitatory and inhibitory afferent input (Carlson & Wyss, 2011). 
The MCPA is another sympathoexcitatory region that is located in the most ventrolateral 
medulla that extends caudally as far as the third cervical segment. This pressor area is 
distinct from the caudal pressor area (CPA), because is not dependent on the integrity of 
the RVLM and does not appear to mediate its effects via suprabulbar regions but via 
bulbospinal sympathetic neurons in the region. Using retrograde tracing MCPA neurons 
projecting to thoracic levels (which are neurochemically heterogeneous) that directly 
innervate the sympathetic preganglionic neurons (Seyedabadi et al., 2006). Studies have 
demonstrated that bilateral RVLM blockade eliminates the responsiveness of the more 
rostrally located CPA (Gordon & McCann, 1988; Possas et al., 1994; Natarajan & 
Morrison, 2000). In contrast, responses evoked from the MCPA are unaffected by 
bilateral RVLM blockade (Seyedabadi et al., 2006). Thus, it seems that the MCPA does not 
appear to play a role in maintaining vasomotor tone after RVLM blockade and is distinct 
in both location and axonal outputs to the CPA. 
Several studies, both in human subjects and animal models, have demonstrated an 
association between the circadian variation of BP values, the hypertensive condition, the 
sympathetic activation, the end-organ damage and the worsening of cardiovascular 
outcome (White, 2000; Pickering & Kario, 2001; Weber, 2002).  
Thus, the idea of a long-term modulation of the level of sympathetic activity, at its central 
origin, as a way to control, and treat, high blood pressure, increasing cardiovascular 
compliance and protecting against end-organ damage is very appealing. In particular, the 
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manipulation of sympathetic cell excitability by modulation one of K+ channel expression, 
to hyperpolarize neuronal resting membrane potential, is an attractive hypothetical 
therapeutic strategy (Duale et al., 2007).  
 
On the choice of the lentiviral factor 
Lentivirus was used as its expression has been shown sustained within PVN neurones long 
term (Coleman et al., 2003). In previous studies, Duale et al (2007) and Howorth et al 
(2009) showed that hKir2.1 over-expression hyperpolarized the membrane potential of 
cultured cathecolaminergic PC1  cells by ~10mV which is expected to “electrically 
silence” neurones (Duale et al.   00   Howorth et al.   009). Similar over-expression 
strategies have been used to reveal that electrical silencing of neurones affecting 
development in ovo (Yoon et al., 2008) neuronal activity in vivo (Okada & Matsuda, 2008) 
and the ability of neurones to make and maintain connections in vivo (Yu et al., 2004; 
Mizuno et al., 2007; Hendy, 2010). This viral mediated approach has the advantage of 
being site specific and enabling over-expression in adulthood, avoiding the development 
of putative compensatory mechanisms associated with transgenic animals (Hendy, 2010). 
 
On the blood pressure and autonomic output data 
It seems that the RVLM treatment, takes longer to produce the effect in SBP, but 
generates a higher drop in blood pressure when compared with treatment in the PVN. On 
the other hand, DBP changes were only significant after 50 days in the PVN and 30 days in 
RVLM, suggesting that the LVV-treatment according to the injection site involves different 
mechanisms. In PVN, first promotes a decrease in SBP (at 30 days) and then a decrease in 
DBP (at 50 days). In RVLM, the fall in BP occur first in DBP (at 30 days) and then in SBP (at 
40 days).  
Interestingly, in the PVN, the decrease in LF spectra of SBP (indicative of sympatho-
inhibition) occurred before the fall in SBP (i.e. 20 versus 30 days) suggesting a putative 
association between the changes on both variables. The same was not observed in RVLM. 
Further, the fall in HF SBP, that occurred in both areas is indicative of reduced respiratory 
modulation of arterial pressure and could include reduced respiratory-sympathetic 
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coupling, a phenomena known to raise total peripheral resistance in the SHR (Simms et 
al., 2009).  
 
On the baro and chemoreceptor function in PVN 
In PVN, the effect in blood pressure and sympathetic output could be explained by the 
associated improvement of baroreflex gain and/or a down-regulation of peripheral 
chemoreflex responsiveness to stabilize lowers levels of blood pressure, as we observed. 
We propose that these changes were a result of reduced electrical excitability of PVN pre-
motor sympathetic neurones but cannot rule out reduced release of vasopressin and 
oxytocin. This is consistent with our neuroanatomical western blot analysis confirming 
hKir2.1 protein over-expression was within the PVN region.  
In fact, it is well accepted that neurogenic hypertension is accompanied by an impairment 
of the baroreceptor reflex (Grassi et al., 1998). Our data showed that depressing PVN 
neuronal activity improved baroreflex gain. Previous work from several authors has 
shown that during the course of an alerting reaction there is a decrease in baroreflex 
efficacy and a facilitation of the carotid chemoreceptor reflex due to modifications of 
synaptic integration at the level of the NTS; this might include mechanisms involving 
GABA and angiotensin II release within the nucleus tractus solitaries (Jordan et al., 1988; 
Spyer, 1990; Silva-Carvalho et al., 1995a; Silva-Carvalho et al., 1995b; Kasparov et al., 
1998; Kasparov & Paton, 1999; Head & Mayorov, 2001; Rocha et al., 2003). Such an 
angiotensinogenic mechanism seems to be particularly active in pathophysiological 
conditions like myocardial ischemia and hypertension (Rocha et al., 2003; Rosário et al., 
2003; Maximino et al., 2006) and its behavior can be modulated by intervening 
pharmacologically on NTS AT1 receptors (Kasparov et al., 1998; Kasparov & Paton, 1999; 
Rocha et al., 2003; Rosário et al., 2003). In fact, during myocardial ischemia, AT1 blockade 
reversed the remodeling of baroreceptor and chemoreceptor reflex function in a way 
similar to that elicited upon the over-expression of hKir2.1 in PVN neuronal cells (Rocha et 
al., 2003; Rosário et al., 2003). 
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On the baro and chemoreceptor function in RVLM 
Despite the fall in arterial pressure in the SHR, LVV-hKir2.1 microinjection had no effect 
on the peripheral chemoreflex evoked cardiovascular and respiratory responses. This 
result was unexpected given the importance of the RVLM in mediating the peripheral 
chemoreceptor reflex evoked sympathoexcitation in acute anaesthetized rats (Koshiya & 
Guyenet, 1996a). We can hypothesize that the chronic depression of RVLM excitability 
could lead to neuronal plasticity and enhanced functional expression of peripheral 
chemoreflex pathways that bypass RVLM, such as those routing via the PVN, the lateral 
hypothalamus or the pre-limbic cortex (Owens & Verberne, 1996; Olivan et al., 2001; 
Gabbott et al., 2005).   
In the RVLM the microinjection of the lentiviral vector (LVV-hKir2.1) did not evoke any 
change in the baroreflex sensitivity (BRS) in the SHR. This is already impaired in the SHR 
compared to normotensive rats, indicating a deficit in the vagal capacity to reduce heart 
rate (Verberne et al., 1988; Widdop et al., 1990; Minami & Head, 1993). However, 
impairment of BRS controlling heart rate was not associated with impairment of BRS 
controlling efferent sympathetic nerve activity in human hypertension (Grassi et al., 1998) 
suggesting distinct reflex pathways. So, the impairment of BRS in the SHR is related to the 
efferent parasympathetic, vagal pathway. Due to these facts, we were not surprised that 
there are no changes in baroreflex gain, since this reflects cardiac reflex gain that is 
mainly determined by the activity of cardiac vagal motoneurons and these were not 
targeted in the present study.  
Given that the peripheral chemoreflex and the baroreflex were tested under anesthesia 
the depressant effect of the agent cannot be neglected as it may exacerbate the reduced 
excitability of RVLM neurons and might alter the normal pattern of cardiovascular control 
(Korner, 1971). In particular, by stimulating the GABA-ergic system barbiturates will 
enhances the inhibitory pathway between the caudal ventrolateral medulla and the 
RVLM, further decreasing RVLM excitability. Future studies should focus on the baroreflex 
sympathetic vasomotor gain in SHR before and after LVV-hKir2.1 in the RVLM.  
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On the respiratory data 
Interestingly, respiratory rate remained unchanged in all experimental groups suggesting 
that there is no tonic excitatory drive from the PVN or RVLM affecting this variable in 
hypertensive rats. Additionally, we see no tonic influence from the PVN on the resting 
arterial pressure level in normotensive rats, which contrasts with a previous acute in vivo 
study (Allen 2002). 
 
On the day and night data 
The demonstration of a non-dipper blood pressure profile in animal models remains 
difficult mainly due to the failure in establishing a clear distinction between day and night 
values. This was confirmed in our study as through PVN or RVLM-sympathetic 
manipulations, we were only able to modify BP light/dark values of SHR which 
approached those of WKY rats. However, we were unable to modify the day and night 
profile of BP values variation in both strains. This inability of defining a light/dark profile 
in rats similar to the one set for human subjects may be due to rats intermittent behavior 
alternating awake and sleep periods both in the light and dark phase. Probably the only 
way of better defining rats light and dark phase profiles would be by monitoring of 
cerebral activity through EEG which was out of the scope of the present work. 
Interestingly, LVV-hKir2.1microinjection of SHRs in RVLM promoted the concurrent 
overall decrease of LF power of systolic blood pressure with the lowering of HR in the 
light phase of the 24h period when the animals have a strong decrease in their activity 
with longer periods of sleep.  Despite the study design was not appropriate to analyze the 
sleep awake cycle, the decrease of HR suggests a regained circadian variation of HR and a 
rebuilt, at least partially, of the circadian clock. In fact, a slowing of the heart during sleep 
is well established despite some controversy on the origin of the circadian variation of HR, 
which seems more likely due to a sympathetic withdrawal rather than a parasympathetic 
effect (Massin et al., 2000). 
However, Makino et al, reported, in contradiction to our results, that the impairment of 
the baroreceptor reflex is known to eliminate selectively the circadian rhythms of 
cardiovascular BP and that the elimination of the sympathetic nervous system suppresses 
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the circadian rhythms of BP and HR by decreasing BP and HR during the dark period 
(Makino et al., 1997). Further studies need to be performed to clarify the autonomic 
modulation upon circadian rhythms. 
 
On signalling changes evoked by the decrease of sympathetic activity 
Gene expression analysis is one of the several recent technologies available for studying 
cardiovascular signalling systems under physiological or pathological conditions. It is also 
a valuable tool to evaluate the molecular remodeling of tissues under therapeutics of 
different natures (pharmacological, surgical, devices). As mentioned before, the heart, 
kidney, vessels and brain are key hypertensive target organs. In fact, hypertension, 
specially non-treated hypertension, accelerates these organs damage in such a way that it 
can provoke eventual organ failure and cardiovascular disability or death. In the moment, 
there are some pharmacological schemes that not only decrease blood pressure values 
but also interfere with the damaging processing leading to a reverse remodeling process. 
In order to determine the existence and the direction of the signalling changes by the 
decrease of sympathetic activity induced by chronic overexpression of hKir2.1 channels in 
the PVN and RVLM, the mRNA levels of 17 pre-selected genes have been evaluated. Our 
overall finding is that the decrease of sympathetic activity induced a remodeling process 
in molecular and genetic signalling at the target organs.  
a) Heart and vessel 
Taking in to account the 9 genes evaluated in the present study, only 1 was different from 
WKY rats – the myosin heavy chain β (β-MHC). The β-MHC 7 (V3 cardiac myosin) was 
downregulated (3,6 fold) in treated RVLM SHR and are involved in regulation of 
contractility or hypertrophy. Compagno showed that the β-MHC was markedly expressed 
in the ventricle of 15-week old SHR vs WKY (Compagno et al., 2001). Hence, our results 
showed that the LVV-treatment decreased the β-MHC expression in RVLM SHR in 
comparison to the WKY rats, similar to Ang II receptor type 1 antagonist that promotes 
the decrease in BP and downregulate MHC in the aorta of SHR (Fujii et al., 1999).  
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There was no significant difference between treated SHR and WKY rats in the expression 
of AT1 receptor, ATPase Ca2+, Endothelin-1, Myosin 6, Nitric oxide synthase 3, Troponin 
T   Tropomyosin 1 (α) and Tropomyosin   (β) in the heart.  
Both treated SHR had a down-regulation of AT1 (3,9 fold and 3,8 fold), ATP2C1 (2,6 fold 
and 2,5 fold) and Tnnt2 (2,7 fold and 2,0 fold) in the heart. The RVLM SHR group has also 
showed a down-regulation of Tpm2 when compared to the SHR sham group. Thus, it 
seems that there is a remodeling process in the hypertrophied heart of this animal model, 
since there is a continued improvement in gene expression in the heart of these animals, 
approaching the normality. However in our study we did not include a measurement of 
wall stress, which is influenced by pressure, chamber radius and wall thickness. 
In the carotid artery, there is an up-regulation of endothelin receptor type A (Ednra) in 
treated PVN and RVLM SHR in comparison to WKY rats (1,7 fold and 1,5 fold, 
respectively). We have also found an up-regulation (2,1 fold) of endothelin converting 
enzyme 1 (Ece1) - in treated RVLM SHR compared with WKY rats.  
When compared to the sham group, the treated PVN and RVLM SHR showed an up-
regulation (4,7 fold and 3,0 fold, respectively) of endothelin-2 (ET-2). In the PVN SHR 
group there is also a down-regulation of Ece1 (3 fold) and in the RVLM SHR group there is 
an up-regulation of Ece1 (2,0 fold). So it seems that the vasculature is trying to 
compensate the decrease in blood pressure values obtained by central manipulation 
though the up-regulation of Edrna (in the PVN and RVLM SHR group) and Ece1 (in the 
RVLM SHR group) .   
b) Kidney 
In the kidneys of PVN and RVLM treated SHR for the 8 genes studied only  2 were up-
regulated -ET-1 and AT2 - with a fold change of 3,0 and 2,2 for PVN SHR and 5,3 fold and 
8,3 fold for RVLM SHR, respectively, when compared to WKY rats. In the rest of the genes 
analyzed there were no differences between the two groups: Angiotensinogen, AT1a, 
AT1b, ATPase Ca2+, Nitric oxide synthase 3 (Nos3) and Renin.  
ET-1 is a potent vasoconstrictor but the role of ET-1 in SHR remains unclear. Hughes et al 
found that SHR and aged-matched WKY rats had no difference in renal ET-1 levels until 
AHT appeared. After the development of AHT the SHR had a significantly reduced ET-1 in 
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the urine and in the outer and inner medulla of the kidney (Hughes et al., 1992; Largo et 
al., 1997). Hence, the up-regulation of ET-1 found in the kidneys of treated SHR relative to 
normotensive rats (WKY) and to Sham SHR seems not to participate in the progression of 
AHT in this animal model. 
The renin-angiotensin system in the kidney plays an important role in the regulation of 
hemodynamic and tubular functions and it is established that renin, angiotensinogen, and 
angiotensin converting enzyme can produce angiotensin II locally (Johns, 1989). Wu 
observed in the kidneys of SHR an up-regulation in Ang II receptor AT-1 in comparison to 
WKY rats (Wu et al., 1994). Therefore, we can assume that the LVV-treatment in SHR can 
reduce the mRNA levels of AT-1 in the kidneys, since these are similar to the mRNA AT-1 
levels in WKY rats, thus close to normality, which is also a limitation to the 
vasoconstrictive effect of Ang II. 
Ang-(1–7) has been shown to directly downregulate another RAS component, the AT-1 
receptor, in cultured vascular smooth muscle cells (Clark et al., 2001). Our results showed 
an up-regulation in AT-2 receptor in the treated SHR, thus contradicting the biological 
effects of AT1 receptor activation, promoting vasodilation, growth inhibition and cell 
differentiation (Suzanne Oparil, 2003). In the present study we didn´t analyze the Ang-(1-
7) expression, so, we can not speculate about the vasodilatation action of Ang-(1-7).   
Cosentino et al. showed that long-term treatment with the AT1R antagonist, losartan, in 
SHR promotes a significantly increase in AT2R mRNA in thoracic aortas, supporting our 
finding about the beneficial up-regulation of AT2R mRNA in the kidney of treated SHR 
(Cosentino et al., 2005).  
An increased expression of AT2 by LVV-treatment may be a possible way to normalize or 
improve the peripheral chemosensitivity and result in decrease of sympathetic activation 
and blocd pressure in SHR (Geraldes et al., 2013). In patients with systemic arterial 
hypertension, the statin therapy has the same effect though the down-regulation of AT-1 
receptors. There are also studies showing the increase in NO synthase in SHR in 
comparison to WKY rats (Vaziri et al., 1998; Fernández et al., 2003), so it seems that the 
LVV-treatment tends to decrease NO synthase expression in the kidney of treated SHR 
similar to WKY rats. 
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In the kidney, the renin release is regulated by the renal sympathetic nerves (mediated by 
β1-adrenoceptors); by the pressure-sensitive renal baroreceptor; and by the macula 
densa, which is responsive to tubular fluid composition (Skøtt & Jensen, 1993). According 
to several studies, there is an increase in renin mRNA expression in the kidneys of SHR 
(Antonaccio et al., 1984; Samani et al., 1989; Nakamura & Johns, 1995). There is also 
evidence of a relation between renal sympathetic nerve activity and the production and 
release of renin. In fact, renal denervation in the rat blunted the increase in renal renin 
mRNA after long-term ureteral obstruction (el-Dahr et al., 1991). Similarly, renal renin 
mRNA levels were lower in denervated than innervated kidneys (Page et al., 1992). These 
studies showed that tonic activity in the renal nerves could elevate renin gene 
expression. Therefore, we can speculate that the decrease in sympathetic nerve activity 
promoted through the LVV-treatment can decrease the renin expression in the kidneys of 
treated SHR, since mRNA levels of renin are similar to WKY rats. 
There is a positive correlation between the angiotensinogen levels and the blood pressure 
found in rats and in humans (Dzau VJ, 1989, El-Dahr SS, 1991, Page WV, 1992, Nakamura 
A, 1994; Bruna RD, 1993). Other studies using the rat and human angiotensinogen genes 
have suggested that the transcriptional mechanism of the angiotensinogen gene is 
involved in the pathogenesis of AHT (Ingelfinger et al., 1986; Ingelfinger et al., 1990; 
Nakamura & Johns, 1995). In addition, the angiotensinogen-deficient mice doesn´t 
produce angiotensinogen and are hypotensive, what shows the impact of 
angiotensinogen in the maintenance of BP and in the development of AHT (Pratt et al., 
1989; Tanimoto et al., 1994).  
The kidneys of the SHR contain lower levels of angiotensinogen mRNA compared with the 
WKY rats (Pratt et al., 1989). There is also evidence that low levels of renal sympathetic 
activity may increase angiotensinogen gene expression (Nakamura & Johns, 1994). In our 
study, the LVV-treatment decreased the sympathetic activity and increased the 
angiotensinogen mRNA in the kidneys of treated PVN and RVLM SHR compared to sham 
SHR (1,9 fold and 2,7 fold) and to similar levels found in WKY rats. One hypothesis is that 
the decrease in sympathetic activity found after the LVV-treatment could be the cause for 
the increase in angiotensinogen gene expression found in the kidney of treated SHR. 
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Therefore, the central manipulation that promoted the decrease in the blood pressure 
values and sympathetic activity also affected the expression in the target organs, mainly 
through the up-regulation of angiotensinogen and AT-2 genes in the kidney and down-
regulation of AT-1 in the heart. However, it is important to consider that the balance 
between components of Renin Angiotensin System (RAS) is not linear; therefore any final 
functional result from modification of RAS components expressions can only be proved by 
comprehensive studies. 
 
On the concepts underlying sympathoexcitation in hypertension 
Control of blood pressure requires complex integration of regulatory mechanisms across 
multiple physiological systems. A sustained increase in arterial pressure therefore reflects 
a failure of one or more of these controls.  
One likely mechanism of essential hypertension is an increased in sympathetic nervous 
system. The increase of sympathetic outflow to the heart results in increased cardiac 
output and neurally mediated vasoconstriction leading to elevated blood pressure values 
(Schlaich et al., 2012). So, the reduction of the enhanced sympathetic activity has been 
considered as an antihypertensive strategy (Del Colle et al., 2007; Biaggioni, 2008; 
Signolet et al., 2008; Fisher & Fadel, 2010; Grassi et al., 2010). However, the precise 
mechanisms responsible for the sympathetic activation in essential hypertension remain 
enigmatic, since they are complex and multifactoral, although it is known that the 
interaction of genetic influences with behavioural and lifestyle factors are important. 
However several hypotheses can be discussed.  
One hypothesis believed to be responsible for this sympathoexcitation is increased 
systemic and central angiotensin II signalling. Most of the Ang II actions are mediated by 
the angiotensin II type 1 (AT1) receptor and the central nervous system is richly endowed 
with AT1 receptors(Zucker & Gao, 2005). In fact, the paraventricular nucleus and the 
rostroventrolateral medulla appears to have an especially dense distribution of AT1 
receptors and Ang II signalling is enhanced in this two central areas (Zucker & Gao, 2005). 
Plasma angiotensin II is increased in humans and animals with hypertension and exerts 
central sympathoexcitatory effects, promotes the release of norepinephrine and amplifies 
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the adrenoreceptor response to stimuli in subjects with elevated levels of renin and 
angiotensin, but also in subjects with low levels of rennin. Circulating angiotensin II also 
reduces the transmission between baroreceptor afferents and NTS efferent neurons by 
activating endothelial angiotensin II receptors type 1 (AT1).  The mechanism of 
angiotensin II control of the baroreflex involves the production of nitric oxide (NO) by the 
capillary endothelium, and this mechanism could have a role in neurogenic hypertension 
(Paton et al., 2001).  
Another hypothesis is that the sympathetic hyperactivity may be due to insulin resistance, 
since the presence of hypertension is often associated with hyperinsulinemia and is 
known that insulin resistance/hyperinsulinemia increases the sympathetic traffic and the 
release of norepinephrine. However, the reciprocal is also true, so it is difficult to 
determine whether it is sympathoexcitation that precedes insulin resistance or otherwise. 
During short-term hyperinsulinemia, insulin-induced sympathoexcitation helps to 
maintain blood pressure, and not only sympathetic overactivation, but also denervation 
are associated with insulin resistance (Scherrer & Sartori, 1997). Moreover, there is 
evidence that suggests that insulin sympathoexcitatory effects are mediated at least in 
part by a central neural action (Muntzel et al., 1995), since insulin crosses the blood-brain 
barrier (Margolis & Altszuler, 1967) and insulin receptors have been demonstrated in 
several distinct regions of the central nervous system (Sauter et al., 1983). 
Another mechanism is could be related to the fact that the sympathetic activation is 
associated with baroreflex dysregulation, since hypertension is characterized by a 
baroreflex modulation and sympathetic traffic resetting towards high blood pressure 
blood pressure values. The major objective of this mechanism is to maintain blood 
pressure, more than reduce the increased blood pressure values, since apparently also 
the action of other cardiac reflex arcs that affect the sympathetic outflow to the vessels, 
the release of norepinephrine and renin are inhibited. 
Other hypothesis that is linked to the maintenance of increased central sympathetic 
outflow may be related to excessive subcortical control caused by persistent excessive 
environmental stress. Other hypotheses include adipokines, endothelial dysfunction, 
cyclic intermittent hypoxemia and aldosterone effects on central nervous system.  
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And the last hypothesis, which is the basis of the present work and has been previously 
described, is that the increased sympathetic activity may result from an abnormal 
elevated sympathetic drive from brain centres, such PVN and RVLM.  
 
In conclusion, the present work shows that the intervention on central 
sympathoexcitatory neurone excitability through the genetic manipulation of potassium 
channels expression is able to alter peripheral blood pressure long term. This occurs by 
sympathetic outflow remodeling and by signalling changes that occurred in hypertensive 
target organs that maintain cardiovascular homeostasis. Our data, from an animal model, 
give insights into the pathophysiological mechanisms involved in the aetiology of essential 
hypertension of neurogenic origin and provide novel hypothetical therapeutic 
interventions at central level of the autonomic nervous system to control 
sympatoexcitation. 
 
II. Summary of main results 
This work focused on the enhanced sympathetic nervous system activity in an animal 
model of neurogenic hypertension. We found that: 
1. The over expression of an inwardly rectifying potassium channel in the PVN and in the 
RVLM provided a long term (>60 days) anti-hypertensive response in conscious 
spontaneously hypertensive rats (SHR) that was associated with reductions in 
neurohumoral mediated vasoconstriction; 
a) LVV-hKir2.1 expression in PVN produced a time-dependent and significant 
decreases in systolic (158±3 to 132±6 mmHg P<0.05) and diastolic BP (135±4 to 113±5 
mmHg P<0.05). SBP low frequency band was reduced (0.79±0.13 to 0.42±0.09 mmHg2; 
P<0.05), suggesting reduced sympathetic vasomotor tone.  
b) In RVLM, but not in MCPA, LVV-hKir2.1 expression produced a decrease in systolic 
(155±3 to 116±8 mmHg; SBP), and diastolic (130±3 to 90±12 mmHg) BP and HR (310±4 
to 293±6) 60 days post-injection (P<0.01); Low frequency spectra of SBP decreased 
from 0.69±0.11 to 0.42±0.10 mmHg2. 
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2. In the PVN, this decrease in blood pressure values was also associated with an 
enhanced baroreflex sensitivity and reduced peripheral chemosensitivity; 
3. Blood pressure values and low frequency spectra of SBP in normotensive rats and in 
the sham groups (LVV-eGFP microinjected SHR) didn´t decreased; 
4. Baro and chemoreflexes remain unchanged in in normotensive rats and in the sham 
groups; 
5. Respiratory rate remained unchanged in all experimental groups; 
6. LVV-hKir2.1 expression in PVN and RVLM produced a remodeling process in target 
organs:  
a) In the heart among the 9 genes studied we did not found differences between 
the PVN treated SHR group and the WKY group. In the heart RVLM treated 
SHR, only 1 gene was downregulated – myosin 7 (3,6 fold) - in relation to WKY 
group. 
b) In the heart, in relation to the sham SHR group there was a downregulation of 
AT1 (3,9 fold and 3,8 fold), ATP2C1 (2,6 fold and 2,5 fold) and Tnnt2 (2,7 fold 
and 2,0 fold) in treated PVN SHR and in treated RVLM SHR, respectively. Also, 
Tpm2 was down-regulated (3,0 fold) in treated RVLM SHR group. 
c) There was no significant difference between treated SHR and WKY rats in the 
expression of AT1 receptor, ATPase Ca2+, Endothelin-1, Myosin 6, Nitric oxide 
synthase 3, Troponin T2, Tropomyosin 1 (α) and Tropomyosin   (β) in the 
heart. 
d) In the kidney of PVN and RVLM treated SHR between the 8 genes studied only 
2 were up-regulated – endothelin 1 (3,0 fold and 5,3 fold) and AT2 (2,2 fold 
and 8,3 fold), respectively, in comparison with the WKY rats.  
e) In the kidney, comparing the mRNA expression in treated SHR with sham SHR 
rats: 3 genes were up-regulated – Angiotensinogen (1,9 fold and 2,7 fold), AT2 
(11,1 fold and 42,1 fold) and ET-1 (8,5 fold and 14,7 fold) in treated PVN SHR 
and in treated RVLM SHR, respectively.  
f) In the rest of the genes analyzed in the kidney there were no differences 
between the PVN and RVLM treated SHR group and the WKY group: 
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Angiotensinogen, AT1a, AT1b, ATPase Ca2+, Nitric oxide synthase 3 (Nos3) and 
Renin.  
g) In the carotid artery, in the PVN SHR group, among the 5 genes studied only 1 
was up-regulated (1,7 fold) - endothelin receptor type A (Ednra) – compared 
with WKY rats. In RVLM SHR group, 2 were up-regulated – endothelin 
converting enzyme 1 (Ece1; 2,1 fold) and endothelin receptor type A (Ednra; 
1,5 fold) - compared with WKY rats. 
h) In the carotid artery, comparing the mRNA expression in treated PVN SHR with 
sham SHR rats 1 gene was a down-regulated  - endothelin converting enzyme 1 
(3,0 fold) - and 1 gene was up-regulated - endothelin-2 (ET-2) (4,8 fold). 
Comparing with the sham SHR group there was an up-regulation of Ece1 (2,0 
fold) and ET-2 (3,0 fold) in RVLM treated SHR. 
i) In the carotid artery, there was no significant difference in mRNA expression 
between treated SHR and WKY rats in: endothelin 1 (ET-1); endothelin 2 (ET-2) 
and endothelin receptor type B (Ednrb). 
 
III. Strengths and limitations of the study  
 
We propose that the changes found in sympathetic output and blood pressure values 
were a result of hyperpolarized PVN and RVLM pre-motor sympathetic neurons that leads 
to a reduced electrical excitability in that areas. However cannot rule out reduced release 
of vasopressin and oxytocin in the PVN. 
The demonstration of a non-dipper blood pressure profile in animal models remains 
difficult mainly due to the failure in establishing a clear distinction between day and night 
values. This was confirmed in our study as through PVN-sympathetic manipulations, we 
were only able to modify BP light/dark values of SHR which approached those of WKY 
rats. However, we were unable to modify the day and night profile of BP values variation 
in both strains. This inability of defining a light/dark profile in rats similar to the one set 
for human subjects may be due to rats intermittent behavior alternating awake and sleep 
periods both in the light and dark phase. Probably the only way of better defining rats 
CHAPTER 4 - DISCUSSSION 
153 
light and dark phase profiles would be by monitoring of cerebral activity through EEG 
which was out of the scope of the present work. 
In metabolic evaluation, the animals were not subjected to an adaptation period to the 
metabolic cages, which could impact on our metabolic data, constituting a study 
limitation. 
The sympathetic activity was evaluated indirectly with power spectrum analysis of heart 
rate and blood pressure variability. Even though these indices are well validated for that 
purpose, it is important recognized that this is not a direct sympathetic drive evaluation 
and, as such, only association and not causation should be claimed. 
Also, the fact that the study uses a rat model allows only conclusions/associations for 
mechanisms of hypertension in that model. Implications for treatment of hypertension 
should be addressed by subsequent human studies.  
 
 
 
  
 
 
 
 
 
CHAPTER 5 
 157 
CHAPTER 5 
PERSPECTIVES AND FUTURE WORK 
 
I. Possible mechanisms for sympathetic overactivity in hypertension 
The genesis of the sympathetic nervous system overactivity found in pathological 
conditions, such hypertension continues to be an area of intense research. 
In the central nervous system, the great majority of the key regulatory sites that control 
sympathetic outflow have already been identified despite some of their interrelationships 
are not yet completely defined. Beyond these physiological aspects, the challenge, now, is 
also to find a way to control the SNS or, in another words, to restore the SNS overactivity 
to normal levels.  
The mechanisms contributing to central sympathetic activation are complex and 
multifactorial and involve several brain sites, neurotransmitters and neuromodulators 
(Weiss et al, 2003). It has been suggested that the increased sympathetic activity is due to 
alterations in autonomic reflex pathways and/or in the central autonomic 
neuroanatomical sites accompanied by modifications on hormonal and inflammatory 
factors.  
Some hypotheses on sympathetic activity during hypertension have been advanced, such 
as the derangement of the sympathoinhibition exerted by the reflexogenic areas: arterial 
or cardiopulmonary baroreflexes, somatic reflexes and central or peripheral 
chemoreflexes that tonically could restrain adrenergic outflow (Brown & Fisher, 1980; 
Grassi et al., 1997; Grassi, 2001; Lip et al., 2007; Schultz & Li, 2007; Smith & Pacchia, 
2007). Also, functional alterations in several autonomic areas including the RVLM, NTS 
and PVN that have been associated with changes in central concentrations of Ang II, 
aldosterone, NO, reactive oxygen species and inflammatory cytokines (Patel et al., 2001; 
Zucker et al., 2001; Zimmerman & Davisson, 2004; Gao et al., 2005; Waki et al., 2006; Yu 
et al., 2007; Guggilam et al., 2008; Zhang et al., 2008; Waki et al., 2010). 
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Another hypothesis, which has been tested and proven, is that sympathetic activation 
accompanying hypertension is in part due to an exaggerated central nervous system drive 
resulting from excessive environmental stress (Mancia et al., 1997). 
It has also been suggested that the metabolic alterations frequently detectable in 
hypertension, such as the hyperinsulinaemic state and the related insulin resistance, may 
be the triggering factors. This hypothesis is based on the evidence that insulin may have 
central sympathoexcitatory effect which may thus be enhanced the sympathetic tonus in 
hypertensive patients (Grassi et al., 2007).  
The sympathetic activation in hypertension can also depend on the renin–angiotensin 
system, since angiotensin II exerts central sympathoexcitatory effects and the 
pharmacologic blockade of the renin–angiotensin system via ACE-inhibitors or 
angiotensin II receptor blockers exerts sympathomodulatory effects (Fig. 5-1) (Grassi et 
al., 1997; Grassi, 2001; Grassi et al., 2007). 
 
 
 
Figure 5-1. Diagram showing location and connections of some of the primary hypothalamic structures 
responsible for central angiotensin II signalling and the integration of the stress response. AP, area 
postrema; AV3V, anteroventral third ventricle; BNST, bed nucleus stria terminalis; CeA, central amygdala; 
MPO, median preoptic nucleus; NTS, nucleus of the solitary tract; PBN, parabrachial nucleus; PVN, 
paraventricular nucleus; RVLM, rostral ventrolateralmedulla; SFO, subfornical organ; and SON, supraoptic 
nucleus. Extracted from Marvar & Harrison, Exp Physiol 97.11 (2012). 
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Other studies indicate that increases in central sympathetic outflow can be mediated via 
Ang II activation of NAD(P)H oxidase with production of reactive oxygen species, which 
may directly activate central SNA pathways along with scavenging NO thereby removing 
the tonic restraint on sympathetic outflow (Fisher et al., 2009).  
Beyond the link between hypertension and angiotensin or reflexes impairment, essential 
hypertension may also be induced per se by changes in the cerebral vasculature leading 
to a decrease in the vessel internal diameter (Baumbach et al., 1988; Baumbach & 
Heistad, 1988). This could be due to modifications of the shear stress upon the cerebral 
vessels walls (Agabiti-Rosei et al., 2009). The induced vascular remodeling can be 
hypertropic in nature due to smooth cells increase in volume (Baumbach et al., 1988) or 
eutrophic due to smooth cells novel rearrangements (Rizzoni et al., 2009; Cates et al., 
2012). These narrowing of cerebral vasculature could activate primary a Cushing reflex 
that will, along time, be transformed in a persistent response, termed as the Cushing 
mechanism, which ultimately purpose is to improve brain perfusion. Interestingly, this 
progressive narrowing linked to a functional effect can be observed in young (pre-
hypertensive) and adult SHR (Paton et al., 2007; Paton & Waki, 2009). 
In recent years, however, a major research effort has been focused on the role of 
inflammation in the genesis of hypertension. In fact, the role of brain inflammation in the 
pathogenesis of this disease is now a target of medical research and is the basis of our 
ongoing study (For detailed description, see II) (Paton & Waki, 2009; Felder, 2010; Marvar 
et al., 2010; Shi et al., 2010). 
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II. Future perspectives: the role of inflammation at PVN level in the 
origin of neurogenic hypertension 
 
The idea that insufficient perfusion of key areas of the brain elicit an increase in 
sympathetic output and blood pressure due to the release of inflammation mediators is 
very attractive as a working hypothesis on the understanding of some of the mechanisms 
underlying neurogenic hypertension.  
There is limited but compelling evidence that links essential hypertension with changes in 
cerebral circulation, inflammation and the adaptive immune system. When intracranial 
pressure is elevated >33mmHg over a short period, cerebral blood flow is significantly 
reduced. The elicited cerebral ischemia stimulates the vasomotor areas and systemic 
blood pressure rises, heart rate decreases and respiration is slowed accordingly.  
This triad of reflex physiological responses helps to maintain cerebral blood flow and is 
termed the Cushing reflex. Not only Cushing but also Guyton and co-workers were 
impressed by the protective nature of this reflex response but they have just looked at it 
as the last effort of the brain to protect itself in ischemic conditions (Sagawa et al., 1961; 
Smith & Guyton, 1963). In accordance, they speculated with others (Dickinson, 1991; 
Osborn, 2005) about the existence of a central baroreceptor system, located in the 
brainstem, which could be activated at normal blood pressure values.  
In fact, the brainstem holds the primary station of sensory integration of autonomic 
nature as well the motor and respiratory centers. All of them participate on the 
generation of both baro and chemoreflex responses, the last one the major protective 
reflex of sympathetic nature. 
Within the rostral ventrolateral medulla which projects neurons to the thoraco-lombar 
spinal cord, there are neurones which are intrinsically sensitive to hypoxia (Wang et al., 
2001) that can provide an explanation by which brainstem ischemia results in 
sympathoexcitation to ensure adequate central perfusion. The same type of neurons was 
found in the spinal cord (Braga et al., 2007) showing that apparently the central nervous 
system is prepared to self protected itself to central ischemia and oxygen decrease, at 
different levels of the neuroaxis. 
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An association between narrowed vertebral arteries, due to atheroma plaques deposition 
and a medical history of essential hypertension was made back in the 1960’s by Dickinson 
and Thompson. However, being this work performed post-mortem was not possible to 
understand which was the cause and the effect in this association.  
But with time, as our understanding on end-organ damage associated with hypertension 
increased, the role of inflammation in these damaging processes as well as in the 
pathogenesis of hypertension have been highlighted.  
The ATTICA study revealed that pre-hypertensive subjects have higher values of C-
reactive protein, TNF-α, amyloid-a, homocysteine and white blood cell counts when 
compared with normal subjects and, authors suggested, that pre-hypertension might be a 
pro-inflammatory condition (Chrysohoou et al., 2004). Other studies in hypertensive 
patients also showed increased levels of TNF-α, IL-6 and IL-1ß correlating positively with 
higher values of blood pressure (Dalekos et al., 1997; Bautista et al., 2005).  
Studies in normal subjects indicated a putative link between plasma levels of ICAM-1 and 
IL6 and the values of systolic blood pressure, with the highest levels being related to 
systolic blood pressure values >140 mmHg (Chae et al., 2001). Also, the administration of 
intracerebral angiotensin II, suggested as a major signal contributing to neurogenic 
hypertension (Brody, 1988; Johansson et al., 1999; DiBona & Jones, 2001; Davern & Head, 
2007), increased the genetic expression of proinflammatory splenic cytokines, such as 
interleukin-1β and interleukin-6 (Ganta et al., 2005) together with an increase of blood–
brain barrier permeability and cerebral microvasculature inflammation (Zhang et al., 
2010).  
Also T-cells seem to play an important role in the development of hypertension as they 
can produce cytokines and release other mediators that affect the smooth muscle cells 
and vascular endothelium (Guzik et al., 2007). The link between angiotensin II and T-cell 
activation has been showed by several authors. In an experimental animal model of T-
cells lacking, mice failed to become hypertensive when were infused for 14 days with 
angiotensin II (Guzik et al., 2007; Hoch et al., 2009; Marvar et al., 2010). These data 
indicate that not only angiotensin II facilitates the entrance in the brain of inflammatory 
cells and cytokines but also that central angiotensin II can elicit a peripheral immune 
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response via the autonomic nervous system as the autonomic denervation of the spleen 
abolished the immune response (Marvar et al., 2010).  
Microglial cells are also activated in hypertension, and their inhibition reduces blood 
pressure (Shi et al., 2010). Thus, it can be hypothesized that pathological signalling 
molecules, most of them linked to neuroimmune mechanisms, released from the 
vasculature would exert a deleterious action on neuronal excitability, which in turn, 
would alter both the central set point of arterial pressure and its reflex control (Paton & 
Waki, 2009; Waki et al., 2010). In these conditions, the brain could be both the target for 
inflammatory mediators in hypertension and a mediator of inflammation through its 
communication with the immune system.  
Several studies showed that pro-inflammatory chemotactic proteins are more produced 
in the brainstem areas involved in cardiovascular control of the spontaneously 
hypertensive rats (SHR) than in normotensive rats (Waki et al., 2007; Waki et al., 2008). 
Also, some drugs used to treat hypertension also have general anti-inflammatory effects 
in the brain (Zhou et al., 2005; Benicky et al., 2009). 
In our work, we showed that the decrease of neuronal excitability in two central areas 
evoked a decreased of sympathetic activity and blood pressure. This work called the 
attention, for the first time, for RVLM role on hypertension but the morphological and 
functional reverse remodelling was more effective through PVN genetic manipulation. 
Accordingly, and despite several studies (Paton & Waki, 2009; Waki et al., 2010; Waki et 
al., 2011; Almado et al., 2014) pointed the brainstem as the key area for the initiation of 
the sympathoexcitation and increase of blood pressure, we believe that the 
hypothalamus, and in particular the PVN is the central area to be target in hypertension 
of neurogenic origin (Hilton & Spyer, 1980; Spyer, 1989; Benarroch, 2006; Macefield et 
al., 2013).  
In fact, the control of visceral functions and adaptation is integrated throughout the areas 
of the central autonomic network. The hypothalamus, through all its subdivisions, is part 
of that network and has a central role on the integration of autonomic and endocrine 
responses critical for homeostasis and adaptation to internal and external stimuli of 
several origins.  
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Acute and transient challenges triggering successful adaptations produce a short duration 
response consisting in sympathoadrenal excitation with tachycardia, hypertension, 
increase in cardiac output, redistribution of blood flow to the limbs, inhibition of the 
baro- and facilitation of the chemoreflex (Hilton & Spyer, 1980; Spyer, 1989; Silva-
Carvalho et al., 1995a; Silva-Carvalho et al., 1995b; Benarroch, 2005; Benarroch, 2006). 
However, if the stimuli persist, a persistent adaptative response of deleterious nature is 
elicited leading to “pathological adaptations” both at central and peripheral level 
(Cersosimo & Benarroch, 2013; Zucker et al., 2014).  
The hypothalamus also contains osmosensitive and Na+ sensitive neurons critical for 
water and sodium homeostasis. Likewise is a site of bidirectional communication between 
the immune system and the autonomic and the endocrine systems (Rivest, 2001; 
Benarroch, 2006; Nater et al., 2013), eg, is well documented that during febrile 
conditions, circulating cytokines stimulate prostaglandin E2 secretion at hypothalamic 
levels, which results in activation of the hypothalamo-pituitary-adrenocortical and 
sympathetic outputs leading to an inhibition of inflammatory response (Rivest, 2001; 
Benarroch, 2005).  
In particular, the PVN generates coordinate endocrine and autonomic responses to 
stimuli of different nature including vasopressin secretion, and activation of sympathetic, 
adrenomedullary and adrenocortical systems. Also the different neuronal clusters within 
this nucleus respond to visceral, limbic, and humoral signals such as pain, fear and 
circulatory cytokines (Hilton & Spyer, 1980; Spyer, 1989; Stern, 2001; Benarroch, 2005; Kc 
et al.   010  Japundžić-Žigon   013  Hueston & Deak   014  Ni et al., 2014).  
Measurements of hypothalamic gene expression together with electrophysiological 
studies suggest that AT1 receptors, in the PVN, mediate inflammation (de Kloet et al., 
2013). This central inflammation is associated with metabolic and cardiovascular 
disorders and the deletion of PVN AT1 receptors decreases the levels of inflammation in 
this central area (de Kloet et al., 2013). 
The SHR, a widely used as an animal model of hypertension, also presents an activated 
inflammatory system, in a similar way to what seen in human hypertensive patients. 
Overall, the increased inflammation observed in both, SHR and patients with essential 
hypertension, may precede the onset of hypertension.  
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It is also believed that this inflammatory process may contribute to end-organ damage 
observed in the SHR (Schmid-Schönbein et al., 1991). Results of several genetic 
expression studies revealed the supportive role of the hypothalamus and brainstem for 
factors such as neuronal nitric oxide synthase, inflammation and reactive oxygen species 
and their influence on hypertension of neurogenic origin (see (Marques & Morris, 2012), 
for a review). 
Accordingly, and as an attempt to contribute to the future clarification on the role of PVN 
and inflammation in the origin of neurogenic hypertension, we started a new set of 
protocols intended to understand the role of central and localized inflammation on the 
genesis of the higher sympathetic tone and hypertension.  
For that, a model of central inflammation in rodents by the stereotaxic administration of 
the Escherichia coli wall lipopolysaccharide (LPS) (Espinosa-Oliva et al., 2013) was used. 
This model postulates that glial cells are activated after intracranial microinjection of LPS, 
inducing cytokines and chemokines production in the brain (Szczepanik et al., 1996; Sun 
et al., 2008; Campbell et al., 2012) together with an intense recruitment of monocytes 
(Montero-Menei et al., 1994; Montero-Menei et al., 1996).  
Briefly, normotensive Wistar-Kyoto, male rats of 12 weeks old were used in this 
preliminary study. Blood pressure, heart rate and respiration were monitored by 
radiotelemetry. A craniotomy was performed using our previously determined 
coordinates for PVN and animals (n=6) were bilaterally microinjected with Escherichia coli 
serotype 055:B5 lipopolysaccharide (50ηL  1mg/kg) into the PVN. Control rats were 
microinjected in the same region with sodium cloride (n=6).  
At 20 days, animals were re-anesthetised and the trachea was cannulated to include 
tracheal pressure to set the previous recorded variables. Baroreceptor (phenylefrine) and 
peripheral chemoreceptor (lobeline) reflexes were stimulated twice with an interval of 5 
minutes between each stimulation. Animals were killed with an overdosis of anesthetic 
and the brain was removed for histology.  
Immunohistochemistry for microglial marker, laminin, VEGFR1, VEGFR2, PDGFR beta, IL-6 
and lipocalin-2 was performed and the fluorescence intensity shown was related to 
expression of protein levels in each sample and measured with a semiquantitative 
CHAPTER 5 - PERSPECTIVES AND FUTURE WORK 
165 
method. Blood pressure, heart rate, respiration and were evaluated. BP and HR variability 
and baroreflex evaluation were performed with on the frequency domain.  
The very preliminary results show that during 60 days of radiotelemetry recording there 
were no changes on blood pressure (from 112±1 mmHg to 110±1 mmHg) or heart rate 
(from 378±4 bpm to 361±4 bpm) values. Also, no changes were found in autonomic 
evaluation. Immunofluorescence analysis will be done in order to confirm 
neuroinflammation in the PVN (Ongoing work). 
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APPENDIX  1  
 
I. The autonomic nervous system  
 
Almost all bodily functions are dependent of the autonomic nervous system. The 
precision and biological importance of the autonomic nervous system (ANS) on the 
control of visceral functions is well known but the mechanisms by which ANS exerts these 
functions are not generally understood. Also, most of them are not yet completely known 
due to the complexity of the system and to its continuous adaptations that are 
complemented with the actions of the endocrine and somatomotor systems. However, 
these three systems are able to regulate individual’s homeostasis  including the 
adaptations to internal and external stimuli (Fig. 1-A). 
 
Figure 1-A. The interactions between the autonomic nervous system, the brain and the body. From Jänig, 
2008. 
 
The essential role of the autonomic nervous system is to integrate homeostatic and 
allostatic programs to distribute specific signals generated in the central nervous system, 
either in the resting state or during particular body behaviors, to the various target 
organs. 
Despite being a system that is able to hide its own dysfunction, the latter can occur and 
be perceived in three conditions: when there is a functional failure, a physical defect in 
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the nervous network and during the aging process. In this case, the term disautonomy or 
autonomic failure is used. In these conditions, the system remains overactivated and an 
allostatic load is maintained being believed to contribute to several diseases eg, 
hypertension, atrial fibrillation, myocardial infarction, obesity, diabetes, atherosclerosis, 
sleep apnea and metabolic syndrome (Dampney, 1994; Robertson & Biaggioni, 1994; 
Appenzeller et al., 2000; Folkow, 2000; McEwen, 2000; McEwen & Wingfield, 2003; Rocha 
et al., 2003; Rocha et al.   004  J nig   008  Low & Benarroch   008  Oliveira et al., 2009; 
Oliveira et al., 2010; Mathias & Bannister, 2012; Geraldes et al., 2014). 
In the classical sense, ANS is one of two major divisions of the peripheral nervous system 
and works mainly through negative feedback mechanisms and under the concept of reflex 
arc, which is the basic morpho-functional unit of the nervous system. In this way, the 
system is able to have specific neuronal pathways in the periphery and specific 
organization in the central nervous system in order to have precision and flexibility in its 
actions. This implies that there is a common central integration, yet formed by various 
central areas, that have multiple but distinct peripheral motor pathways. The autonomic 
effector organs are diverse, and thus their cell types, making clear that the autonomic 
nervous system outweighs the other systems in size and diversity of its functions (Loewy 
& Spyer, 1990; Dampney, 1994; Mathias & Bannister, 2012; Jänig, 2008, Appenzeller et al, 
2000). 
Definitions 
The usage of inappropriate terms when referring to the autonomic nervous system, lead 
to generalizations and scientific inferences, which are not in accordance with the 
neurobiology and differentiation of autonomic function, thus creating functional 
misunderstandings and wrong impressions on how the system works. Langley (1921) 
proposed the term autonomic nervous system to describe the peripheral nervous system 
that regulates body tissues and organs except the skeletal muscle. In the present text, we 
will use Langley neuroanatomical terminology and the terms sympathetic, 
parasympathetic and enteric only to refer to the motor portion of the autonomic reflex 
arc. This arc also includes integrative centers located at the central nervous system – 
central autonomic network- where is conveyed sensory information from peripheral 
sensors located at specific reflexogenic areas (Fig 2-A). 
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Figure 2-A. The autonomic reflex arc. The relative morphological relations between its different 
components are shown. The autonomic motor fibres include the sympathetic, parasympathetic and enteric 
divisions. From Rocha 2009. 
 
 
The visceral afferent pathways 
The afferent pathways are the interface between the visceral organs and the central 
nervous system. Most of the afferent fibres are unmyelinated but also myelinated fibres 
which can also conduct information up to about 30m/s (Loewy and Spyer, 1990). There 
are two types of visceral afferents: the primary afferent fibres and enteric afferent fibres, 
with the latter encoding chemical and mechanical events and having the cells bodies in 
the wall of the gastrointestinal tract (Loewy & Spyer, 1990; Jänig, 2008). 
The nervous impulses of the primary afferent fibres are carried orthodromically to the 
spinal cord, brain stem or prevertebral sympathetic ganglia (Fig. 3-A) (Loewy & Spyer, 
1990). The degree of physiological specificity of these afferent neurons is described by the 
elicited quantitative responses either to their chemical and mechanical stimulation.  
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Figure 3-A. Projection of visceral afferent neurons. On the right side are shown spinal visceral afferent 
neurons projecting to the thoracic and upper lombar spinal cord whereas vagal afferent neurons projecting 
to the MTS and spinal visceral neurons projecting via splanchnic nerves to the sacral spinal cord. From Jänig, 
2008. 
 
The afferent neurons are involved in two main functions: the regulation of visceral actions 
including protective organ reflexes and the transport of painful information including pain 
from deep somatic tissues, hyperalgesia, deep pain and inflammation. This duality of 
function makes them fundamentally different from the somatic afferents, since the 
sensory and regulatory properties of the latter ones cannot be separated. In fact, the 
afferent impulses from skin or from muscle trigger a reflex and behavioural regulation as 
well as evoke a sensory experience, which is not true for the visceral afferents as some of 
their stimuli never reach the level of consciousness (eg, BP changes or gut distension) 
(Loewy and Spyer, 1990). 
The primary afferents have their cells bodies in the spinal and cranial ganglia and their 
receptors are located in the walls or in the parenchyma of internal organs, in the vessels 
that supply the viscera, or in the serosal membranes that cover them (Loewy and Spyer, 
1990). If the majority of these afferents transmit information from the viscera to the 
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central nervous system, there are some of them that also make contact with sympathetic 
preganglionic neurons in prevertebral ganglia (Matthews & Cuello, 1984). These 
anatomical relations indicate that in addition to their central actions visceral primary 
afferents may also play a role as part of peripheral regulatory reflexes (Matthews & 
Cuello, 1984) mainly those that are active in pathological conditions through positive 
feedback mechanisms. The same type of anatomical pattern is seen in enteric afferent 
fibres that, running in mesenteric nerves, can reach prevertebral sympathetic ganglia 
suggesting that enteric fibres also can participate in the regulation of visceral functions 
(Matthews & Cuello, 1984). The neuropeptides that appear to be involved in this sensory 
transmission are substance P, calcitonin gene-relate peptide and vasoactive intestinal 
peptide (Molander et al., 1987; Sharkey et al., 1987). 
 
 
 
Figure 4-A. Drawing showing the dual afferent innervations of viscera according to their relative 
anatomical location in the body. From Loewy and Spyer, 1990. 
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The great majority of the viscera show dual afferent innervations with the larger majority 
of afferent fibres travelling in mixed parasympathetic nerves as the vagus and pelvic 
nerves (Andrews, 1986). There is not yet a conclusion about the physiological significance 
of this dual innervation – afferent fibres being carried in sympathetic and 
parasympathetic nerves- but data suggest that reflex and regulatory functions evoked by 
visceral stimulation are mainly triggered by activity in afferent fibres running in vagus and 
pelvic nerves while visceral sensation, and in particular visceral pain together with some 
visceral reflexes with origin in the mesenterium, is mediated by afferent fibres in 
sympathetic nerves (Loewy and Spyer, 1990, Jänig, 2008).  
 
The efferent pathways 
The efferent pathways of the autonomic reflex arc or the peripheral autonomic nervous 
system have three major subdivisions that are spatially segregated: the sympathetic, the 
parasympathetic, and the enteric nervous system. In other words, it can be said that the 
sympathetic and parasympathetic nervous systems consist in several functionally distinct 
subsystems each of them associated with a distinct type of target tissue (Jänig, 2008). 
They constitute the final autonomic pathway (Jänig & McLachlan, 1986) as each of them is 
based on a set of pre and postganglionic neurons that are synaptically connected in 
autonomic ganglia, constituting the connection between the brain centres and the target 
organ. These sets of neuronal pathways are the building blocks of the motor part of the 
autonomic reflex arc (Jänig, 2008).  
It is generally accepted that, except for the enteric nervous system, the parasympathetic 
nervous pathways organization is simpler than the sympathetic one. If this can be true for 
some pathways and target organs like the pupillae and ciliary muscle seems unlikely to 
other target organs like the heart or the urinary bladder (Furness & Costa, 1987; Furness 
et al.   003  Furness   006  J nig   008). 
Each autonomic nerve pathway extending from the central nervous system (CNS) to an 
innervated organ is a two-neuron chain (Fig. 5-A) (except to the adrenal medulla that 
itself behaves as a sympathetic ganglion). The first neuron cell body, located in the CNS, 
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synapses with a second order neuron which cell body lies within an autonomic ganglion 
(Sherwood, 2010). 
 
 
Figure 5-A. Schematic diagram of autonomic nerve pathway. From Human Physiology: from Cells to 
Systems, Sherwood, 2010. 
 
The nerve fibres of the sympathetic and parasympathetic components are not present at 
all levels of brain-spinal cord axis. In fact, they leave the CNS at different levels - the 
sympathetic fibres from the thoracic and lumbar regions of the spinal cord, and the 
parasympathetic fibres from the brain and the sacral portion of the spinal cord. 
Therefore, the sympathetic division is also called the thoracolumbar division, whereas the 
parasympathetic is refered as the craniosacral division (Vander et al., 2001). 
 
I a. Sympathetic Nervous System 
Sympathetic preganglionic neurons are an heterogeous population of neurons. 
Morphologically, they vary in somal shape, size and dendritic arborisation (Fig. 6-A) giving 
rise to either non-myelinated or myelinated axons, which are not singularly selective in 
relation to their target.  
APPENDIX 1 
176 
 
Figure 6-A. The sympathetic preganglionic neurons show several types of morphogical characteristics. 
Extracted from Cabot, 1990. 
 
At the spinal cord, sympathetic preganglionic neurons are located in four nuclei: lateral 
funicular, intermediolateral, intercalated, and central autonomic nucleus of the spinal 
cord, being the most relevant for cardiovascular regulation the intermediolateral one (Fig. 
7-A).  
 
 
Figure 7-A. The sympathetic preganglionic cell bodies and axons show a characteristic "ladder" 
arrangement at the spinal cord. ILf, lateral funicular nucleus; IML, intermediolateral nucleus; IC, 
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intercalated nucleus; CA, central autonomic nucleus; dh, dorsal horn; vh, ventral horn; cc, central canal. 
Extracted from Cabot, 1990. 
 
Independently of the way how preganglionic sympathetic neurons are posiotioned within 
the different spinal nuclei, they are segmentally organized providing, in this way, the 
anatomical substrate for a more general rostrocaudal functional topography (Fig 8-A) 
(Loewy and Spyer, 1990). Sympathetic preganglionic neurons leave the spinal cord only 
between the first thoracic and third lumbar segments, whereas sympathetic trunks 
extend the entire length of the cord, from the cervical levels high in the neck down to the 
sacral levels (Fig. 8-A)(Vander et al., 2001).  
 
 
Figure 8-A. The segmental distribution of sympathetic preganglionic neurons (right) which reveals that 
most peripheral sympathetic ganglia receive dominant input from a single thoracic or lumbar spinal cord 
segment whereas those more caudally located receive sympathetic innervations from neurons located 
more caudally in the spinal cord (left). Extracted from Strack et al., 1988.  
 
The sympathetic preganglionic neurons exhibit a low level of tonic activity from less than 
1Hz up to 4Hz and their maximal frequency of discharge rarely exceeds the 20Hz. This 
may reflect the influence of both intrinsic membrane properties as well as the integration 
of excitatory and inhibitory potsynaptic potentials. A typical feature is a clear slowing of 
the depolarization rate due to calcium inward influx followed by an 
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afterhyperpolarization that involves an early phase mediated by potassium voltage 
dependent channels and a late phase dependent on calcium activated potassium 
channels. Preganglionic sympathetic neurons activity is regulated by segmental inputs 
from visceral and somatic afferents and supraspinal pathways through glutamatergic 
synapses and via N-methyl-D-aspartate (NMDA) and non-NMDA receptors which are 
inhibited by GABA receptors (Benarroch, 2006). According to their biophysical properties 
and their correlation with content of peptides and function, the sympathetic 
postganglionicneurons can be divided into three groups: phasic neurons (rapidly 
adapting); tonic neurons (slowly adapting) and neurons with a long after depolarization 
following an action potential (LAH neurons) (Adams and Harper, 1995, Tomikasa and 
Akasu, 1995, Jänig 2008). Almost all postganglionic neurons and some 15-25% of the 
preganglionic neurons are phasic neurons and, in addition, to norepinephrine they also 
have NPY as a co-transmitter. The tonic postganglionic neurons are numerous at 
prevertebral ganglia whereas the LAH neurons are also found in prevertebral ganglia and 
are almost exclusively located at celiac and superior mesenteric ganglia (Jänig, 2008).  
 
I b. Parasympathetic Nervous System 
Comparing with the amount of research on the sympathetic reflex responses, the studies 
on parasympathetic system are relatively few. The reasons are various but they all lie on 
the fact that the majority of the parasympathetic ganglia are located close or within the 
target wall organs and, thus, defining a very short postganglionic parasympathetic 
neuron. These less defined morphologically neuronal structures together with less 
exuberant parasympathetic innervation of the target organs when compared with the 
sympathetic one, lead to difficult activity recordings as well as to deficient peripheral 
modulation, either electrical or pharmacological, of these neuronal parasympathetic 
circuits. Also, evidences showing that some parasympathetic ganglia behave as simple 
relay stations also makes difficult to deeply understand parasympathetic function despite 
this lack of ganglionar functional integration is not so evident for cardiac and pelvic 
ganglia (Jänig, 2008; Keast, 1995, 1999).  
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In neuroanatomical terms, the preganglionic parasympathetic nuclei in the brain stem 
include the Edinger-Westphal nucleus (associated with cranial nerve III), the superior and 
inferior salivary nuclei (associated with cranial nerves VII and IX, respectively), and the 
dorsal motor vagal nucleus (DMNV) and the nucleus ambiguus (both associated with 
cranial nerve X). Preganglionic axons exit the brain stem through cranial nerves III, VII, 
and IX and project to postganglionic neurons in the ciliary, pterygopalatine, 
submandibular, and otic ganglia. Parasympathetic preganglionic fibers from the dorsal 
vagal nucleus project via the nerve X to postganglionic neurons embedded in thoracic and 
abdominal targets - the stomach, liver, gall bladder, pancreas, and upper intestinal tract 
(Fig. 9-A). Neurons of the ventrolateral nucleus ambiguus provide the main 
parasympathetic innervation of the cardiac ganglia, which innervate the heart, 
esophagus, and respiratory airways (Fig. 9-A; Kandel et al., 2000). 
 
 
Figure 9-A. Transverse representation of vagal motor neurons from the nucleus ambiguous and dorsal 
motor nucleus of the vagus. On left, data from retrograde cell body labelling also shows the compact 
part—AMBC and the ventrolateral or external division—AMBe of nucleus ambiguus. TS tractus solitarius, 
DMV dorsal vagal nucleus, AP, area postrema, NTS nucleus tractus solitarius; Pyr pyramidal tract; Spv 
superior paraventricular nucleus (from Loewy and Spyer, 1990 and Bieger and Hopkins, 1987).  
 
The heart is innervated by, at least, two parasympathetic pathways of central origin. One, 
acting directly on sinus node and other pacemaker cells, is involved in heart beat 
regulation and atrial inotropism. These myelinated neurons emerge from the nucleus 
ambiguus (Fig. 10-A) located in the caudal portion of the medulla and are activated by the 
baroreceptors’ stimulation. They can show spontaneous and rhythmic activity, being the 
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absence of activity coincidental with inspiration whereas the activation is simultaneous to 
expiration. This coupling to the central respiratory activity is the basis of heart rate 
respiratory sinus arrhythmia. The second pathway is formed mainly by unmyelinated 
neurons that originate at dorsal motor nucleus of the vagus. Some of these neurons can 
also show spontaneous activity not modulated by the central respiratory drive or by 
baroreceptor activity and, upon the heart, their main function seems to generate 
coronary vasodilation when they are activated (Jänig, 2008, Izzo et al., 1993; Feigl, 1998; 
Jones et al., 1998; Cheng et al., 1999).  
 
 
Figure 10-A- Discharge of parasympathetic cardiovascular neuron showing the cardiovascular-respiratory 
coupling. CV  cardiovascular  BP  blood pressure  ∫PhrN  integral of phrenic nerve activity. 
 
The airways seem to be innervated by three parasympathetic pathways, two of them 
supplying the smooth muscle and the third one related to bronchial secretomotor 
neurons (Mazzone et al., 2005) originating mainly at nucleus ambiguus (McAllen and 
Spyer, 1997). In this way, the first two pathways are responsible, respectively, for the 
cholinergic smooth muscle contraction under the activation of airway nociceptors, 
arterial chemoreceptors, upper airway and esophageal mechanoreceptors and the 
nitrergic relaxation of the smooth muscle related to the stimulation of nociceptors or 
rapidly adapting stretch afferents. Most of these neurons seem to be spontaneously 
active, being one type of them active during inspiration and postinspiration while, the 
other, is excited during expiration and hyperinflation. The broncho-secretomotor neurons 
seem to be activated by both pulmonary stretch receptors and nociceptors (Jänig, 2008, 
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Mitchell et al., 1987, Jordan et al., 1997) but their activation type is unknown (Kesler et 
al., 2002).  
The parasympathetic pathways to the gastrointestinal tract are rather complex with the 
preganglionic neurons emerging at the DMNV. These neurons are functionally 
differentiated to regulate the different gastrointestinal functions (Robertson et al., 2012). 
There are also parasympathetic neurons innervating the salivary, and possibly the 
nasopharyngeal glands, which are located at the superior and inferior salivary nucleus. 
These neurons are of two types, motor (vasodilator) and secretor being mainly activated 
by chemical and mechanical stimuli at the naso-oro-pharyngeal cavity (Kim et al., 2004; 
Bradley et al., 2005; Fukami & Bradley, 2005). 
In the eye, the pupillomotor and the vasodilator neurons are activated or inhibited by 
light while the accommodation pathway are specifically activated through target tracking 
(Jänig, 2008). These preganglionic neurons seems to be functionally organized at Edinger-
Westphal nucleus with the pupilloconstrictor ones located more caudally whereas those 
involved in accommodation are located more lateral by opposition to the vasodilator of 
the choroidal circulation which have a medial predominance (Gamlin & Yoon, 2000). 
In the sacral spinal cord, located at the second, third, and fourth sacral segments (S2-S4), 
the parasympathetic preganglionic neurons occupy the intermediolateral column. Axons 
of spinal parasympathetic neurons leave the spinal cord through the ventral roots 
between the caudal lumbar and sacral segments, and project in the pelvic nerve to the 
pelvic ganglion plexus (Robertson et al., 2012). Pelvic ganglion neurons innervate the 
descending colon, bladder, and external genitalia (Fig. 11-A; (Kandel et al., 2000). The 
sacral parasympathetic pathways to the hindgut are rather complex and little is 
understood in their physiology. They innervate the myenteric and serosal plexus, the last 
ones in a similar way of the sympathetic vasoconstrictor pathways to the gastrointestinal 
tract (Jänig, 2008). Apparently the sacral parasympathetic innervation is only involved in 
the control of gastrointestinal motility and in the control of defecation and continence. 
The lower urinary tract is supplied by, at least, two sacral parasympathetic pathways, one 
innervating the bladder body and, the other, the urethra. The first one leads to urinary 
bladder contraction whereas the last one, when activated, relaxes the urethra probably 
by the relase of NO and VIP (Michaelis et al., 1996; Birder et al., 2002; de Groat, 2002). 
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The sacral innervation of reproductive organs is also complex due to, not only, the type of 
target cells but, also, to the integration of lumbar sympathetic spinal systems and sacral 
spinal systems (McKenna, 1998, 1999, 2002). The spinal parasympathetic innervations of 
reproductive organs consists of, at least, one pathway innervating the erectile tissue in 
the man but the female innervation is not yet fully understood (McKenna, 1998, 1999; 
Giuliano et al., 2001; McKenna, 2002).  
 
 
 
Figure 11-A. Sympathetic and parasympathetic divisions of the autonomic nervous system. Sympathetic 
preganglionic neurons are clustered in ganglia in the sympathetic chain alongside the spinal cord, extending 
from the first thoracic spinal segment to upper lumbar segments. Parasympathetic preganglionic neurons 
are located within the brain stem and in segments S2-S4 of the spinal cord. The major targets of autonomic 
control are shown here. Adapted from Principles of Neural Science, Kandel, 2000. 
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I c. Autonomic ganglia 
The preganglionic efferent innervations to sympathetic neurons reside in ganglia 
dispersed in three arrangements: paravertebral, prevertebral, and previsceral or terminal 
ganglia. Paravertebral ganglia are paired structures that are located bilaterally along the 
vertebral column. They extend from the superior cervical ganglia, located rostrally at the 
bifurcation of the internal carotid arteries, to ganglia located in the sacral region (Fig. 8-
A). There are three cervical ganglia (superior, middle and inferior cervical ganglion, which 
is usually termed the cervicothoracic or stellate ganglion), eleven thoracic ganglia, four 
lumbar ganglia, and four to five sacral ganglia. More caudally, two paravertebral ganglia 
join to become the ganglion impar. Prevertebral ganglia are midline structures located 
anterior to the aorta and vertebral column, and are represented by the celiac ganglia, 
aortic-renal ganglia, and the superior and inferior mesenteric ganglia. Previsceral or 
terminal ganglia are small collections of sympathetic ganglia located close to target 
structures (also referred to as short noradrenergic neurons). Generally, the sympathetic 
preganglionic fibers are relatively short and the postganglionic fibers are quite long in the 
SNS (Robertson et al., 2012). 
 The target organs of sympathetic neurons include smooth muscle and cardiac muscle, 
glandular structures, and parenchymal organs, as well as, other cutaneous structures (Fig. 
2-A; (Robertson et al., 2012). 
 Some neurons of the cervical and upper thoracic ganglia innervate cranial blood vessels, 
sweat glands, and hair follicles; others innervate the glands and visceral organs, including 
the lacrimal and salivary glands, heart, lung and blood vessels. Neurons in the lower 
thoracic and lumbar paravertebral ganglia innervate peripheral blood vessels, sweat 
glands, and pilomotor smooth muscle (Fig. 11-A; Kandel et al., 2000). Some preganglionic 
fibers pass through the sympathetic ganglia and branches of the splanchnic nerves to 
synapse on neurons of the prevertebral ganglia, which include the coeliac ganglion and 
the superior and inferior mesenteric ganglia (Fig. 11-A). Neurons in these ganglia 
innervate the gastrointestinal system and the accessory gastrointestinal organs, including 
the pancreas and liver, and also provide sympathetic innervation of the kidneys, bladder, 
and genitalia (Fig. 11-A). Another group of preganglionic axons runs in the thoracic 
splanchnic nerve into the abdomen and innervates the adrenal medulla, which is an 
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endocrine gland, secreting both epinephrine and norepinephrine into circulation. The 
cells of the adrenal medulla are developmentally and functionally related to 
postganglionic sympathetic neurons (Kandel et al., 2000). 
Sympathetic preganglionic neurons are cholinergic cells but some of them express, at 
least, one additional chemical phenotype. In particular, subpopulations of sympathetic 
preganglionic neurons contain the transmitter substances with or without co-localisation 
with acetylcholine like substance P, adrenaline, GABA, serotonin neurotensin, 
somatostatin, enkephalin, luteinizing hormone- releasing hormone, adenosine and ATP 
(Loewy & Spyer, 1990a; Burnstock, 2007).  
The function of the sympathetic and parasympathetic neurons is also to distribute their 
information to the periphery having an anatomical and functional interface, which is the 
autonomic ganglia. At this level, the information is converged or diverged in order to 
match the size and type of target organ avoiding to increase the number of pos-ganglionic 
neurons that would be required to innervate a larger target organ (Purves, 1988; 
Voyvodic, 1989). The sympathetic preganglionic neurons converging to one 
postganglionic neuron originate from several contiguous spinal segments but the synaptic 
input of the postganglionic neuron is dominated by the spinal segment where the 
paravertebral ganglion lies (see above section Ia and Fig. 8-A). When stimulated, 
preganglionic axons converging on a postganglionic neuron elicit excitatory postsynaptic 
potentials (EPSP’s) which depend on the number of acetylcholine quanta released  the 
membrane properties of the posganglionic neuron and the geometry of the synapse 
(McLachlan, 1995; Jamieson et al., 2003). These excitatory inputs can be called “strong” if 
they elicit an action potential with the fast sodium current activated before the calcium 
current, or “weak” when less acetylcholine is released and the synaptic contacts are not 
associated with voltage sensitive calcium channels. In this way, spontaneously active 
neurons receive one or two preganglionic “strong” synaptic inputs and several “weak” 
ones not being normally activated physiologically by summation of the weak inputs 
because the firing rates of individual convergent inputs are too low (Jänig, 2008, 
McLachlan et al., 1997). The prevertebral sympathetic ganglia have several functions like 
mediation of peripheral reflexes and the integration of impulse activity from spinal cord 
and the periphery.  
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The parasympathetic ganglia are different from the sympathetic ones not only 
anatomically but also functionally. Most of the parasympathetic postganglionic neurons 
receive a small number of synaptic inputs of “strong” nature and the parasympathetic 
ganglia seem to have only one relay function (Jänig, 2008). 
 
I d. Dual autonomic innervation 
The two divisions of the autonomic nervous system rarely operate independently, and 
autonomic responses generally represent the regulated interplay of both divisions (Table 
1-A). The heart, glands and smooth muscles are innervated by both sympathetic and 
parasympathetic fibers; that is, they receive dual innervation. Whatever effect one 
division has on the effector cells, the other division usually has the opposite effect 
(exceptions to this rule are indicated in Table 1-A).  
Moreover, the two divisions are usually activated reciprocally; that is, as the activity of 
one division is increased, the activity of the other is decreased. Dual innervation by nerve 
fibers that cause opposite responses provides a very fine degree of control over the 
effector organ. The sympathetic system promotes responses that prepare the body for 
stenuous physical activity in emergency or stressful situations, such as a physical threat 
from the outside. Indeed, a sympathetic response is characterized by an increase of heart 
rate, blood pressure and blood flow to the skeletal muscles, heart, and brain, release of 
glucose by the liver and pupils dilatation.  
Simultaneously, activity of the gastrointestinal tract and blood flow to the skin are 
decreased by inhibitory sympathetic effects (Vander et al., 2001; Sherwood, 2010; Table 
1-A). The parasympathetic system dominates in quiet, relaxed situations. Under such 
nonthreatening circumstances  the body can be concerned with its own “general 
housekeeping” activities  such as digestion (Sherwood, 2010).  
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Table 1-A. Some Effects of Autonomic Nervous System Activity. Adapted from Neural Control Mechanisms, 
Vander, 2001. 
Effector Organ Receptor Type Sympathetic Effect Parasympathetic Effect 
Eyes    
    Iris muscle Alpha Contracts radial muscle 
(widens pupil) 
Contracts sphincter muscle (makes 
pupil smaller) 
    Ciliary muscle Beta Relaxes (filattens lens for far 
vision) 
Contracts (allow lens to become 
more convex for near vision) 
Heart    
    SA node Beta Increases heart rate Decreases heart rate 
    Atria Beta Increases contractility Decreases contractility 
    AV node Beta Increases conduction velocity Decreases conduction velocity 
    Ventricles Beta Increases contractility Decreases contractitily slightly 
Arterioles    
    Coronary Alpha Constricts – 
 Beta Dilates  
    Skin Alpha Constricts – 
    Skeletal muscle Alpha Constricts – 
 Beta Dilates  
    Abdominal viscera Alpha Constricts  
 Beta Dilates – 
    Salivary glands Alpha Constricts Dilates 
Veins Alpha Constricts – 
 Beta Dilates  
Lungs    
    Bronchial muscle Beta Relaxes Contracts 
    Bronchial glands Alpha Inhibits secretion Stimulates secretion 
 Beta Stimulates secretion  
Salivary glands Alpha Stimulates watery secretion Stimulates watery secretion 
 Beta Stimulates enzyme secretion  
Stomach    
    Motility, tone Alpha and Beta Decreases Increases 
    Sphincters Alpha Contracts Relaxes 
    Secretion  Inhibits (?) Stimulates 
Intestine    
    Motility Alpha and Beta Decreases Increases 
    Sphincters Alpha Contracts (usually) Relaxes (usually) 
    Secretion Alpha Inhibits Stimulates 
Gallbladder Beta Relaxes Contracts 
Liver Alpha and Beta Glycogenolysis and 
gluconeogenesis 
– 
Pancreas    
    Exocrine glands Alpha Inhibits secretion Stimulates secretion 
    Endocrine glands Alpha Inhibits secretion – 
 Beta Stimulates secretion  
Fat cells Alpha and Beta Increases fat breakdown – 
Kidneys Beta Increases rennin secretion – 
Urinary bladder    
    Bladder wall Beta Relaxes Contracts 
    Sphincter Alpha Contracts Relaxes 
Uterus Alpha Contracts in pregnancy Variable 
 Beta Relaxes  
Reproductive tract 
    (male) 
Alpha Ejaculation Erection 
Skin    
    Muscles causing  
    hair erection 
Alpha Contracts – 
    Sweat glands Alpha Localized secretion Generalized secretion 
Lacrimal glands Alpha Secretion Secretion 
 
There are several exceptions to the general rule of dual reciprocal innervation by the two 
branches of the autonomic nervous system. The innervated blood vessels (most arterioles 
and veins are innervated; arteries and capillaries are not) receive only sympathetic nerve 
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fibers. Regulation is accomplished by increasing or decreasing the firing rate above or 
below the tonic level in these sympathetic fibers. The only blood vessels to receive both 
sympathetic and parasympathetic fibers are those supplying the penis and clitoris. Most 
sweat glands are innervated only by sympathetic nerves. The postganglionic fibers of 
these nerves are unusual because they secrete acetylcholine rather than norepinephrine. 
Salivary glands are innervated by both autonomic divisions, but sympathetic and 
parasympathetic activity is not antagonistic. Both stimulate salivary secretion, but the 
saliva’s volume and composition differ  depending on which autonomic branch is 
dominant (Sherwood, 2010). 
 
I e. Autonomic Neurotransmission 
The transmission principles at the autonomic nervous system were originally defined on 
the release or acetylcholine or norepinephrine. However, the current knowledge indicates 
that together with these two classical neurotransmitters, other co-transmitters as well as 
neuropeptides are involved in autonomic transmission at several levels. 
The sympathetic and parasympathetic preganglionic fibers release the same 
neurotransmitter, acetylcholine (ACh), but the postganglionic endings of these two 
systems show different types of neurotransmission. Most of the postganglionic 
sympathetic neurons release norepinephrine (NE) but the sympathetic sudomotor and 
the muscle vasodilators transmission is cholinergic in nature as well as in the 
parasympathetic postganglionic neurons. Epinephrine is released by the adrenal medulla. 
These cathecolamines and their precursor dopamine are synthesized from L-tyrosine by 
the action of tyrosine hydroxylase (Fig. 12-A) (Benarroch, 2006). 
Acetylcholine (Ach) is the neurotransmitter of preganglionic sympathetic and 
parasympathetic neurons as well as parasympathetic ganglion cells and sympathetic 
neurons innervating the sweat glands. ACh exerts its effects through two classes of 
receptors, nicotinic and muscarinic, the first mediating the fast transmission between the 
preganglionic fibres to the autonomic ganglia while muscarinic receptors are responsible 
for the effects of Ach on target organs and modulate the excitability of autonomic 
ganglion neurons and pre-synaptic neurons (Benarroch, 2006).  
APPENDIX 1 
188 
Two main categories of receptors -M1 and M2 types – enclose five types of muscarinic 
receptors. The M1 type receptors include the M1-, M3- and M5- receptors (Benarroch, 
2006). M1 stimulate gastric secretion in the stomach whereas M3 mediate excitatory 
effects of Ach on smooth muscle and exocrine secretion. The M2-type (M2 and M4) 
mediate the pre and postsynaptic inhibitory effects of ACh (Benarroch, 2006) (Fig. 13-A). 
 
 
Figure 12-A. Diagram showing the biochemical pathways of catecholamine release at synaptic terminals.  
NE release is primarily inhibited by 2- autoreceptors and together with epinephrine impress 1, 1 and -
adrenoreceptors. AC, adenylate cyclase; Ach, acetylcholine; COMT, catechol O-metyltransferase; DAG, 
diacylglycerol  DBH  dopamine β-hydroxylase; DDC, Dopa decarboxylase;DHPG, dihydroxyphenylglycol; IP3, 
inositol triphosphate; MAOA, monoamine oxidase A; MHPG, methoxyhydroxyphenylglycol; NE, 
norepinephrine; NET, norepinephrine transporter;  PIP2, phosphatidylinositol biphosphate; PKA, protein 
kinase A; PKC, protein kinase C; PLC, phospholipase C;  TH, Tyrosine hydroxylase; VMA, vanillylmandelic 
acid; VMAT, H+/adenosine triphosphate-dependent vesicular monoamine transporter; Extracted from 
Benarroch, 2006. 
However, for autonomic postganglionic neurons, muscarinic and cathecolaminergic 
blockers do not abolish completely their activation, suggesting that autonomic excitation 
is also dependent of other forms of neurotransmission. That is the case with the NANC 
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(NorAdrenergic NorCholinergic) signalling which is also observed at autonomic synapses. 
The NANC transmission is particularly important in the enteric nervous system and 
involves nitric oxide (NO) and purines, in particularly adenosine triphosphate (ATP) acting 
on P2 receptors and adenosine acting via P1 receptors. The autonomic classical neuro- 
and co-transmission is complemented with the release of neuropeptides like 
neuropeptide Y (NPY), vasoactive intestinal peptide (VIP) and galanin (GAL). There are 
also other peptides can be effectively involved at autonomic synapses like tachykinins, 
calcitocin gene related peptide (CGRP) but their interaction 
 
 
Figure 13-A. Mechanisms of ACh synthesis, storage, release and metabolism. Acetyl CoA, acetyl coenzyme 
A;  Ach, acetylcholine;  AChE, acetylcholinesterase;  ChAT, choline acetyltransferase;  DAG, diacylglycerol;  
GIRK, inward-rectifying K+ channels; HACU, high-affinity choline uptake;  IP3, inositol triphosphate;  nAChR, 
nicotinic ACh receptors;  PIP2, phosphatidylinositol biphosphate;  PKC, protein kinase C;  PLC, phospholipase 
C;  VAChT, vesicular ACh transporter; Extracted from Benarroch , 2006. 
within autonomic neurotransmission processes is still a matter of debate. NPY is mainly 
associated to postganglionic sympathetic vasoconstrictors neurons acting complementary 
with norepinephrine. However, in the heart, it attenuates the decrease of heart rate 
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elicited by the parasympathetic activation (Potter, 1987). In opposition, VIP seems to 
have mainly vasodilator actions reinforcing acetylcholine dilator actions (Gibbins et al., 
1984; Lundberg, 1996). Apparently, vasoconstriction in some vascular beds, like the skin 
and mesentery, could have also the interference of substance P and CGRP, being 
vasodilation the final effect (Holzer, 1992; Häbler et al., 1997; Häbler et al., 1999). 
 
I f. Central autonomic network 
Central autonomic pathways are organized at two levels of complexity. Some pathways 
are organized for reflex adjustments of the end organ and  others are organized in a more 
complex way by connecting to higher neural centers that form a central autonomic circuit 
capable of producing widespread autonomic, endocrine, and behavioral responses 
(Loewvy and Spyer, 1990) through preganglionic sympathetic and parasympathetic 
neurons, pituitary and peripheral endocrine organs and motoneurons innervating the 
respiratory and sphincteric muscles, respectively (Benarroch, 2006). 
 
Figure 14-A. Drawing depicting the two main types of visceral information processing by the central 
autonomic network. Information with origin in periphery is processed either for reflex responses or for an 
integrated autonomic, hormonal and behavioral output which prototype is thermoregulation at 
hypothalamic level. Extracted from Loewy and Spyer, 1990. 
 
Central control of autonomic function involves several interconnected areas distributed 
throughout the neuraxis (Robertson et al., 2012). This central autonomic network has a 
critical role in moment-to-moment control of visceral function, homeostasis, and 
adaptation to internal or external challenges. In particular, it receives and integrates 
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information with origin in several sources: a) sensory information with visceral, 
nociceptive, thermal and muscular origin; b) limbic information through the central 
nucleus of the amygdala; c) humoral inputs directly or via circumventricular organs; d) 
information with origin in central oscillators that regulate the pacemaker cells at 
suprachiasmatic nucleus; and, e) information with origin in the pathways regulating the 
sleep-wake cycle (Loewy and Spyer, 1990, Benarroch, 2006, Rocha, 2009, (Robertson et 
al., 2012, Mathias & Bannister, 2012).  
The functions of the central autonomic network are organized in four hierarchical levels 
that are closely interconnected: spinal, bulbopontine, pontomesencephalic and forebrain 
levels (Fig. 15-A).  
 
 
Figure 15-A. Central autonomic control areas and levels of interaction of autonomic control. Extracted 
from Robertson, 2012. 
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These areas are reciprocally interconnected. In fact, they receive convergent inputs of 
visceral and somatic nature and generate stimulus specific profiles of autonomic, 
endocrine and motor responses which are regulated to the behavioural state. The spinal 
level mediates segmental sympathetic or sacral parasympathetic reflexes and is engaged 
in stimulus-specific patterned responses under the influence of the other levels.  
The bulbopontine (lower brainstem) level is involved in reflex control of circulation, 
respiration, gastrointestinal function, and micturition. In particular, at this level, is located 
the nucleus of solitary tract, which is the primary relay station for the reception of 
peripheral visceral information, as well as, the ventrolateral medulla (RVLM), which 
contains bulbospinal neurons that are fundamental for the vasomotor, cardiac and 
respiratory functions control and for the coordination of several cardiovascular reflexes. 
These RVLM neurons also control hypothalamic function and neurons of ventral 
respiratory group involved in respiratory rhythmogenesis (Loewy and Spyer, 1990, 
Benarroch, 2006, Rocha, 2009, (Robertson et al., 2012, Mathias & Bannister, 2012). 
Located more rostrally, the parabrachial nucleus is a major relay center for the 
convergence of sensory information of several natures: visceral, nociceptive and 
thermoreceptive and contains separate subnuclei linked to taste, salivation, 
gastrointestinal, cardiovascular and respiratory regulation together with clusters of 
neurons involved in osmo- and thermoregulation (Loewy and Spyer, 1990, Benarroch, 
2006, Rocha, 2009, Robertson et al., 2012, Mathias & Bannister, 2012).  
  
 
Figure 16-A. Drawing representing NTS visceral organization. In this way, sensory information originated 
from different visceral organs is conveyed to the same cluster of NTS cells. NTS also shows a functional 
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organization, where the convergence of sensory information is stimuli specific (Silva Carvalho et al, 1997) 
(Extracted from Loewy and Spyer, 1990) 
 
The midbrain periaqueductal gray matter (PAG) is involved in the integration of 
autonomic, somatic and antinociceptive responses to stressful stimuli. Morphologically, 
PAG is divided into columns which control cardiorespiratory and urinary function as well 
as pain, thermoregulation and reproductive function including vocalization (Loewy and 
Spyer, 1990, Benarroch, 2006, Rocha, 2009, Robertson et al., 2012, Mathias & Bannister, 
2012).  
The forebrain level includes the hypothalamus and components of the anterior limbic 
circuit, including the insular cortex, anterior cingulated cortex and amygdala. The 
hypothalamus which contains three main areas- periventricular linked to neuroendocrine 
control, lateral involved in arousal and a medial zone controlling behaviour- has a central 
role in neuroendocrine integration being critical for the homeostasis and integrative 
adaptive responses. The hypothalamus is also the location where the autonomic, 
endocrine and immune system communicate. Also regulates sleep –wake cycle, body 
temperature, food intake, osmolarity and fluid balance. Hypothalamic nuclei contain 
neurons that project to preganglionic neurons and in particular those cells of the 
paraventricular nucleus are involved in the stress response (Loewy and Spyer, 1990, 
Benarroch, 2006, Rocha, 2009, Robertson et al., 2012, Mathias & Bannister, 2012).  
The hypothalamus together with PAG are also involved in the defense reaction, an acute 
but active reaction of adaptation to stressful stimuli with lead to sympathetic activation 
with tachycardia, hypertension, positive inotropism, increase in stroke volume and 
cardiac output, redistribution of blood flow, tachypneia and inhibition of baroreflex and 
facilitation of the chemoreceptor reflex (Silva Carvalho et al, 1995a,b). In this situation, 
the paraventricular nucleus coordinates the neuroendocrine integration that includes 
sympathoexcitation and secretion of vasopressin and activation of the adrenomedullary 
and adrenocortical systems (Loewy and Spyer, 1990, Benarroch, 2006, Rocha, 2009, 
Robertson et al., 2012, Mathias & Bannister, 2012). 
The amygdala, in particular the central nucleus, initiates the endocrine, autonomic and 
motor outputs that are critical for the expression of emotions included conditioned 
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behaviours. The anterior cingulated cortex at the insular cortex, which is organized in a 
viscerotopic way, is responsible for the initiation of autonomic responses related to 
motivation and goal-directed behaviours (Jänig, 2008). The anterior cyngulate gyrus, 
ventromedial prefrontal cortex, amygdala, striatum, hypothalamus and PAG form a 
functional unit involved in the assessment of emotional content of stimuli and in the 
context-dependent autonomic, endocrine and motor outputs play a critical role in the 
integrated responses to stress, emotional responses and motivated behaviour. 
 
II. Autonomic Nervous System Evaluation 
II a. Autonomic manoeuvres and Ewing battery of tests 
Autonomic dysfunction may result from primary modifications of the autonomic nervous 
system or secondary to a wide range of diseases eliciting severe morbidity and mortality. 
Together with a detailed history and physical examination, laboratory autonomic 
evaluation has became essential for the evaluation of several clinical conditions and the 
establishment of effective therapeutic schemes more personalized and refined. There are 
several standard autonomic provocative manoeuvres which goal is to test the system 
with a stimulus of supra-threshold to maximal intensity in order to observe the target 
organs evoked responses in terms of presence/absence, duration and magnitude. These 
manoeuvres should be performed at an autonomic laboratory which should fulfil several 
requirements: temperature and humidity control (20-23ºC and 25-35%, respectively) with 
an area of around 20 square metres. All tests should be performed by experienced 
technicians under medical supervision and, depending on the type of evaluation, their 
required number can be of two per patient. Technicians’ training is critical to the 
successful performance of an autonomic test battery and cannot be stressed enough (Low 
& Benarroch, 2008; Mathias & Bannister, 2012). Technicians’ must be familiar with 
sudometrics, ECG, beat to beat BP and blood flow recordings, they must have a practical 
understanding of computers and must be able to recognize technical problems and their 
management as well as be knowledgeable in electrical safety and recognition of the main 
ECG abnormalities and be trained in cardiopulmonary resuscitation (Low & Benarroch, 
2008; Mathias & Bannister, 2012). There are some patient’s preparation requirements 
APPENDIX 1 
195 
which should be followed. No food and tobacco is allowed, at least 4 hours, before the 
study, alcohol is not permitted, at least for 12 hours before the study and compressive 
clothing should not be used in the morning of the test which should, preferentially be 
performed in the morning period. Medications should be discontinued according with the 
drugs half-life and the patient condition and, particularly, those that affect directly the 
autonomic nervous system. Due to the large intra and inter-individual variability, 
normative data values are per laboratory and should be grouped by sex, age and decades 
of life. There are different ways of categorising autonomic tests which take into account 
the target system, the type of variables recorded and the degree of invasion. Usually, and 
due to the nature of the recording devices, most of the manoeuvres are targeting the 
cardiovascular system and are non-invasive in nature (see table 2-A).  
 
Table 2-A.  Summary of the autonomic provocative manoeuvres using for autonomic evaluation 
(Extracted fom Mathias and Bannister, 2012). 
Cardiovascular Head-up tilt (60°) Standing; Valsalva manoeuvre 
Pressure stimuli–isometric exercise, cutaneous cold, mental arithmetic 
Heart rate responses-deep breathing, hyperventilation standing, head-
up tilt 
Liquid meal challenge 
Exercise testing 
Carotid sinus massage, head and neck movements 
24-hour ambulatory blood pressure and heart rate monitoring 
Biochemical Plasma noradrenaline, adrenaline, dopamine–supine and head-up tilt 
or standing urinary catecholamines; plasma rennin activity and 
aldosterone 
Pharmacological Noradrenaline–α-adrenoceptors, vascular 
Isoprenaline–β-adrenoceptors, vascular and cardiac 
Tyramine–pressor and noradrenaline response 
Edrophonium–noradrenaline response 
Atropine–parasympathetic cardiac blockade 
Clonidine–stimulation or suppression test 
Sudomotor Central regulation–thermoregulatory sweat test 
Sweat gland response-intradermal acetylcholine, quantitative 
sudomotor axon reflex test (QSART), localized sweat test 
Sympathetic skin response, sympathetic vasomotor response 
Gastrointestinal Barium studies, videocinefluoroscopy, endoscopy, gastric emptying 
studies 
Renal function and 
urinary tract 
Day and night urine volumes and sodium/potassium excretion 
Urodynamic studies, intravenous urography, ultrasound examination, 
sphincter electromyography 
Sexual function Penile plethysmography 
Intracavernosal papaverine 
Respiratory Laryngoscopy 
Sleep studies to assess apnoea/oxygen desnaturation 
Eye Schirmer’s test 
Pupillary function–pharmacological and physiological 
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The evaluation protocol as well as the data analysis protocol should be designed 
appropriately to the study. One standard and the most common evaluation protocol is 
called the Ewing battery (Ewing et al, 1985) which comprises the assessment of heart rate 
response to deep metronomic breathing, blood pressures changes upon isometric hand-
grip and blood pressure and heart rate responses to Valsalva manoeuvre and active 
standing (Ducla-Soares et al., 2007; Low & Benarroch, 2008; Xavier et al., 2008; Mathias & 
Bannister, 2012, Lahrmann et al, 2011).  
Additional non-invasive manoeuvres like cold pressure test, mental stress and tilt table 
are also currently used in autonomic evaluation.  
The Valsalva manoeuvre assesses the sympathetic and the parasympathetic reaction to 
baroreflex activation when a subject maintains an expiratory pressure of 40mmHg for 15 
seconds with an open glottis. The test responses are divided into four phases, two of 
which are reflex in nature (II and IV) and two mechanical (I and III). Results depend on the 
position, age and gender of the subject, as well as the duration and intensity of the 
expiratory pressure. In patients with autonomic dysfunction, typically there is a loss of 
both the BP overshoot and the reflex bradycardia (Lahrmann et al, 2011) (Fig. 17-A). 
 
Figure 17-A. The Valsalva manoeuvre. On the left, data from a normal subject: following a brief decrease in 
HR and increase in BP due to aorta compression (I), BP first decreases and then increases (II); at III, due to 
the strain release, a consecutive decline in BP and increase in HR is observed which precedes a BP 
overshoot due to persistent sympathetic activity together with normalisation of venous return (IV). The 
increased BP mediates baroreflex-induced bradycardia and is quantified using the Valsalva ratio (i.e. the 
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ratio of the highest HR (II) vs the lowest HR (IV)). Results depend on the position, age and gender of the 
subject, as well as the duration and intensity of the expiratory pressure. (data extracted from CNSystems, 
Graz). On the right, a Valsalva manoeuvre in a patient with disautonomy showing the absence of phase IV 
(from Mathias and Bannister, 2008). In patients with autonomic dysfunction, typically there is a loss of both 
the BP overshoot and the reflex bradycardia Vs: stroke volume; Co: cardiac output; TPR: total peripheral 
resistance 
 
On deep (metronomic) breathing HR autonomic function is assessed with the patient 
breathing metronomically at a rate of six cycles/minute for three minutes, when 
respiratory sinus arrhythmia is maximal. Changes of HR with deep respiration can be 
considered a parameter of parasympathetic cardiac control (Lahrmann et al, 2011; Low & 
Benarroch, 2008; Mathias & Bannister, 2012)).  
 
Figure 18-A. HR responses on deep breathing. On the left, a normal subject (from CNSystem, Graz) and on 
the right, data from a patient with disautonomy where the imprints of respiration are not observed in HR 
recording (from Mathias and Bannister, 2006)  
 
HR variability during deep breathing is influenced by the position of the test subject, the 
rate and depth of breathing, hypocapnia, sympathetic activity, bodyweight and use of 
salicylates and other drugs (Larhmann et al, 2011). 
To evaluate cardiovascular changes upon active orthostatic challenge (Fig. 19-A), Ewing 
introduced two concepts: the 30/15 ratio for HR and BP fall analysis which when 
corresponds to a fall in systolic pressure of at least 20mmHg or in diastolic pressure of at 
least 10mmHg within three minutes of standing or head-up tilt defines orthostatic 
hypotension (Lahrmann et al, 2011, Low and Sletten, 2009, Mathias and Bannister, 2008, 
2013). The 30/15 ratio corresponds to the ratio between the shortest RR interval around 
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the 15th heart beat and the longest RR interval around the 30th heart beat after standing 
up.  
 
 
Figure 19-A. Active standing evaluates the simultaneous acute changes on BP and HR. On the left, a 
normal response (from CNSystems, Graz) and on the right, responses elicited by a patient with autonomic 
failure: in this case, HR increases strongly in an attempt to compensate baroreceptor impairment and the 
continuous decrease of BP (from Mathias and Bannister, 2006).  
 
To complement the autonomic evaluation of active standing, the head up tilt test (HUT) is 
currently performed. Conceptually, it allows the detection of the haemodynamic 
modifications elicited by baroreceptor reflex activation without the interference of the 
muscular pump of the legs. However, rarely it occurs, in this conceptually way, as subjects 
usually develop an alert reaction at the initial stages of the bed tilting which 
superimposes in visual terms to the changes on BP and HR elicited by baroreflex 
activation. Classically, haemodynamic changes associated with HUT have two phases: an 
initial cardiovascular acute response with a duration of 30 seconds, and a stabilisation 
phase composed of two periods – an adaptation period occurring one to two minutes 
after orthostasis, and a later response to prolonged orthostasis lasting for more than five 
minutes (Fig 20-A) (Lahrmann et al, 2011, Low & Benarroch, 2008; Mathias & Bannister, 
2012). 
The cutaneous cold test evaluates sympathetic activation mediated by nociceptors, which 
is observed mainly through BP changes, upon hand until the arm immersion in a freezing 
cold water at 4ºC (Fig. 21-A). 
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Figure 20-A. The normal HR and BP responses to HUT (left, Ducla Soares et al, 2007). To perform this 
manouvre the subject is lying down in a tilt test table, being tilt up at 60-70º after a period of resting of, at 
least, 5minutes. On the right, two examples, of abnormal responses from two patients with different 
degrees of autonomic impairment: on top, a late adaptation is shown, whereas in the bottom the patient 
was unable to adapt and the bed had to return to the initial position before the end of the test (from 
Mathias and Bannister, 2006). 
 
This test, which is a predominantly sympathetic test, differs from the cold face test by 
which the application of cold stimulus to the face, stimulates the trigeminal nerve and 
elicits bradycardia. On the background of the cold face test is the diving response. (For 
more and deep information on autonomic evaluation tests see Mathias and Bannister 
2012 and Low and Benarroch, 2008). 
 
 
Figure 21-A. The cutaneous cold test is likewise the hand grip and the mental stress, a test that evaluates 
mainly adrenergic function. All of them, have the physiological feature of integrating at cortical level. On 
the left, a normal response (CNSystems, Graz) and on the right a response of a patient with disautonomy 
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showing the absence of sympathetic activation, well observed in the absence of BP changes (Mathias and 
Bannister, 2008). 
 
II b. Sudomotor function 
Sudomotor function complements the cardiovascular autonomic testing as impairment of 
sweating, either by hypo- or hyperhidrosis, focal or generalised, are quite frequently 
associate to autonomic failure. There are several tests available categorized according to 
its qualitative, semi-quantitative or quantitative nature and ability to evaluate central or 
peripheral sudomotor function. The thermoregulatory sweat test (TST), the quantitative 
sudomotor axon reflex test (QSART), the sympathetic skin response test (SSRT), the 
quantitative direct and indirect axon reflex test (QDIRT), silastic imprint test (SIT) and the 
dynamic sweat test (DST) are some the most used tests. While TST assesses central 
function, QSART, QDIRT, DST, SSRT and SIT may be used to study sweat gland activity in 
more detail (see Lahrmann et al, 2011, Low and Sletten, 2009, Mathias and Bannister, 
2006, 2012 for a review). Limitations to the sweat tests which can affect its reproducibility 
and fiability are the sensitivity of the results to ambient temperature and humidity and 
the patient´s hydration status and caffeine intake. 
 
II c. Invasive and biochemical techniques applied to autonomic 
evaluation 
A good method for measuring sympathetic nervous system activity in patients is applying 
tests that assess individual sympathetic nervous outflows such as microneurography and 
measurement of norepinephrine (NE) spillover to plasma from the sympathetic nerves of 
individual organs (Esler et al., 2003; Esler, 2011). Alternatively, global sympathetic activity 
may also be assessed from analysis of plasma or urine catecholamine concentrations 
(Goldstein et al., 1983; Dimsdale & Ziegler, 1991). 
Microneurography permits to separate recordings of sympathetic nerve activity to muscle 
(MSNA) or skin (SSNA) vessels. MSNA reflects the vasoconstrictor signal to the skeletal 
muscle vasculature. It is highly sensitive to BP changes and is regulated by both arterial 
and cardiopulmonary reflexes. These reflexes do not affect SSNA. SSNA reflects 
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vasomotor neural traffic to skin blood vessels with almost no sudomotor activity. The two 
recordings (MSNA and SSNA) differ significantly with regard to morphology. Studies to 
date have shown that measurement of sympathetic nerve activity from peripheral nerves 
is safe, accurate and reproducible. Furthermore, it has been proved that recordings from 
one limb can be reliably assumed to reflect recordings of sympathetic nerve activity to 
the muscle vascular bed throughout the body. The method's quantitative nature is also a 
significant advantage (Sinski et al., 2006; Zygmunt & Stanczyk, 2010). 
The evaluation of the activity of the SNS based on the plasma or urine NE concentration 
have significant limitations, as NE is subjected to changeable reuptake dependent on the 
density of the basilar plexus and blood flow velocity in a specific organ. Moreover, 
circulating NE represents only a small fraction (5–10%) of the amount of neurotransmitter 
secreted from nerve terminals (Sinski et al., 2006). The measurement of plasma NE is, 
however, an improvement over the assessment of urine epinephrine (E), NE and their 
precursors and metabolites, which were traditionally used to evaluate the ANS tone 
(Sinski et al., 2006; Zygmunt & Stanczyk, 2010). 
Norepinephrine spillover rate has advantages over the above-mentioned, since allows the 
assessment of NE release from specific target organs. The NE radiolabelled method is 
based on intravenous infusion of small amounts of tritiated NE, which allows tissue 
clearance of this substance to be subtracted from plasma NE values and the remainder to 
be made a marker of the neurotransmitter “spillover” from neuroeffector junctions. This 
“spillover” in steady-state conditions mirrors the secretion of NE from the sympathetic 
nerve terminals (Sinski et al., 2006; Zygmunt & Stanczyk, 2010). Invasive techniques 
measure not only total body but also regional NE spillover in the heart, splanchnic and 
renal circulation, and the brain (Mathias, 2003). 
Experimental quantification of the activity of the SNS in animals can be undertaken using 
several methodologies (Grassi, 1998; Grassi & Esler, 1999; Esler et al., 2003). Direct 
recordings of SNA (e.g. renal or lumbar) are commonly obtained in animals by the surgical 
implantation of recording electrodes onto the appropriate sympathetic fibres (Stocker & 
Muntzel, 2013).  
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II d. Evaluation of baroreflex function 
Baroreceptor function is one of the most important regulatory mechanisms of moment to 
moment BP which can be evaluated through baroreflex sensitivity tests which relate the 
changes in heart period resulting from a change in BP. There are several methods to 
evaluate baroreceptor sensitivity (BRS) under dynamic or steady state conditions by using 
physiological or pharmacological approaches. The most common techniques to quantify 
BRS include pharmacological methods using vasoactive drugs (Oxford method), the 
Valsalva manoeuvre, the neck chamber technique and analysis of spontaneous 
fluctuations of BP and HR. The Oxford method uses phenylephrine (an 1 agonist) to 
induce a rapid increase in BP (15mmHg to 40mmHg) together with HR changes. 
Modifications of the Oxford method evaluate BRS through sequential injections of 
depressor and pressor drugs. There is some controversy on the usage of phenylefrine due 
to the selectivity of the reflex arc target as other reflex arcs, namely the chemoreceptor 
and the pulmonary mechano and chemoreceptors, can also be activated. Applying 
negative or positive pressures to the neck allows the selective activation of carotid 
baroreceptors and can act as an excitatory or inhibitory stimulus depending if positive or 
negative pressure is applied.  
Computer-based techniques allow assessment of BRS by correlating spontaneous 
fluctuations of BP with consecutive HR changes. These computational methods may be 
divided into time domain, frequency domain and computational modelling (see table 3-A 
for detail). Time (sequence) and spectral techniques have proven reliability and have 
become a standard tool in many autonomic testing devices (Lahrmann et al.,2011).  
The sensitivity of the baroreceptor reflex (BRS) can be determined by the sequential 
method (Di Rienzo et al., 1983). This method searches ramps of blood pressure and RR. A 
ramp defines a variation of at least 1 mmHg and 4ms between adjacent values of BP and 
RR, respectively. This concept only can be applied to 3 or more cardiac cycles when they 
vary monotonically either increasing or decreasing. When a BP ramp occurs at the same 
time of a RR ramp, a BRS event is found. The sensitivity of the baroreflex can be 
determined by the average BRS slope: BRS =∆RRI (ms)/ ∆sBP (mmHg) (Gratze et al., 1998). 
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A steeper slope indicates a high sensitivity while a smaller slope indicates a lower 
sensitivity of the baroreflex. The baroreflex effectiveness index (BEl) is the relationship 
between the total number of BRS events divided by the total number of pressure ramps, 
increasing or decreasing, for a given period of time. BEl is an indicator of the effectiveness 
of baroreceptor-mediated cardiac regulation. 
 
Table 3-A. Summary of time, frequency and modelling methodologies of BRS evaluation 
 Method Brief description 
Ti
m
e
 
d
o
m
ai
n
 
Sequences technique 
DiRienzo et al, 1985; Bertineri et al, 1988 
BRS as the average of the slopes between SBP and 
RR values in each identified baroreflex sequence, 
considering SBP with one beat lag 
Dual sequence method 
Malberg et al, 2002 
Equivalent to the sequences technique, allowing 
identification of baroreflex sequences considering 
the SBP and RR with a shift up to 3 beats 
xBRS 
Westerhof et al, 2004 
BRS as the slope between the SBP and RR values 
over 10s widows choosing the shift (up to 5 beats) 
that maximizes the SBP and RR cross correlation. 
SBP and RR series resampled at 1Hz 
Events technique 
Gouveia et al, 2009 
BRS as one global slope between the SBP and RR 
values in all identified baroreflex events 
considering SBP with one lag with respect to RR 
Fr
eq
u
en
cy
 
d
o
m
ai
n
 Transfer function 
Robbe et al, 1987 
BRS as the mean value of the transfer function 
magnitude between SBP and RR in the LF 
frequency band 
Alpha technique  
Pagani et al, 1988 
BRS as the square root of the ratio between RR and 
SBP powers in the LF frequency band 
M
o
d
el
 
b
as
e
d
 
Closed-loop bivariate 
Barbieri and Saul, 1999 
Quantification of the feedback feedforward SBP 
and RR pathways assuming a closed loop SBP and 
RR system 
Closed loop trivariate 
Barbieri et al, 1997 
Quantification of the feedback feedforward SBP 
and RR pathways two ways pathway between SBP, 
RR and respiration 
xAR 
Porta et al, 2000 
Quantification of the feedback feedforward SBP 
and RR pathways considering respiration as an 
exogenous input in the SBP and RR loop assuming 
a closed loop SBP and RR system 
Causal analysis 
Nollo et al, 2001 
Quantification of the BRS assuming exogenous 
input model able to separate the RR variability SBP 
related and unrelated parts 
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II e. Analysis of biological signals variability 
The fact that physiological signals rhythm is not entirely regular has called the attention 
for the possibility of extracting an autonomic signature from these signals using signal 
processing methods. Extremely complex neural mechanisms are responsible for these 
fluctuations. They are based mainly on interactions between the sympathetic and 
parasympathetic nervous system. So, they represent a rich source of information that can 
provide considerable insight into the mechanisms of cardiovascular control (Akselrod et 
al., 1981; Malliani et al., 1983; Mancia, 1983; Mancia et al., 1986; Appel et al., 1989; 
Parati et al., 1992; Mancia, 1993). The cardiovascular signals, in particular HR, are the 
most commonly used. However, like in any biological evaluation where the environment 
conditions the result, standardization is still a problem mainly due to the fact that the 
great majority of autonomic evaluation is performed without the deep knowledge of 
methods and a light physiological background. At this point, confounding data are 
generated and misinterpretations of physiological phenomena have been drawn. Despite 
that, signal processing methods have been revealed, when correctly used, an important 
tool for the construction of autonomic markers and to the refinement of all types of 
therapeutics (pharmacological, surgical and others) allowing a better patients follow-up. 
Signal processing can be applied, at least, in three domains, time, frequency and time –
scale, each of them in an individual or complementary way being able to evidence 
different pathological response profiles, such as delays in the adaptive responses to the 
provocative manouvres, dysynergy between BP and HR responses and/or exaggerated 
responses such as orthostatic hypotension, postural orthostatic tachycardia or syncope 
(Lahrmann et al., 2011; (Hilz & Dütsch, 2006). 
In particular, the application of FFT and autoregressive spectral analysis to HR and BP 
signals has made a very important contribution to autonomic evaluation (Fig. 22-A) 
(Akselrod et al., 1981; Akselrod et al., 1985; Pomeranz et al., 1985; Pagani et al., 1986, 
Lahrmann et al., 2011; Hilz & Dütsch, 2006). FFT, by using sinus functions of different 
frequencies and amplitudes, decomposes the signals allowing a definition of a power 
spectrum where two major ranges of frequencies for human subjects can be recognised: 
very low frequencies (VLF; < 0.04Hz), low frequencies (LF; 0.04–0.15Hz) and high 
frequencies (HF; 0.15–0.4Hz) (M Malik, 1996).  
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Figure 22-A. FFT application to RRI and sBP signals from a normal subject and a patient with paroxysmal 
atrial fibrillation. Extracted from Oliveira et al, 2010. 
 
The VLF band is believed to be related to non-neural factors, such as temperature and 
hormones (Bianchi et al., 1997). The HF band is dominated by the PNS (Malik et al., 1996; 
Akselrod et al., 1997), whereas the LF band is believed to be mediated by both the cardiac 
sympathetic and parasympathetic nervous outflows. In rats, LF is between 0.15–0.6 Hz 
and the HF between 0.6–2.0 Hz (Malik et al., 1996; Marques-Neves et al., 2004) and for 
the rabbit the values are LF between 0.072 - 0.28Hz and HF between 0.29 – 1Hz (Rocha et 
al, 2006).  
Guzzetti  and co-workers reported that patients with essential hypertension are 
characterized by a greater LF power and a smaller HF power of RR interval during supine 
rest when compared with normotensive subjects (Guzzetti et al., 1988). They also 
referred that the powers showed a smaller increase and decrease, respectively, during 
passive tilting. These observations were interpreted as indicating that cardiac sympathetic 
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tone is increased and cardiac vagal tone and modulation are decreased in essential 
hypertension, a conclusion that is in accordance with previous studies in which autonomic 
cardiac modulation was investigated by different techniques (Folkow, 1982; Julius & 
Johnson, 1985). FFT analysis, however, shows important limitations as it requires a 
stationary signal and a long period of data collection of, at least, 5 minutes and is not 
useful to locate and follow changes of a frequency over time. To overcome some FFT 
limitations, like its application to nonstationary and nonlinear signals, a wavelet based 
methodology was proposed to provide a time evolution of LF and HF frequencies (Fig. 23-
A) (Ducla-Soares et al., 2007; Laranjo et al, 2011, Postolache et al., 2003).  
 
 
Figure 23-A. Wavelet analysis of RRI and SBP signals of a patient with paroxysmal atrial fibrillation 
compared with the same type of data analysis from a normal subject matching age and sex. Extracted 
from Laranjo et al, 2011. 
 
Wavelet analysis is a linear and nonstationary representation method of signals in time 
and frequency domains. For the wavelet analysis it is necessary to have a basic function, 
called mother wavelet, which allows the decomposition of the original signal in 
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translational versions of this function with different base scale. A mother wavelet 
function is a nonperiodic, oscillatory function that begins and ends at zero in time domain 
(Kaiser & SpringerLink, 2011). However, being a good alternative to FFT, wavelets (WT) 
lack in resolution, particularly in low frequencies.  
The Hilbert Transform (HT) is a linear operator able to determine the instantaneous 
frequency of a signal, corresponding to the convolution of the input signal with the 
kernel. In order to reach a physiological meaning for the amplitude, the frequency and 
the phase, the signal to be transformed must have an instantaneous null DC component 
(Huang et al., 1998).  
Recently, Huang proposed to fulfil this condition through the Empirical Mode 
Decomposition (EMD) applied to nonlinear and nonstationary processes. The combination 
of Hilbert Transform with the EMD has resulted in what is known as the Hilbert-Huang 
Transform (HHT) (Fig. 24-A and 25-A). In our laboratory, we developed an integrated and 
modular system - FisioSinal® - for clinical and laboratorial autonomic evaluation using 
cardiovascular signals. 
 
 
Figure 24-A. RRI and BP recorded during an HUT of a patient with multiple system atrophy (MSA) where 
analysed using HHT. Data are compared with a response of a normal individual matching sex and age. MSA 
is characterised by a strong disautonomy as shown by HHT analysis. Extracted from Tavares et al, 2010. 
 
The computational tools that are included in FisioSinal are: statistics (Fig. 25-A), fast 
Fourier transform, Wavelet and Hilbert-Huang transforms, baroreflex effectiveness index 
and wavelets coherence (Fig. 26-A) (Tavares, 2011a; Tavares et al., 2012) 
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Figure 25-A. The statistical methods are also used for autonomic evaluation. This figure shows the 
statistical analysis of RRI and SBP values showed through a Poincaré plot (Tavares et al, non published 
observations). 
 
 
Figure 26-A. Autonomic analysis tools used to show reverse autonomic modulation in patients with reflex 
syncope. On the left, are depicted the changes in wavelets coherence evoked by a tilt maneuver in a normal 
subject. After tilting (vertical line) there is a drop of coherence, which reaches its minimum value 
approximately 20 s after tilting, recovering later to a significant lower value. On the right, modification of 
HR and SBP variability coherence along a tilt training period used to induce autonomic remodeling n 
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patients with reflex syncope (A: basal conditions before training program; B, C and D: 1st, 4th and 9th tilt-
training sessions, respectively). The increase of coherence along the training sessions, which relates with an 
increase of baroreceptor remodeling, is represented by an improvement of the band organization together 
with a higher density of the orange/red color. These graphic changes are better seen after tilting-up 
(vertical line). Extracted from Laranjo et al., 2014. 
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